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1.1 Epidemiology of endometrial cancer 
Endometrial cancer (EC) is the most frequent gynaecologic malignancy in 
Western countries with incidence rates ranging between 15 and 25 per 100.000 
women annually.1,2 In the Netherlands, the incidence over the last decade was 
16-19 per 100.000 women annually (European standardized rate). In 2010 
there were 1930 new cases, 425 deaths and approximately 19.000 women 
alive after having been diagnosed and treated for EC during the previous 20 
years in the Netherlands.3 Due to the increased life expectancy and increasing 
age of the population, there has been an increase in the number of patients 
diagnosed with EC during the past decade.4 Since mortality rates have remained 
stable in this period the prevalence has increased (Figure 1). The increasing 
numbers of long-term survivors stress the importance of potential long-term 
treatment related morbidities. 
EC is typically a cancer of postmenopausal women between 50 and 85 years of 
age, with peak incidence between 65 and 80 years.4 The majority of patients 
present with early symptoms of postmenopausal vaginal blood loss, leading 
to diagnosis and treatment at an early stage when the disease is confined 
to the uterus.5 In 1988, the International Federation of Obstetricians and 
Gynecologists (FIGO) has replaced clinical staging with a surgical-pathologic 
staging system, which has been updated in 2009 (Figure 2).6,7 According to 
the 26th FIGO annual report, using the 1988 classification, 71% of patients 
presented with FIGO stage I; 12% with stage II; 14% stage III; and 3% of patients 
were diagnosed with stage IV disease. The reported 5-year survival rates are 
80% for all patients, 85-90% for patients with stage I disease, 75-85% for stage 
II, 50-65% for stage III and 20-25% for stage IV.8
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Figure 1. Netherlands Cancer Registry: Incidence, mortality and 10-year prevalence
of endometrial cancer in the Netherlands.3
Year Incidence Mortality
2000 1484 400
2001 1565 392
2002 1592 421
2003 1661 365
2004 1813 421
2005 1844 425
2006 1700 395
2007 1790 397
2008 1926 393
2009 1819 422
2010 1930 425
10-year Prevalence
2007 11692
2008 11962
2009 12340
2010 12606
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Figure 2. 
FIGO 1988 staging 
IA: limited to endometrium 
IB: <50% myometrial invasion 
IC: >50% myometrial invasion 
IIA: endocervical glandular involvement 
IIB: cervical stroma invasion 
IIIA: Tumor invades the serosa of the 
corpus uteri and/or adnexae and/or 
positive peritoneal cytology
IIIB: Vaginal involvement
IIIC: Metastasis to pelvic and/or para-
aortic lymph nodes
IVA: Tumor invades bladder and/or 
bowel mucosa
IVB: Distant metastasis
FIGO 2009 staging 
IA: <50% myometrial invasion; 
IB: >50% myometrial invasion
II: invasion of the cervical stroma; 
IIIA: Tumor invades the serosa of the 
corpus uteri and/or adnexae
IIIB: Vaginal and/or parametrial in-
volvement
IIIC: Metastasis to pelvic (C1) and/or 
para-aortic (C2) lymph nodes
IVA: Tumor invades bladder and/or 
bowel mucosa
IVB: Distant metastasis
Risk factors for the development of EC include those factors that are associated 
with prolonged exposure of the uterus to unopposed estrogens, such as 
anovulation, nulliparity, early menarche, late onset of menopause, obesity 
and exogenous (unopposed) estrogen or tamoxifen treatment.9 In general, EC 
occurs in elderly women with a high prevalence of co-morbid conditions such 
as obesity, diabetes, cardiovascular disorders and arthropathy with associated 
use of medications, which can provide challenges with regard to the delivery 
of optimal treatment.10 Less than 1-5% of EC are attributable to familial and 
hence potential hereditary genetic factors.11,12 These are typically younger 
patients who develop EC as part of a Lynch syndrome, who have 60-70% life 
time risk for developing endometrial cancer.13
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1.2 Pathology
Endometrial carcinoma arises in the endometrium, the glandular tissue that 
lines the inside of the cavum uteri. The most common histological type of 
endometrial cancer (80-85%) has a glandular growth pattern that shows a 
strong resemblance with normal endometrial glands, and is therefore called 
endometrioid endometrial cancer (EEC).14 EEC is graded according to FIGO 
grading criteria, based on the percentage of solid growth and nuclear atypia 
(Figure 3).6
Figure 3. FIGO grading system: grade 1 tumors have 5% or less; grade 2 have 6% to 50% and grade 3 have more than 
50% of an nonsquamoues or nonmorular solid growth pattern. A higher degree of nuclear atypia (in companson with 
the architectural grade) raises the grade of a G1 or G2 tumor by 1.
Glands Solid growth Nuclear atypia 
Figure 3. FIGO grading system: grade 1 tumors have 5% or less; grade 2 have 
6% to 50% and grade 3 have more than 50% of a nonsquamous or nonmorular 
solid gr wth pattern. A higher degree of nuclear atypia (in comp rison with the 
architectural grade) raises the grade of a G1 or G2 tumor by 1.  
Most EEC (80%) are well differentiated (grade 1) or intermediate grade tumors. 
Other histological subtypes are referred to as non-endometrioid endometrial 
cancers (NEEC) and among others include serous carcinoma (5%), and 
clear cell carcinoma (1-5%), which are considered high grade tumors.14 Pre-
malignant lesions commonly precede EEC and NEEC.15 EEC usually develop in 
an estrogen rich environment, are often found in a background of endometrial 
hyperplasia and can be preceded by atypical endometrial hyperplasia. NEEC is 
often preceded by endometrial intraepithelial carcinoma (EIC), and found in a 
background of atrophic endometrium. Mesenchymal and mixed tumors, such 
as leiomyosarcoma, stromacelsarcoma and carcinosarcoma are rare uterine 
tumors and are seen as separate entities both from the pathogenetic and 
clinical point of view.5,14 These are not further discussed in this thesis. 
In 1983, Bokhman described two different types of endometrial cancer 
based on both clinical and pathological observations.16 Patients with type I 
tumors (the majority of patients) showed signs of hypothalamopituitary and 
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ovarian hyperactivity resulting in hyperestrogenia, lipid and carbohydrate 
metabolic disturbances (prolonged duration of symptoms due to anovulatory 
uterine bleeding, hyperplasia, obesity, hyperlipidemia, diabetes mellitus and 
hypertension). Type II patients were usually older and characterized by the 
absence of endocrine-metabolic disturbances (short duration of symptoms, 
background of atrophic endometrium). Type I patients more often had 
superficial invasive well differentiated (low-grade EEC) tumors and a good 
prognosis, while type II patients more often had deep invasive high grade NEEC 
with a more aggressive clinical course. 
Over the past decades different (epi)genetic alterations involved in type I and 
II carcinogenesis have been found (Table 1).14,15,17-19 
Table 1. Biological markers involved in endometrial cancer with a focus on the distinction of Type I 
from Type II.
Marker Function Type I (%) Type II (%)
ER/PR Transcription factor 70-75 20-25
PTEN Tumor suppressor 35-55 0-10
KRAS Oncogene 15-25 0-10
PIK3CA Oncogene 25-35 25-35
MSI* DNA repair 20-30 0-5
ß-catenin Oncogene 25-40 0-5
E-cadherin Tumor suppressor 20-45 55-75
TP53 Tumor suppressor 5-10 80-90
CDKN2A Tumor suppressor 10 10-40
ARID1a Tumor suppressor 30-40 0-10
ERBB2 Oncogene rare 20-80
*Defects in mismatch repair genes (i.e. MLH-1, MSH-2, MSH-6).
In type II cancers mutation of the tumor suppressor gene TP53 seems to play a 
central role as it is found in 90% of the tumors.20,21 Because TP53 mutations are 
found both in the invasive and the intraepithelial precursor lesions, TP53 loss 
is considered an early event in type II carcinogenesis.21 Other characteristic 
alterations for type II tumors include mutation of the tumor suppressor gene 
CDKN2A (encoding for the tumor suppressor protein p16), and amplification 
of the oncogene ERBB2 (encoding for the Human Epidermal Growth Factor 
Receptor 2, HER-2). For type I tumors there seems not to be a single specific 
genetic alteration which plays a major role in the carcinogenesis. Type 1 
tumors are a heterogenous group of tumors in which different combinations 
of genetic alterations have been observed.15,19 The main genetic alterations 
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known to drive type I (EEC) development are mutations in the tumor suppressor 
gene PTEN and in the oncogenes KRAS, PIK3CA, and CTNNB-1 (ß-catenin).15 
PTEN, KRAS and PIK3CA converge in the PI3K-AKT signalling pathway, which 
has been implicated in nearly all aspects of tumor biology.22,23 ß-catenin is a 
key component of the Wnt signaling pathway, interacting with the TCF/LEF 
family of transcription factors.24,25 In addition micro-satellite instability (MSI), 
a marker for defects in mismatch repair genes, is found in 20-30% of the type 
I tumors.26-28 The vast majority of tumors with MSI are sporadic tumors. It 
is estimated that less than 1-5% of endometrial carcinomas are caused by 
potential hereditary genetic factors such as Lynch syndrome.11,12 In patients 
with sporadic MSI, silencing of the mismatch repair gene MLH1 by promoter 
hypermethylation is the main cause of a mismatch repair deficiency.29 In Lynch 
syndrome, MSI is caused by a germline mutation in one of the mismatch repair 
genes (most often MLH1, MSH2 and MSH6).30 ARID1a is a tumor suppressor 
gene that has recently been established in endometrial cancer and is involved 
in the SWI/SNF complex of chromatin remodeling. Loss of ARID1a expression 
has been found most frequent in endometrioid type tumors (30-40%) and clear 
cell histology (20%) and very rare in serous carcinoma.31-33 Mutations in PTEN, 
KRAS and ARID1a, and nuclear accumulation of ß-catenin as a sign of activated 
Wnt signaling have been found in atypical endometrial hyperplasia, suggesting 
these are early events in type I carcinogenesis.15,32 On the other hand, a small 
proportion (10-15%) of invasive type I EEC have a mutation in TP53, which 
is not seen in atypical hyperplasia, implying that this is a late event in type I 
carcinogenesis.34,35
Despite the observed differences in genetic alterations there remains overlap 
between type I and type II tumors, and heterogeneity within both types. For 
example PIK3CA mutations are found both in type I and type II EEC, and in 
type I tumors MSI is often found in absence of other genetic alterations which 
reflects the heterogeneity of tumors within this group. 
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1.3 Prognostic factors 
Clinico-pathological prognostic factors for survival in patients with endometrial 
cancer have been well documented in numerous studies, of which the GOG#33 
surgical staging study has been of major importance.6 FIGO stage is (per 
definition) one of the most important prognostic factors.8 Histologic subtype 
represents another major prognostic factor.6,36 Endometrioid type endometrial 
cancer has a favorable prognosis compared to the far less common serous and 
clearcell cancer subtypes. The 5-year survival rate for EEC is 80-85%, compared 
to 50-55% for serous, and 60-65% for clearcell cancers. Other major prognostic 
factors include age, histological grade, depth of myometrial invasion and 
lymph vascular space invasion, which are further discussed in paragraph 1.5. 
In addition to these clinicopathologic risk factors, several studies have 
investigated the prognostic capacity of genetic alterations involved in 
endometrial carcinogenesis.17,27,34,35,37,38 The majority of studies indicate that 
expression of the estrogen and progesterone hormone receptors (DNA-binding 
transcription factors) and activation of the Wnt/ß-catenin signaling pathway 
and mutations in CDH1 (encoding for the cell adhesion protein) are associated 
with a good prognosis, while mutation of TP53, CDKN2A and activation of the 
PI3K-AKT pathway are indicators of tumors with a more aggressive clinical 
course. Conflicting results have been reported with regard to the prognostic 
significance of MSI, mutations in PTEN, KRAS and amplification of ERBB2. Most 
studies were relative small, retrospective and included a heterogenous group of 
patients including both higher FIGO stages and a combination of endometrioid 
type and non-endometrioid type tumors. For these reasons genetic alterations 
are not yet used as prognostic factors in clinical practice. 
1.4 Treatment of endometrial carcinoma
Surgery, consisting of total abdominal or laparoscopic hysterectomy with 
bilateral salpingo-oophorectomy (TAH/TLH-BSO), is the mainstay of treatment. 
Already in 1878 Freund performed the first successful total abdominal 
hysterectomy for endometrial carcinoma.39 Radiotherapy, either used as 
adjuvant therapy or as an alternative for operation in medically unfit patients, 
was well recognized around 1920.40 During the first half of the 20th century 
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preoperative external beam radiotherapy or intrauterine brachytherapy 
followed by surgery were used as standard treatment.41,42 However, when it 
became clear that at postoperative pathological evaluation most patients had 
low risk features, from 1970 onwards surgery with adjuvant radiotherapy 
tailored to prognostic factors gained interest, and became the standard 
treatment approach.6 During the second half of the 20th century complication 
rates of the TAH-BSO procedure decreased due to advances in surgical 
techniques and perioperative care. With the development of laparoscopic 
surgical techniques, both laparoscopic-assisted vaginal hysterectomy and 
total laparoscopic hysterectomy have gained interest because of the faster 
postoperative recovery. These techniques were introduced in the 1990s for 
early stage disease, and studies since then have shown a decreased length of 
hospital stay, less pain, a faster resumption of daily activities and improved 
patient reported quality of life compared to the traditional TAH-BSO.43-45
The role of pelvic and para-aortic lymphadenectomy has been the subject of 
ongoing debate. Although formally the surgical/pathological FIGO staging 
is based on information with regard to lymph nodes, it is specified that the 
performance of a staging lymphadenectomy should be a clinical decision 
weighing the benefit of the additional information with regard to lymph 
node status against potential complications and long-term side effects 
associated with lymphadenectomy.46,47 Two recent large randomised trials 
allocated patients to TAH-BSO with or without lymphadenectomy and found 
no benefit in overall and disease free survival, nor differences in rates and 
sites of recurrence, while lymphadenectomy was associated with higher 
rates of treatment related morbidity, especially lymphedema.48,49 Since both 
trials predominantly included patients with intermediate risk EC, routine use 
of pelvic and para-aortic lymphadenectomy is not recommended in low and 
intermediate risk patients. Trials are being planned to investigate its role in 
high-risk (grade 3) EC.
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1.5 Adjuvant treatment for endometrial cancer
Adjuvant treatment has increasingly been tailored to prognostic factors. Risk 
groups have been defined based on clinico-pathological risk factors (Table 
2).50,51 Approximately 55% of patients present with early stage, low-risk 
endometrial cancer. These patients have 95% probability of relapse-free survival 
without further treatment, and adjuvant radiation therapy is not indicated. 
Table 2. Risk groups for adjuvant therapy.
Criteria
Endometrioid type, grade 1 or 2, without myometrial invasion
Low-intermediate 
risk
Endometrioid type, age <60 years, grade 1 or 2 with superficial 
(<50%) myometrial invasion or grade 3 without invasion, or grade 3 
with superficial myometrial invasion without lymph vascular invasion 
PORTEC: Endometrioid type, age ≥60 years, grade 1 or 2 with deep 
(≥50%) myometrial invasion or grade 3 with superficial invasion
GOG#99: age ≥70 years and 1 of the following risk factors: deep 
myometrial invasion, grade 2 or 3, lymph vascular space invasion; or 
age 50-70 and 2 risk factors; or all ages and all risk factors
Endometrioid type, grade 3 and deep myometrial invasion
Endometrioid type stage II-III
Non-endometrioid high grade (serous or clearcell type) stage I-III
Low risk
Risk group
High-intermediate 
risk
In
te
rm
ed
ia
te
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k
High risk
Four randomized trials have established the role of radiation therapy in 
intermediate risk stage I endometrial carcinoma (Table 3).50-53 Conclusions 
are that pelvic radiotherapy provides a highly significant improvement of 
locoregional control (vaginal and/or pelvic), but without survival advantage, 
and at the cost of (predominantly mild) gastrointestinal toxicity. Therefore, 
the use of radiation therapy has been limited to patients at higher risk of 
locoregional recurrence to warrant the risk of treatment-associated morbidity 
in order to maximize local control and relapse-free survival.
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Both PORTEC-1 and GOG#99 trials established risk factors to better select 
patients at risk of recurrence within the intermediate risk group.50,51 Using 
these risk factors (age, grade, depth of myometrial invasion and lymph 
vascular space invasion), in both trials devised a so-called high-intermediate 
risk (HIR) group was defined (Table 2). Patients with HIR features in the no-RT 
arm of the PORTEC-1 trial had a 10-year locoregional recurrence risk of 23%, 
compared to 5% in the RT group.54 The locoregional recurrence rate in the low-
intermediate risk patients was 5% at 5 years and there was no clinical relevant 
decrease with radiotherapy. In the GOG#99 trial, RT resulted in a reduction of 
4-year isolated local relapse in their HIR group from 13% to 5%. The indication 
for RT is currently restricted to patients with HIR features. The implementation 
of these high-intermediate risk factors to select patients led to an important 
reduction in the indication for adjuvant radiotherapy in stage I patients.
Approximately 75% of the locoregional recurrences in PORTEC-1 patients who 
did not receive additional radiotherapy were located in the proximal vagina.50 
With vaginal brachytherapy the vaginal vault and scar area are treated locally, 
with decreased radiation exposure of the surrounding normal organs compared 
to EBRT (Figure 4). Most (retrospective) studies using postoperative vaginal 
brachytherapy alone have reported high rates of vaginal control (92-98%), 
using a variety of dose and fractionation schedules (Table 4).55-64  However, 
most of these studies included mainly low-risk patients.
A. B. 
Figure 4. (A) Pelvic external beam radiotherapy d s  
distribution in the sagital midplane, in red 95% isodose of 46 
Gy. (B) Vaginal brachytherapy using a 3.5cm vaginal cylinder, 
in red 100% isodose of 7 Gy at 0.5 cm distance of the 
applicator surface. 
Figure 4. (A) Pelvic external beam radiotherapy dose distribution on CT in the sagittal midplane, in 
red 95% isodose of 46 Gy. (B) Vaginal brachytherapy using a 3.5 cm vaginal cylinder, dose distribu-
tion on MRI in the sagittal midplane, in red 100% isodose of 7 Gy at 0.5 cm distance of the applicator 
surface.
Introduction
21
 
A
u
th
o
r 
(r
e
f)
 
a
cr
u
a
l 
p
e
ri
o
d
N
o
. 
p
a
ti
e
n
ts
, 
e
li
g
ib
il
it
y 
T
re
a
tm
e
n
t
V
a
g
in
a
l 
re
cu
rr
e
n
ce
Lo
co
re
g
io
n
a
l 
re
cu
rr
e
n
ce
S
u
rv
iv
a
l
S
e
ve
re
 c
o
m
p
li
ca
ti
o
n
s
S
or
be
 e
t 
al
.6
0
40
4;
 S
ta
ge
 I
0,
7%
3,
0%
92
%
 O
S
 a
t 
5-
ye
ar
s
6.
9%
 s
ig
ni
fic
an
t
pu
bl
 1
99
0
M
ac
Le
od
 e
t 
al
.5
7
14
1;
 S
ta
ge
 I
-I
II
A
4 
x 
8.
5 
G
y 
at
 s
ur
fa
ce
1,
4%
2,
0%
91
%
 O
S
 a
t 
5-
ye
ar
s
no
 g
ra
de
 3
/4
19
85
-1
99
3
W
ei
ss
 e
t 
al
.6
1
12
2;
 S
ta
ge
 I
-I
I
3 
x 
7 
G
y 
at
 s
ur
fa
ce
1,
6%
4,
1%
94
%
 N
ED
 a
t 
5-
ye
ar
s
no
 g
ra
de
 3
/4
19
87
-1
99
3
El
ta
bb
ak
h 
et
 a
l.5
5
33
2;
 S
ta
ge
 I
A
 g
rd
 1
-2
1 
x 
30
 G
y 
LD
R
 a
t 
su
rf
ac
e
0,
0%
0,
6%
99
%
 D
FS
 a
t 
5-
ye
ar
s
2.
1%
 g
ra
de
 3
/4
19
58
-1
99
4
Pe
te
re
it
 e
t 
al
.5
8
19
1;
 S
ta
ge
 I
A
 g
rd
 1
-2
2 
x 
16
.2
 G
y 
at
 s
ur
fa
ce
0,
0%
0,
5%
95
%
 O
S
 a
t 
5-
ye
ar
s
0.
5%
 g
ra
de
 4
19
89
-1
99
7
ov
oi
ds
A
nd
er
so
n 
et
 a
l.5
3
10
2;
 S
ta
ge
 I
3 
x 
5 
G
y 
at
 0
.5
 c
m
1,
0%
1,
9%
84
%
 O
S
 a
t 
5-
ye
ar
s
no
 g
ra
de
 3
/4
19
90
-1
99
6
H
or
ow
it
z 
et
 a
l.5
6
16
4;
 S
ta
ge
 I
-I
I
3 
x 
7G
y 
at
 0
.5
 c
m
1,
2%
0,
6%
87
%
 O
S
 a
t 
5-
ye
ar
s
no
 g
ra
de
 3
/4
19
89
-1
99
9
A
le
kt
ia
r 
et
 a
l.5
2
38
2;
 S
ta
ge
 I
-I
I
3 
x 
7G
y 
at
 0
.5
 c
m
0,
8%
0,
0%
93
%
 O
S
 a
t 
5-
ye
ar
s
0.
5%
 g
rd
 3
/0
.3
%
 g
rd
 4
19
87
-2
00
2
S
ol
hj
em
 e
t 
al
.5
9
10
0;
  
S
ta
ge
 I
 g
rd
 2
-3
 a
nd
3 
x 
7G
y 
at
 0
.5
 c
m
0,
0%
0,
0%
98
%
 O
S
 a
t 
3-
ye
ar
s
no
 g
ra
de
 3
/4
19
98
-2
00
4
IB
 g
rd
 1
-2
 if
 >
2c
m
A
ta
ha
m
 e
t 
al
.5
4
12
8;
 S
ta
ge
 I
5 
x 
5.
5 
G
y 
at
 0
.5
 c
m
0,
0%
1,
6%
96
%
 O
S
 a
t 
5-
ye
ar
s
no
 g
ra
de
 3
/4
19
94
-2
00
5
LD
R
: 
lo
w
 d
os
e 
ra
te
. 
V
B
T:
 v
ag
in
al
 b
ra
ch
yt
he
ra
py
. 
N
AT
: 
no
 a
dj
uv
an
t 
th
er
ap
y.
 N
ED
: 
no
 e
vi
de
nc
e 
of
 d
is
ea
se
. 
O
S
: 
ov
er
al
l s
ur
vi
va
l
In
st
it
u
ti
o
n
a
l 
se
ri
e
s 
in
cl
u
d
in
g
 a
t 
le
a
st
 1
0
0
 p
a
ti
e
n
ts
Table 4. Results of postoperative vaginal brachytherapy for endometrial cancer.
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The randomized PORTEC-2 trial was initiated to investigate if vaginal 
brachytherapy would be equally effective as pelvic external beam radiotherapy 
in reducing vaginal recurrence in endometrial cancer patients with HIR features, 
with less treatment related toxicity and better quality of life. The outcomes of 
this trial are discussed in the following chapters of this thesis. 
External beam pelvic radiotherapy remained indicated only for patients with 
high-risk and advanced stage endometrial carcinoma to maximize pelvic 
control. However, distant metastases determine the inferior outcome for 
high-risk patients, with reported 5-year overall survival rates of 60-65%.65 Two 
randomised trials comparing pelvic external beam radiotherapy with adjuvant 
chemotherapy in high risk patients did not show an improvement in overall or 
disease free survival.66,67 Recently, the results of the combined analysis of the 
NSGO 9501 / EORTC 55991 and MaNGO-ILIADE III trials have been published.68 
In both trials postoperative external beam radiotherapy was randomly 
compared to radiotherapy with adjuvant chemotherapy (4 cycles of platinum-
based chemotherapy given either before or after radiation therapy), showing a 
significantly improved 5-year progression free survival of 78% vs 69%, p=0.009, 
but only a trend for improved overall survival (82% vs 75%, p=0.07). Current 
ongoing trials (PORTEC-3, GOG#249 and GOG#258) are investigating the role 
of chemotherapy in combination with radiotherapy, or replacing radiotherapy 
for high risk and advanced stage endometrial cancer patients.
A wide range of systemic therapies have been evaluated in patients with distant 
metastasis or recurrent disease. Hormonal treatment is an attractive option, 
because this treatment is relative well tolerated compared to chemotherapy. 
Progestins show the highest response rates in patients with progesterone 
receptor positive and/or low grade EC, with response rates ranging between 
20-35% and a median response duration of 4 months.69 However, most patients 
with metastatic disease have grade 3, hormone receptor negative disease. 
Paclitaxel- and platinum-based combination chemotherapy is currently the most 
effective treatment. The addition of paclitaxel to doxorubicin and cisplatinum 
was associated with improved response rates (50%) and survival, however at 
the cost of increased toxicity.70 The combination of paclitaxel with carboplatin 
is potentially less toxic, and has been shown to be at least equally effective in 
phase 2 studies.71,72 Premliminary results of the GOG#209 trial in which 1300 
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women were randomized between carboplatin and paclitaxel versus paclitaxel-
doxorubicin-cisplatinum confirm the equivalence with an identical progression 
free and overall survival, together with reduced toxicity for patients treated 
with carboplatin-paclitaxel.73 Finally, several targeted therapies such as MTOR 
inhibitors, and (multitarget) protein kinases are currently being tested for their 
efficacy in ongoing clinical trials.37,74
1.6 Aims and outline of this thesis
The main purpose of the Post Operative Radiotherapy in Endometrial Carcinoma 
(PORTEC) trials has been to provide evidence with regards to risks (short 
and long-term treatment related morbidity) and benefits (disease control) of 
adjuvant radiotherapy, with the ultimate goal to improve the overall outcome 
and quality of life of endometrial cancer patients. 
After publication of the results of the PORTEC-1 trial, in the Netherlands and 
many other countries postoperative radiotherapy became restricted to patients 
with high-intermediate risk features. This has led to a significant decrease 
of overtreatment of endometrial cancer patients. Because the majority (75%) 
of the locoregional recurrences in the no additional therapy arm of the trial 
were located in the vagina, the rationale of the subsequent randomized trial 
(PORTEC-2) was to compare the efficacy of vaginal brachytherapy and external 
beam pelvic radiotherapy, to determine which treatment provides optimal local 
control with least morbidity and best quality of life for patients with high-
intermediate risk endometrial cancer. 
This thesis describes results of the first and second PORTEC trials. The first aim 
of this thesis was to establish the role of postoperative vaginal brachytherapy as 
compared to pelvic external beam radiotherapy in terms of efficacy, treatment 
related toxicity, patient-reported symptoms and health related quality of life in 
the PORTEC-2 trial. The second aim of this thesis was to analyze the very long-
term outcomes of the PORTEC-1 trial, including an analysis of patient reported 
symptoms and health related quality of life of long-term survivors. The third 
aim of this thesis was to investigate whether adverse molecular prognostic 
factors established by analysis of genetic alterations in the main pathways 
involved in endometrioid type (EEC) carcinogenesis can improve the currently 
used method of risk assessment based on clinicopathological factors, with 
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the ultimate goal to further reduce both over- and undertreatment. Chapter 2 
describes the short-term health related quality of life reported by patients in 
the PORTEC-2 trial during the first two years after randomization. In Chapter 
3 the final results of the PORTEC-2 trial are presented, with analysis of the 
primary (vaginal recurrence) and secondary (locoregional, distant recurrence, 
overall and disease free survival and toxicity) endpoints at a median follow-up 
of 45 months, including central pathology review.
Chapter 4 describes the very long-term health related quality of life (HRQL) of 
patients who participated in the PORTEC-1 trial, 10-12 years after treatment. 
General HRQL of patients in both arms of the trial was compared to an age-
matched norm population. In Chapter 5 the 15-year outcomes of the PORTEC-1 
trial are analyzed, focusing on the role of high-intermediate risk criteria for 
radiotherapy treatment selection, and the long-term risk of developing second 
cancers.
Chapter 6 describes the long-term health related quality of life of patients in 
the PORTEC-2 trial with a median follow-up of 65 months, including comparison 
with an age-matched Dutch norm population.
Chapter 7 describes the analysis of genetic alterations in the main pathways 
involved in endometrioid type (EEC) carcinogenesis (PI3K-AKT, Wnt/β-catenin, 
P53-pathway activation and MSI) in formalin fixed paraffin embedded primary 
tumor samples of 65 patients that were selected from the PORTEC-2 trial. 
Both by uni- and multivariate analysis, the prognostic capacity of alternations 
in these individual pathways were tested as well as the prognostic impact of 
combined alternations in multiple carcinogenic pathways.
Chapter 8 provides a general discussion of the results, focusing on current 
issues and future directions.
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Abstract
Purpose: Studies on quality of life (QOL) among women with endometrial 
cancer have shown that patients who undergo pelvic radiotherapy report lower 
role functioning and more diarrhea and fatigue. In the Post Operative Radiation 
Therapy in Endometrial Cancer (PORTEC) trial endometrial carcinoma patients 
were randomly assigned to receive external beam radiotherapy (EBRT) or 
vaginal brachytherapy (VBT). QOL was evaluated using European Organisation 
for Research and Treatment of Cancer Quality of Life Questionnaire C30 and 
subscales from the prostate cancer module, PR-25, and the ovarian cancer 
module, OV-28. 
Patients and Methods: PORTEC-2 accrued 427 patients between 2002 and 
2006, of whom 214 were randomly assigned to EBRT and 213 were randomly 
assigned to VBT. Three-hundred forty-eight patients (81%) were evaluable for 
QOL. QOL outcomes were analyzed at a median follow-up of 2 years.
Results: At baseline, after surgery, patient functioning was at the lowest level, 
and it increased during and after radiotherapy to reach a plateau after 12 
months. Patients in the VBT group reported better social functioning (p<0.002) 
and lower symptom scores for diarrhea, fecal leakage, the need to stay close 
to the toilet, and limitation in daily activities because of bowel symptoms 
(p<0.001). At baseline, 15% of patients were sexually active; this increased 
significantly to 39% during the first year (p<0.001). Sexual functioning and 
symptoms did not differ between the treatment groups.
Conclusions: Patients who received EBRT reported significantly higher levels of 
diarrhea and bowel symptoms. This resulted in a higher need to remain close 
to a toilet and, as a consequence, more limitation of daily activities because 
of bowel symptoms, and decreased social functioning. Vaginal brachytherapy 
provides a better QOL, and should be the preferred treatment from a QOL 
perspective.
Short-term quality of life PORTEC-2
35
Introduction
Endometrial carcinoma is the most common gynecological malignancy among 
postmenopausal women in western countries.1 Most patients are diagnosed at 
an early stage, and surgery, which consists of total abdominal hysterectomy 
and bilateral salpingo-oophorectomy is the cornerstone of treatment. 
Randomized trials on postoperative radiotherapy in endometrial carcinoma 
have shown that pelvic external-beam radiotherapy (EBRT) significantly 
reduced the rate of locoregional relapse. However, reduction of relapse did 
not translate into a survival benefit, and was achieved at the cost of more 
(predominantly mild) gastro intestinal toxicity.2-7  
As a result of the first Post Operative Radiation Therapy in Endometrial 
Cancer (PORTEC) trial, the indication for radiotherapy was abandoned in the 
Netherlands for patients with a very low risk of locoregional recurrence.3 For 
the remaining so-called ‘high-intermediate risk’ patients (ie, age 60 years or 
older and stage IC grades 1 or 2, or stage IB grade 3) the benefit in terms 
of locoregional control (ie,19% locoregional relapse without radiotherapy vs. 
5% with EBRT) and disease-free survival was considered to outweigh the risks 
in terms of treatment-related toxicity. As most (75%) locoregional relapses 
were located in the vagina,  the multicenter, randomized, PORTEC-2 trial 
was initiated to investigate if vaginal brachytherapy (VBT) would be equally 
effective in reducing the risk of locoregional recurrence, while at the same 
time reducing treatment-related toxicity and improving health-related quality 
of life (HRQOL).
Little is known about HRQOL and the impact of adjuvant radiotherapy on 
HRQOL in endometrial cancer survivors. All studies are retrospective, most 
are quite small and have low questionnaire return rates (<40%).8-12 One 
retrospective study with an adequate return rate (75%) found that EBRT was 
negatively associated with vitality and physical and social well-being, but 
scores of patients treated both with or without radiotherapy were similar to 
those of an age-matched population.13 Although patient-perceived HRQOL is 
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an important factor to be used in the decision making process, whether or not 
postoperative radiotherapy should be recommended, there is a clear lack of 
data on HRQOL among patients with endometrial cancer.
The aim of this analysis was to investigate short-term HRQOL of patients with 
high-intermediate risk endometrial carcinoma treated in the PORTEC-2 trial 
and to evaluate the impact of EBRT compared with VBT on patient-perceived 
HRQOL. 
Tabel 1. Patient characteristics of responders and non-responders
% % P-value‡ % P-value*
Age, years
mean 0,45 0,16
range
<60 years 7 4,2 6 3,3 0,29 3 3,8 0,33
≥60 years 159 95,8 176 96,7 75 96,2
FIGO-stage 0,73 0,99
1B 11 6,1 13 7,2 8 9,2
1C 137 82,9 147 80,7 58 75
2A 18 11 22 12,2 9 11,8
Histologic Grade 0,83 0,42
Grade 1 77 46,4 89 48,9 36 46,1
Grade 2 78 47 79 43,4 34 43,4
Grade 3 11 6,6 14 7,7 9 10,5
KPS 0,18 0,10
0 118 71,1 119 65,4 61 78,2
1 47 28,3 59 32,4 16 20,5
2 1 0,6 4 2,2 1 1,3
Comorbidity
IBD 2 1,2 2 1,1 0,93 2 2,6 0,34
Diabetes 19 11,4 31 17 0,14 12 15,4 0,82
Hypertension 61 37 63 34,8 0,68 26 33,3 0,68
Cardiovascular 38 23 42 23,1 0,99 18 23,4 0,95
Other 24 14,5 28 15,5 0,79 14 17,9 0,51
EBRT: external beam radiotherapy; VBT: vaginal brachytherapy 
KPS: Karnofski Performance Score; IBD: inflammatory bowel disease 
FIGO: International Federation of Gynaecology and Obstetrics
‡: P-value for comparison EBRT vs. VBT
*: P-value for comparison responders vs. non-responders
52-88 46-86 52-89
69,5 70,1 71,3
Responders (n=348) Non-responders (n=79)
EBRT (n=166) VBT (n=182)
No. of 
Patients
No. of 
Patients
No. of 
Patients
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Patients and Methods
Patient selection and study design of the PORTEC-2 trial
The PORTEC-2 trial was a multicenter, randomized trial that was conducted 
throughout the Netherlands to compare EBRT and VBT. Surgery consisted of 
total abdominal hysterectomy and bilateral salpingo-oophorectomy; clinically 
suspicious pelvic and/or periaortic lymph nodes were removed, but no routine 
lymphadenectomy was performed. The diagnosis of endometrial carcinoma, 
grade, histological subtype and depth of myometrial invasion were made by 
the regional pathologist. International Federation of Gynecology and Obstetrics 
1988 staging was assigned on the basis of surgical and pathological findings.14
Patients were eligible for the study if they had one of the following combinations 
of age and postoperative International Federation of Gynecology and Obstetrics 
stage: age ≥60 years and stage 1C grade 1 or 2, or stage 1B grade 3 disease; 
or any age and stage 2A disease (except grade 3 disease with >50% myometrial 
invasion). All patients had a WHO-performance score of ≤2. Written informed 
consent was obtained from all patients. The protocol was approved by the 
Dutch Cancer Society and the medical ethics committees of all participating 
centers.
EBRT was given to a total dose of 46 Gy in 2-Gy daily fractions, and five fractions 
were given per week. VBT was delivered to the upper half of the vagina using 
a vaginal cylinder. High-dose-rate (HDR; 90% of patients) and low-dose-rate 
(LDR; 10% of patients) schedules were used, aiming at an equivalent of 45-50 
Gy to the vaginal mucosa with HDR schedules of 21 Gy at 5-mm depth, given 
in 3 fractions of 7 Gy, each 1 week apart; and LDR schedules of 30 Gy at 5-mm 
depth, in one session at 0.50 Gy/hr.
The primary endpoint was 5-year vaginal relapse rate (VRR) as cumulative 
incidence, with death as a competing risk.15 Secondary endpoints were HRQOL, 
treatment-related toxicity, pelvic lymph node and distant relapse rates, and 
overall survival. To detect a clinical relevant difference in VRR with sufficient 
precision, a total of 400 patients were required during an accrual period of 4 
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years. For evaluation of HRQOL this sample size would be more than sufficient 
to obtain significant and clinically relevant results, even when taking dropout 
into account. 
QOL Assessment
Cancer-specific HRQOL was measured with the European Organization for 
Research and Treatment of Cancer C30 questionnaire (EORTC QLQ-C30, 
version 3.0).16 The EORTC QLQ-C30 is a multidimensional, cancer-specific 
quality of life questionnaire developed for repeated assessments in clinical 
trials and has been found valid and reliable in various cancer populations. 
The QLQ-C30 questionnaire contains five functional scales (physical, cognitive, 
emotional, social and role functioning), a global health status/quality of life 
scale, three symptom scales (pain, fatigue and nausea/vomiting), and six single 
items assessing additional symptoms (dyspnea, insomnia, loss of appetite, 
constipation, diarrhea) and perceived financial impact. 
Although an endometrial cancer module is currently being developed by 
the EORTC Quality of Life Group, no endometrial cancer-specific symptom 
questionnaire was available when PORTEC-2 was active. With approval of 
the EORTC Quality of Life Group, relevant subscales from existing published 
EORTC modules, which had previously undergone psychometric evaluation 
and validation, were combined into a symptom module for this study. The 
subscales for bowel and bladder symptoms from the prostate cancer module 
(PR-25) and the subscale for sexual functioning and symptoms from the ovarian 
cancer module (OV-28) were used.17, 18 
For all items, Likert-type response scales were used, and the response scale 
ranged from 4 to 7 points. All subscales and individual-item responses were 
linearly converted to 0 to 100 scales. A higher score for a functional and global 
quality of life scale represented a better level of functioning. For the symptom 
scales and items, a higher score reflected a higher level of symptoms and 
decreased QOL. 
Baseline QOL questionnaires were handed out at the first consultation with the 
radiation oncologist, usually 3 to 4 weeks after surgery, and had to be returned 
before the start of radiotherapy. The end-of-treatment QOL questionnaire was 
handed out 2 to 4 weeks after the completion of radiotherapy. After that time, 
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the questionnaires were sent directly to each patient’s home address at 6, 12, 
18, 24, 36, 48 and 60 months from the date of random assignment. Patients 
were considered evaluable for the QOL assessment if they had returned the 
baseline questionnaire and at least one of the follow-up questionnaires (ie, 
responders).
Statistical methods
All statistical analyses were performed using SPSS, version 14.0 (SPSS, Chicago, 
IL). Data on patient and tumor characteristics from the trial register enabled 
us to compare responders with nonresponders, using chi-square statistics or 
Fisher’s exact test for categorical variables and t test for continuous variables 
(p= 0.05 was considered significant). These tests were also used to compare 
the VBT group with the EBRT group. 
QOL analysis was done according to the guidelines provided by the EORTC 
Quality of life Group.19 Descriptive median scores are listed in the tables. 
Baseline scores of both treatment groups were compared with a t test or the 
Armitage trend test for single items. To exclude a treatment effect on baseline 
scores, baseline forms completed later than the first day of radiotherapy were 
excluded for this comparison. To obtain estimates of the EORTC QLQ-C30, PR-
25 and OV-28 subscales at each of the fixed time points, a linear mixed model 
was used with the patient as random effect and time (categorical), random 
assignment and their interaction as fixed effects. Single items were analyzed 
by using (ordinal) logistic regression with random effects. The difference in 
QOL between the two treatment groups was tested by Wald’s test in the linear 
or ordinal logistic mixed model (p random assignment), which excluded the 
baseline value. The same test was applied to look for significant changes of 
QOL scores over time (p time), and score changes over time were compared 
between both treatment groups (p time by random assignment), which included 
the baseline value. To guard against false-positive results because of multiple 
testing, a two-sided p value of 0.01 was considered statistically significant. 
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Table 2. Patient functioning scores from EORTC QLQ-C30 and sexual functioning and 
symptom scores from OV-28.
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Results
Study population and compliance
The PORTEC-2 trial accrued 427 patients between 2002 and 2006; 214 patients 
were allocated to EBRT and 213 were allocated to VBT. The median follow-up at 
the time of analysis (January 2008) for all randomly assigned patients was 2.7 
years (range, 0.9 to 5.3 years). Baseline questionnaires and at least one follow-
up questionnaire were received from 348 patients (81%), who were considered 
responders. The median follow-up of responders was 2.7 years; because of 
ongoing follow-up at the time of analysis, the rate of responders at the 2-year 
time point was 53% (Appendix 1). 
All returned questionnaires were complete for all items of the QLQ-C30 in 83% 
of the responders and for items on bladder and bowel symptom subscales 
(PR-25) in 92%. When up to two missing items were allowed, these rates were 
96% and 97%, respectively. In contrast, patients were more reluctant about 
responding to questions about their sexual functioning and symptoms. 
The sexual functioning subscale (OV-28) was complete for all items in 66%; 
the sexual symptom subscale was complete for all items in 80% among 
responders who were sexually active. Overall, the treatment groups did not 
differ significantly with regard to questionnaire response rates and missing 
items. Although there were more patients who received EBRT among the 
nonresponders (48 patients in EBRT vs. 31 patients in VBT; p=0.04), patient 
characteristics were equally balanced between the EBRT and VBT groups and 
between responders and nonresponders (Table 1). 
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Table 3.  Symptom scores of EORTC QLQ-C30 and PR-25.
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Figure 1. Patient functioning, subscales from EORTC QLQ-C30 and OV-28
Note: for functioning scales a higher score indicates a higher level of functioning. Bars 
represent 99% confidence intervals. For figures A, B and C the vertical axis is in the up-
per 50% range, for figure D in the lower 50% range.
Patient functioning
Mean scores of the EORTC QLQ-C30 functioning subscales and global health 
status, and for the OV-28 subscales on sexual functioning and symptoms are 
summarized in Table 2. Development of the functioning scores over time is 
displayed in Figure 1. Baseline functioning scores did not differ significantly 
between the treatment groups. For both treatment groups, global heath status 
and functioning scales were low at baseline, showed a significant improvement 
in the first 6 months, and reached a plateau at 12 months (Fig 1). 
Patients treated with VBT reported significantly higher social functioning 
scores after radiotherapy and with additional follow-up than patients treated 
with EBRT. The maximum difference between both treatment groups was 6% 
   1  
Figure 1. Patient functioning, subscales from EORTC QLQ-C30 and OV-28.  
Note: for functioning scales a higher score indicates a higher level of functioning. Bars 
represent 99% confidence intervals. For figures A, B and C the vertical axis is in the upper 
50% range, for figure D in the lower 50% range.  
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after radiotherapy (EBRT 83% vs. VBT 89%, p random assignment = 0.002); 
this difference remained at approximately the same level during the first 
year of follow-up. Mean scores for global health status and for the remaining 
functioning scores were somewhat higher for patients treated with VBT, but 
these differences were not statistically significant.
Sexual activity and interest were lowest at baseline (ie, after surgery), when 
15% of the patients indicated that they were sexually active. Both interest and 
activity increased significantly during the first 6 months to reach a plateau 
(39% active), without significant differences between the treatment groups. 
Of the patients who indicated they were active, 80% reported on their sexual 
symptoms; in these patients there were no significant differences in sexual 
symptoms.
Symptom scores 
Mean scores on the symptom scales of EORTC QLQ-C30, PR-25 and OV-28 are 
summarized in Table 3. Development of the mean symptom scores over time 
is displayed in Figure 2, and development of patient responses is in Figure 3. 
Baseline symptom scores did not differ significantly between the treatment 
groups. Patients treated with EBRT reported a 21% increase in mean diarrhea 
scores after radiotherapy, as compared to patients treated with VBT (30% EBRT 
vs. 9% VBT, p random assignment <0.001). After EBRT, 15.4% and 7.3% of the 
patients reported “quite a bit” or “very much” diarrhea, respectively, whereas 
these rates were 2.8% and 2.8%, respectively after VBT (Fig 3). Although 
diarrhea scores of the patients in the EBRT group decreased, they remained 
at significantly higher levels with additional follow-up. Conversely, diarrhea 
scores in the VBT group remained low, at baseline level (p time < 0.001). 
In addition, patients treated with EBRT reported an 8% increase in mean scores 
of fecal leakage 6 months after radiotherapy (10% EBRT vs. 2% VBT, p random 
assignment <0.001), and scores remained stable with additional follow-up. 
Within the bowel symptom subscale the item on ‘limitations of daily activities due 
to bowel problems’ showed the largest difference (15%) between the treatment 
groups, in favor of VBT (22% EBRT vs. 6% VBT, p random assignment <0.001). 
Although there was a trend toward a higher level of urinary urgency after 
EBRT (p random assignment = 0.015), the same question on limitation of daily 
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activities because of bladder problems did not show a significant difference. 
In fact, the only urinary symptom item that showed a significant difference 
between treatment groups, both after radiotherapy and with additional follow-
up, was the question, “Have you had difficulty going out of the house because 
you needed to be close to a toilet?” This question is however not specific for 
urinary symptoms, and could also be related to bowel symptoms. Two general 
patterns of change in symptom scores over time could be distinguished (Fig 2). 
In the first pattern baseline symptom scores were high, and decreased in the 
subsequent time points to reach a plateau around 12 months. Fatigue, nausea 
and vomiting, pain, appetite loss, and constipation are examples of this first 
pattern and are considered symptoms related to recovery from surgery. The 
second pattern is associated with RT, as baseline scores are low, but increase 
significantly during and after radiotherapy before declining again (eg, bowel 
and urinary symptoms). 
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Figure 2. Summary scores for symptom scales of EORTC QLQ-C30 and PR-25.
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Figure 2. Summary scores for symptom scales of EORTC QLQ-C30 and PR-25. 
  
  
  
Note: for symptom scales a higher score indicates more symptoms. Bars represent 99% 
confidence intervals. For all figures the vertical axis is in the lower 50% range. Scores 
correspond to summary scores presented in Table 3. BS: bowel symptoms.  
Note: for symptom scales a higher score indicates more symptoms. Bars represent 99% 
confidence intervals. For all figures the vertical axis is in the lower 50% range. Scores 
correspond to summary scores presented in Table 3. BS: bowel symptoms.
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Figure 3. Patient responses on single item symptom scales of: diarrhea, fecal leakage, 
need to remain close to the toilet and limitation in daily activities due to bowel symptoms.
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Figure 3. Patient responses on single item symptom scales of: diarrhea, fecal leakage, need to 
remain close to the toilet and limitation in daily activities due to bowel symptoms. 
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Discussion 
To our knowledge, PORTEC-2 is the first phase III, randomized, multicenter 
trial to compare the efficacy of VBT and EBRT, to determine which treatment 
provides optimal local control with least morbidity and best QOL for patients 
with high-intermediate risk endometrial cancer. In this first analysis of patient-
reported QOL during the first two years after treatment, marked differences 
between the treatment groups were found.
Bowel symptoms such as diarrhea and fecal leakage were significantly 
increased after EBRT compared with VBT. Furthermore, patients treated with 
EBRT reported a significantly higher need to remain close to a toilet, which 
resulted in a higher level of limitation of daily activities because of bowel 
problems. Finally, social functioning after EBRT was at a significant lower level 
than after VBT. These differences remained stable with additional follow-up. 
Although higher fatigue rates among the patients who underwent EBRT were 
expected13, a sharp decrease of fatigue rates during radiotherapy and during 
the first year after treatment in both groups was observed. The trend was 
towards less fatigue after VBT compared with EBRT (p=0.06). 
Reported late side effects of vaginal brachytherapy include vaginal dryness with 
painful intercourse and tightening and/or shortening of the vagina.20-23 Little 
is known about the influence of these adverse effects on sexual functioning. 
Patients generally were more reluctant to respond to questions on this subject; 
66% completed the questions on sexual activity. Nonetheless, 39% of these 
elderly women indicated they were sexually active at 6 months after surgery, 
which is in the range of results reported in elderly women.24 Other than the 
significant increase in sexual activity in both treatment groups, there were no 
significant differences in sexual functioning or symptoms between the groups. 
The observed increases in diarrhea scores (on QLQ-C30) and bowel symptoms 
(on PR-25) show the internal consistency of these main findings. The same is 
true for the lower levels of social functioning and increased limitation of daily 
activities reported by patients treated with EBRT. Increased bowel symptoms 
and diarrhea scores after EBRT are consistent both with clinical experience and 
the higher rates of gastro-intestinal toxicity reported in the randomized trials.4,6 
In the PORTEC-1 trial the rate of grade 1-4 late toxicity for EBRT patients was 
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26%, of which 20% was gastro-intestinal toxicity (grades 1 to 2, 17%; grades 3 
to 4, 3%).4 Phase II studies of VBT reported very low rates of gastro-intestinal 
toxicity, consistent with the finding that symptom scores among the PORTEC-2 
VBT arm remained at baseline level.20-23 
Reference values of the Swedish and Danish norm-population for the EORTC 
QLQ-C30 show higher functioning scores and lower symptom rates as 
compared to the baseline scores for both EBRT and VBT groups.25,26 However, 
the plateau that occurred in most scores 6 to 12 months after treatment is in 
the range of these reference values, which indicates that, for most women, the 
stressful period of diagnosis and treatment for endometrial cancer has a clear 
but transient influence on their functioning. This observation is in concordance 
with the largest retrospective HRQOL study among patients with endometrial 
cancer at 5 to 10 years after treatment; in this study, scores of patients treated 
with and without EBRT were similar to those of an age matched population, 
although scores on vitality and physical and social well-being were significantly 
lower when EBRT patients were compared to patients who had received no 
radiotherapy.13 
When changes in QOL scores are interpreted, definition of a clinically relevant 
change in a score is important.  Earlier studies on the magnitude of clinically 
relevant differences agree on a difference of 5% to 10% of the instrument range 
as being clinically relevant.27-29 For the EORTC Core questionnaire, Osoba et 
al28 found that patients valued a change of 5-10% as little, 10-20% as moderate 
and more than 20% as very much difference. For these results, this would 
mean that there was very much improvement in functioning scales in the 
first 6 months after surgery for both groups. Furthermore, patients treated 
with EBRT reported very much diarrhea and little symptoms of fecal leakage, 
while patients treated with VBT did not report an increase in these symptoms. 
In addition, patients treated with EBRT reported a moderate increase in the 
need to remain close the toilet because of bowel symptoms and limitation of 
daily activities. This resulted in little reduction of social functioning for EBRT 
patients. 
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In conclusion, patients who received external beam radiotherapy reported 
significant and clinically relevant higher levels of diarrhea and fecal leakage. 
This resulted in a higher need to remain close to a toilet, more limitation of 
daily activities because of bowel symptoms, and decreased social functioning. 
VBT did not have this negative effect on HRQOL and can be regarded the 
preferred treatment from a HRQOL perspective. This QOL benefit will have to 
be balanced against the outcome of the efficacy analysis. First results suggest 
that VBT is effective and should be regarded as the treatment of choice for 
patients with high-intermediate risk endometrial carcinoma.30
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Summary
Background: After surgery for intermediate-risk endometrial carcinoma (EC), 
the vagina is the most frequent site of recurrence. This study established 
whether vaginal brachytherapy (VBT) is as effective as pelvic external beam 
radiotherapy (EBRT) in prevention of vaginal recurrence, with fewer adverse 
effects and improved quality of life. 
Methods: In this open-label, non-inferiority, randomised trial undertaken in 19 
Dutch radiation oncology centres, 427 patients with stage I or IIA endometrial 
cancer with features of high-intermediate risk were randomly assigned by a 
computer-generated, biased coin minimisation procedure to pelvic EBRT (46 
Gy in 23 fractions; n=214) or VBT (21 Gy high-dose rate in 3 fractions, or 30 
Gy low-dose rate; n=213). All investigators were masked to the assignment of 
treatment group. The primary endpoint was vaginal recurrence. The predefined 
non-inferiority margin was an absolute difference of 6% in vaginal recurrence. 
Analysis was by intention to treat, with competing risk method. The study is 
registered, number ISRCTN16228756. 
Findings: At median follow-up of 45 months (range 18-78), three vaginal 
recurrences had been diagnosed after VBT and four after EBRT. Estimated 
5-year rates of vaginal recurrence were 1.8% (95% CI 0.6 - 5.9) for VBT and 
1.6% (0.5 – 4.9) for EBRT (hazard ratio [HR] 0.78, 95% CI 0.17 – 3.49; p=0.74). 
Five-year rates of locoregional relapse (vaginal or pelvic recurrence, or both) 
were 5.1% (2.8 – 9.6) for VBT and 2.1% (0.8 – 5.8) for EBRT (HR2.08, 0.71 – 
6.09; p=0.17). 1.5% (0.5 – 4.5) vs 0.5% (0.1 – 3.4) of patients presented with 
isolated pelvic recurrence (HR 3.10, 0.32 – 29.9; p=0.30), and rates of distant 
metastasis were similar (8.3% [5.1 – 13.4] vs 5.7% [3.3 – 9.9]; HR 1.32, 0.63 
– 2.74; p=0.46). We recorded no differences in overall (84.8% [95% CI 79.3 – 
90.3] vs 79.6% [71.2 – 88.0]; HR 1.17, 0.69 – 1.98; p=0.57) or disease-free 
survival (82.7% [76.9 – 88.6] vs 78.1% [69.7 – 86.5]; HR 1.09, 0.66 – 1.78; 
p=0.74). Rates of acute grade 1-2 gastrointestinal toxicity were significantly 
lower in the VBT group than in the EBRT group at completion of radiotherapy 
(12.6% [27/215] vs 53.8% [112/208]). 
Interpretation: VBT is effective in ensuring vaginal control, with fewer 
gastrointestinal toxic effects than with EBRT. VBT should be the adjuvant 
treatment of choice for patients with endometrial carcinoma of high-
intermediate risk.
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Introduction
Endometrial carcinoma is the most common gynaecological malignant disease 
in postmenopausal women in developed countries.1 About 80% of patients 
present with early stage disease (International Federation of Gynecology and 
Obstetrics [FIGO] stage I, limited to the uterine corpus) and have a favourable 
prognosis. Surgery consisting of total abdominal hysterectomy and bilateral 
salpingo-oophorectomy is the basis of treatment. 
Both the first Post Operative Radiation Therapy in Endometrial Carcinoma 
(PORTEC-1) trial and the Gynecological Oncology Group (GOG) 99 trial 
compared pelvic external beam radiotherapy (EBRT) with no additional 
treatment for patients with stage I endometrial carcinoma, and showed that 
EBRT significantly reduced the rate of locoregional (vaginal or pelvic, or both) 
recurrence.2-4 Both trials defined a so-called group of high-intermediate risk 
that showed the largest absolute reduction of locoregional recurrence after 
EBRT. In PORTEC-1, major risk factors for recurrence were invasion in the outer 
half of the myometrium, grade 3 histology, and age greater than 60 years.2, 4 
For patients at high-intermediate risk with two of these three major risk factors, 
locoregional at 5 years was reduced from 23% to 5% after EBRT.2, 4 In GOG 99, 
EBRT provided a 58% hazard reduction of 4-year cumulative recurrence in the 
group at high-intermediate risk (from 27% to 13%), and reduction of isolated 
initial local recurrence from 13% to 5%.3 In both trials this reduction was 
mainly caused by reduction of vaginal recurrence, which accounted for 75% of 
locoregional recurrence in the group receiving no additional treatment. EBRT 
did not improve overall survival, and rates of distant metastases were similar. 
In PORTEC-1, adverse effects were recorded in 26% of patients receiving EBRT, 
predominantly mild gastrointestinal toxic effects.5
Retrospective studies reported vaginal brachytherapy (VBT) to be very 
effective in prevention of vaginal recurrence.6-10 The randomised PORTEC-2 
trial was started to investigate whether VBT would be equally effective as 
EBRT in reduction of vaginal recurrence, with fewer treatment-related toxic 
effects and improved quality of life. Analysis of quality of life reported by 
patients in PORTEC-2 during the first two years after treatment has shown that 
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those who had received EBRT reported significantly more, clinically relevant 
gastrointestinal symptoms, especially diarrhoea,11 resulting in restriction of 
daily activities and decreased social functioning.  
This study aimed to compare outcomes and adverse effects after VBT and EBRT, 
and to establish optimum adjuvant treatment for patients with endometrial 
carcinoma of high-intermediate risk.   
Methods
Patient selection and eligibility criteria
The PORTEC-2 trial was a multicenter randomised trial, in which 19 of the 
21 Dutch radiation oncology centres participated. The study was undertaken 
between May 27, 2002 and Sept 25, 2006. Patients were assessed and 
operated on by their regional gynaecologist. Initial assessment included pelvic 
examination, and endometrial tissue biopsy. Preoperative evaluation included 
chest radiography and haematology and chemistry tests. During surgery 
a peritoneal cytology specimen was obtained and abdominal exploration 
undertaken. Surgery consisted of total abdominal hysterectomy and bilateral 
salpingo-oophorectomy; clinically suspicious pelvic or periaortic lymph nodes 
were removed, but no routine lymphadenectomy was done. Diagnosis, typing 
and grading of endometrial carcinoma was done by the regional pathologist. 
FIGO 1988 staging was assigned on the basis of surgical and pathological 
findings.12 
Patients with endometrial adenocarcinoma were eligible for the trial on the 
basis on the following features of high-intermediate risk: (1) Age greater than 
60 years and stage 1C grade 1 or 2 disease, or stage 1B grade 3 disease; and (2) 
stage 2A disease, any age (apart from grade 3 with greater than 50% myometrial 
invasion). All patients had a WHO-performance score of 0-2. Exclusion criteria 
were: serous or clear cell carcinoma; staging lymphadenectomy; interval 
between surgery and radiotherapy more than 8 weeks; history of previous 
malignant disease; previous radiotherapy, hormonal therapy or chemotherapy; 
and previous diagnosis of Crohn’s disease or ulcerative colitis. We obtained 
written informed consent from all patients. The protocol was approved by the 
Dutch Cancer Society and the Ethics Committees of all participating centres. 
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Randomisation and masking 
Participants were assigned to either EBRT or VBT via internet with an application 
trial on line process (TOP). Patient details and answers about eligibility questions 
were entered by the data managers of the participating centres, after which 
treatment was allocated by TOP with a biased coin minimisation procedure, 
with stratification factors FIGO stage, radiotherapy centre, brachytherapy 
(low-dose vs. high-dose rate), and patient age (<60 years vs. ≥60 years). The 
outcome of the allocation was computer generated and not predictable by 
the investigators. Once the trial group was assigned, the treatment and the 
assessment of the outcomes were unmasked. 
Figure 1. Trial profile
EBRT= external beam radiotherapy. VBT= vaginal brachytherapy. ‡ Toxicity analysis 
was performed for treatment received. We did not record data for the total number of 
patients diagnosed and who received primary treatment in the participating centres.
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
427 patients randomly assigned 
214 allocated to external beam 
radiotherapy (EBRT) 
207 received EBRT 
7 did not receive allocated treatment: 
 5 VBT (patient refusal) 
 1 (ineligible: low risk) no radiotherapy 
 1 (ineligible: high risk) EBRT + VBT 
 
213 allocated to vaginal brachytherapy 
(VBT) 
210 received VBT 
3 did not receive allocated treatment: 
 2 (ineligible: low risk) no radiotherapy 
 1 EBRT (brachytherapy not feasible) 
0 patients lost to follow-up 
214 included in intention to treat 
analysis of primary and secondary 
endpoints. 
208 (207+1) analysed for toxicity.‡ 
213 included in intention to treat 
analysis of primary and secondary 
endpoints. 
215 (210+5) analysed for toxicity.‡ 
Figure 1. Trial profile 
EBRT= external beam radiotherapy. VBT= vaginal brachytherapy. ‡ Toxicity analysis 
was performed for treatment received. We did not record data for the total number of 
patients diagnosed and who received primary treatment in the participating centres. 
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Procedures
The primary endpoint was vaginal recurrence.  Secondary endpoints were 
locoregional recurrence (vagina or pelvic, or both), distant metastases, overall 
and disease-free survival, treatment-related toxic effects, and quality of life 
(reported elswhere11). 
The clinical target volume for EBRT consisted of the proximal half of the vagina, 
the parametrial tissues, the internal and proximal external iliac lymph node 
region, and the caudal part of the common iliac lymph node chain (up to 1 cm 
below the level of the promontory). The planning target volume consisted of 
the clinical target volume with a 1 cm three-dimensional margin. 
A dose of 46 Gy, with 2 Gy fractions, five times per week, was prescribed to 
the planning target volume and specified at the isocenter, with homogeneity 
requirements according to recommendations of the International Commission 
of Radiation Units and Measurements (ICRU-50). For all patients computerized 
treatment planning was done using three-dimensional conformal or multiple 
field techniques, with individual shielding in all fields. Centres had to complete 
a dummy-run procedure prior to activation the trial.
Brachytherapy was delivered with a vaginal cylinder, with the reference isodose 
covering the proximal half of the vagina. The dose was specified at 5 mm 
distance from the surface of the cylinder. The dose at 5 mm cranially from the 
vaginal vault along the axis of the cylinder could not vary more than plus or 
minus 10% of the specified dose. Dose schedules with a low-dose and high-
dose rate were prescribed, with a dose equivalent to 45-50 Gy to the vaginal 
mucosa: 21 Gy in three fractions of 7 Gy, 1 week apart for the high-dose rate; 
30 Gy at 50-70 cGy/hr for the low-dose rate; and 28 Gy at 100 cGy/hr in one 
session for the medium-dose rate. Centres had to use the same treatment 
schedule throughout the trial. Doses in the bladder and rectum reference 
points (according to ICRU-38 criteria) and at the vaginal mucosal surface were 
documented.
Patients were assessed by their radiation oncologist 2-4 weeks after completion 
of radiotherapy. Alternating follow-up visits to the gynaecologist and radiation 
oncologist were planned every 3 months in the first 2 years, every 6 months 
until year 5, and then every year, up to ten years. Pelvic examination was
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Table 1. Patient and tumour characteristics. 
No. of 
patients %
No. of 
patients %
Median age ± SD, yrs
Age
≤ 60 years 8 3.7 8 3.8
60-70 years 109 50.9 99 46.5
> 70 years 97 45.3 106 49.8
KPS
0 157 73.4 141 66.5
1 56 26.2 66 31.1
2 1 0.5 5 2.4
Co-morbidity
IBD 4 1.9 2 0.9
Diabetes 28 13.1 34 16.0
Hypertension 75 35.0 75 35.2
Cardiovascular 47 22.0 51 24.0
Other 33 15.4 33 15.5
FIGO stage
IB 19 8.9 16 7.5
IC 172 80.4 171 80.3
IIA 23 10.7 26 12.2
Grade
1 99 46.3 103 48.4
2 97 45.3 94 44.1
3 18 8.4 16 7.5
LVSI
Present 25 11.7 21 9.9
Absent 189 88.3 191 90.1
Distance to serosa
0-1 mm. 17 14.2 23 16.9
2-3 mm. 46 38.3 43 31.6
4-5 mm. 35 29.2 36 26.5
≥ 6 mm. 22 18.3 34 25
not recorded 94 43.9 77 36.2
median mm. (± SD))
Interval surgery-
radiotherapy, days (SE)
Duration of radiotherapy, 
days (SE)
Mean dose, SE (Gy)
EBRT
VBT: HDR‡
VBT: MDR‡
VBT: LDR‡
VBT median cylinder 
diameter (mm. + range)
VBT mean length of 100% 
isodose (mm. + SE) 46.5 (0.7)
3.8 (±2.5) 4.3 (±3.2)
EBRT (N=214) VBT (N=213)
69 ± 7 70 ± 7
30 (20-40)
46.0 (0.9)
21.1 (0.1)
28.5 (0.5)
29.0 (0.3)
43.4 (0.8) 42.5 (0.8)
30.9 (0.2) 12.9 (0.4)
EBRT: external beam radiotherapy; VBT: vaginal brachytherapy KPS: Karnofsky Perfor-
mance Score; IBD: irritable bowel syndrome, LVSI: lymph vascular space invasion
‡VBT was delivered with high-dose-rate (HDR) in 182 (85.4%)patients; with 
low-dose-rate (LDR) in 19 (9.0%) patients; and medium-dose-rate (MDR)
in 8 (3.8%) patients.
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Table 2. Recurrence and survival (all patients), after a median follow-up of 45 months.
Events/Total
Estimated 5-year % 
(95% CI)
Hazard Ratio (95% 
CI)*
Log-rank p 
value*
Vaginal Recurrence
EBRT  4/214 1.6 (0.5 -  4.9) 1 0.74
VBT  3/213 1.8 (0.6 -  5.9) 0.78 (0.17-3.49)
Pelvic Recurrence
EBRT  1/214 0.5 (0.1 -  3.4) 1 0.02
VBT  8/213 3.8 (1.9 -  7.5) 8.29 (1.04-66.4)
Locoregional Recurrence
EBRT  5/214 2.1 (0.8 -  5.8) 1 0.17
VBT 10/213 5.1 (2.8 -  9.6) 2.08 (0.71-6.09)
Distant Metastases
EBRT 13/214 5.7 (3.3 -  9.9) 1 0.46
VBT 16/213 8.3 (5.1 - 13.4) 1.32 (0.63-2.74)
First Failure Type
Vaginal Recurrence
EBRT  2/214 1.1 (0.3 - 4.4) 1 0.57
VBT  1/213 0.9 (0.1 - 6.2) 0.51 (0.05-5.58)
Pelvic Recurrence
EBRT  1/214 0.5 (0.1 - 3.4) 1 0.30
VBT  3/213 1.5 (0.5 - 4.5) 3.10 (0.32-29.9)
Disease Free Survival
EBRT 31/214 78.1 (69.7 - 86.5) 1 0.74
VBT 32/213 82.7 (76.9 - 88.6) 1.09 (0.66-1.78)
Overall Survival
EBRT 26/214 79.6 (71.2 - 88.0) 1 0.57
VBT 29/213 84.8 (79.3 - 90.3) 1.17 (0.69-1.98)
done at every visit. We assessed acute and late side-effects with the grading 
system of the European Organisation of Research and Treatment of Cancer 
and Radiation Therapy Oncology Group (EORTC-RTOG) for radiation toxic 
effects.14 For assessment of late effects in the vaginal mucosa that were 
clinically recorded at pelvic examination, EORTC-RTOG grading for mucous 
membrane was used. Any atrophic changes were reported as grade 1 (minor 
atrophy), and moderate atrophy with or without telangiectasia as grade 2 
mucosal toxic effects. Chest radiograph, blood count and chemistry tests were 
obtained every year. Vaginal or pelvic recurrences had to be confirmed by 
histology, and patients with recurrence were screened for distant metastasis.
Eligibility check and randomization were done based on the original pathology 
diagnosis. Central review of the pathology was done to assess histological 
type, stage and grade, especially as previous studies have indicated poor 
reproducibility of tumour grading.4, 15 At review criteria for high-intermediate 
risk could be confirmed, or patients could be either reclassified to high-risk 
(non-endometrioid type carcinoma, IC grade 3, or stage IIB or higher), or low-
risk groups.
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Statistical Analysis
On the basis of data from the PORTEC-1 trial, vaginal recurrence was expected 
to be 2% after 3 years in the EBRT group. In view of the absence of survival 
benefit with either EBRT and VBT and of the expected reduced risk of side 
effects with VBT, the aim of the trial was to estimate the difference in vaginal 
recurrence with sufficient precision (SE <2%) and to exclude a clinically relevant 
absolute difference in efficacy. An accrual of 400 patients in 4 years would 
provide the study with adequate power (85%) to detect a clinically relevant 
absolute difference of 6% in vaginal recurrence (2% vs 8%, hazard ratio [HR] 
4.1) between both arms (one-sided test). 
Analysis was done by intention-to-treat. Time-to-event analyses were done 
with log-rank tests and Cox proportional hazards regression models with date 
of randomization as starting point. Both log-rank tests and Cox regression 
models were stratified for FIGO stage, but were essentially the same with and 
without adjustment. Data on patients who were alive and free of recurrence were 
censored at date of last follow-up. The competing risks method (with death as 
competing risk) was used for analysis of the rates of vaginal recurrence, pelvic 
recurrence, locoregional recurrence and distant metastases.13 The Kaplan-
Meier method was used for overall and disease-free survival.  A first failure 
competing risks analysis was done when the first failure type was distant if 
there was distant metastasis, with or without simultaneous vaginal or pelvic 
recurrence. The failure type was pelvic recurrence if there was pelvic recurrence 
with or without vaginal recurrence; the failure type was vaginal recurrence 
in the case of isolated vaginal recurrence. Analysis of toxicity was based on 
treatment received.
All statistical analyses were done with SPSS, version 16.0 (SPSS, Inc, Chicago, IL). 
Patient- and tumour characteristics and data for toxic effects were compared 
with chi-square statistics or Fisher’s exact test for categorical variables, and t 
test for continuous variables (p-value < 0.05 was considered significant). The 
study is registered, number ISRCTN16228756.
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Figure 2. Cumulative probability of vaginal recurrence (A), pelvic recurrence (B), locoregional recur-
rence (C), and Kaplan-Meier survival curve for overall survival (D). Inserts show curves with adjusted 
axis from 0 to 10%. EBRT= external beam radiotherapy. VBT= vaginal brachytherapy.
Role of funding source: 
The sponsor of the study reviewed and approved the design of the trial 
and funded data management. The sponsor had no role in data collection, 
data interpretation, data analysis, or writing of the report.  The central data 
manager, principal and associate investigators, and trial statistician had full 
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access to the data. The decision to submit for publication was made after 
presentation and discussion with the trial management group (co-investigators, 
trial statisticians, trial coordinator, and trial pathologist). 
Table 3. Recurrence and survival for true-HIR patients after pathology review (N=366).
Events/Total
Estimated 5-year % 
(95% CI)
Hazard Ratio (95% 
CI)*
Log-rank p 
value*
Vaginal Recurrence
EBRT  4/183 1.9 (0.6 -  5.8) 1 0.39
VBT  2/183 1.5 (0.4 -  6.5) 0.48 (0.09-2.64)
Pelvic Recurrence
EBRT  1/183 0.6 (0.1 -  4.0) 1 0.06
VBT  6/183 3.3 (1.5 -  7.3) 6.10 (0.73-50.7)
Locoregional Recurrence
EBRT  5/183 2.4 (0.9 -  6.5) 1 0.42
VBT  8/183 4.8 (2.4 -  9.7) 1.58 (0.52-4.86)
Distant Metastases
EBRT 10/183 5.0 (2.6 -  9.4) 1 0.79
VBT 11/183 6.4 (3.6 - 11.5) 1.12 (0.48-2.64)
Disease Free Survival
EBRT 24/183 80.2 (71.4 - 89.0) 1 0.89
VBT 25/183 84.5 (78.6 - 90.4) 1.04 (0.59-1.82)
Overall Survival
EBRT 19/183 82.1 (73.5 - 90.7) 1 0.66
VBT 22/183 86.2 (80.5 - 91.9) 1.15 (0.62-2.13)
EBRT: external beam radiotherapy, VBT: vaginal brachytherapy   
*Both log-rank tests and Cox proportional hazards models are stratified for FIGO stage.  
 
Results
Figure 1 shows the trial profile. 427 patients were randomly allocated to EBRT 
(n=214) or VBT (n=213). Data were frozen for analysis on 19 May 2009 and 
all patients were entered in the intention-to-treat analysis. Patient and tumour 
characteristics were well balanced between the groups (table 1). Table 2 shows 
radiotherapy details.
23 (5%) protocol violations occurred, of which 12 (3%) were major (seven in 
EBRT group, five in VBT group). Eleven patients did not receive the allocated 
treatment, one of whom died of cardiac arrest before the start of the first 
treatment (figure 1). Two patients received a higher brachytherapy dose (11 
Gy and 10 Gy per session), because of inaccuracies while introducing a new 
treatment planning system at that centre. 
At median follow-up of 45 months (range 18-78 months), four vaginal 
recurrences had been diagnosed after EBRT and three after VBT. Estimated 
5-year vaginal recurrence rates were 1.8% (95% CI 0.6 – 5.9%) after VBT and 
1.6% (95% CI 0.5 – 4.9%) after EBRT (log-rank p=0.74; figure 2, table 3). The HR 
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for vaginal recurrence after VBT compared with EBRT was 0.78 (95% CI 0.17-
3.49), indicating that a true hazard ratio of 3.5 is highly unlikely. A true hazard 
ratio of 3.5 corresponds with an absolute difference of 4.8% (i.e. 2% after EBRT 
versus 6.8% after VBT), which reliably excludes the clinically relevant difference 
in vaginal recurrence rate of 6% that the trial aimed to exclude. We recorded no 
significant difference in 5-year locoregional recurrence, despite a higher rate 
of pelvic recurrence after VBT (table 3). Moreover, first failure analysis showed 
that most patients with pelvic recurrence had simultaneous distant metastases 
(table 3). Five-year rates of distant metastases did not differ significantly 
between groups (table 3).
55 patients died: 26 after EBRT and 29 after VBT. Of the 26 patients assigned 
to EBRT who died, 16 (62%) died from intercurrent diseases and ten (38%) from 
endometrial cancer. Of the 29 patients assigned to VBT who died, 14 (48%) 
died from intercurrent diseases and 15 (52%) from endometrial cancer. Overall 
and disease-free survival at 5 years were 84.8% (95% CI 79.3 – 90.3) and 82.7% 
(76.9 – 88.6), respectively, for VBT and 79.6% (71.2 – 88.0) and 78.1% (69.7 – 
86.5), respectively, for EBRT, with overlapping survival curves (Figure 2).
Central pathology review of 367 (86%) of the patients had been completed 
at the time of analysis (183 [86%] patients in the EBRT group and 184 [86%] 
in the VBT group). Tumour grading showed poor reproducibility, especially 
for grade 2 (Kappa 0.34), which is consistent with previous studies. Shifts 
were mainly detected from grade 2 to grade 1 disease, and to a lesser extent 
from grade 2 to grade 3 disease (original vs. review grade 1: 48.5% [177/365] 
vs. 78.6% [287/365]; grade 2: 44.4% [162/365] vs. 9.0% [33/365]; grade 3: 
7.1% [26/365] vs. 12.3% [45/365], with similar proportions in EBRT and VBT 
groups. Central review recorded 12 (3%) cases with non-endometrioid type of 
carcinoma (six patients in each group).
After central pathology review, 34 (8%) patients had features of high-risk 
disease (19 [9%] in EBRT group vs. 15 [7%] in VBT group); 27 (6%) were low 
risk, and therefore in retrospect ineligible (12 [6%] vs. 15 [7%]). Analysis of 
outcomes of the 366 patients (86%) who remained high-intermediate risk (true 
high-intermediate risk) at review confirmed the findings of the intention-to-
treat analysis (table 4). Per-protocol analysis did not change these results 
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(data not shown), since there were no recurrences and only one intercurrent 
death in the VBT group in the six patients who had not received their allocated 
treatment.
A significantly higher rate of distant metastasis was recorded in patients 
diagnosed as high risk, or with more advanced stages, or both, after pathology 
review than in cases with true high-intermediate risk (25.6% [95% CI 9.7 – 41.5] 
at 5 years, vs. 5.8% [3.3 – 8.3], p<0.0001), with significantly lower overall 
survival (57.6% [37.4 – 77.8] vs. 84.2% [79.1 – 89.3], p<0.0001) and disease-
free survival (54.2% [31.6 – 75.0] vs. 82.4% [77.1 – 87.7], p<0.0003), without 
differences between the EBRT and VBT groups. 
Grade 1 and 2 gastrointestinal (EORTC-RTOG small/large intestine) toxic effects 
increased significantly at completion of EBRT compared with VBT (EBRT 53.8% 
[112/208] vs. VBT 12.6% [27/215]). This difference decreased with further 
follow-up and lost its statistical significance after 24 months (figure 3). For 
patients assigned to VBT, gastrointestinal toxic effects remained at baseline 
level (figure 3). Late grade 3 gastrointestinal toxic effects were reported in 
four (2%) patients receiving EBRT and in one (<1%) receiving VBT, requiring 
surgery for bowel obstruction due to adhesions or fibrosis. No treatment-
related deaths occurred. From 6 months onwards, grade 1 - 2 mucosal atrophy 
increased, with significantly more grade 2 atrophy after VBT than after EBRT 
(figure 3). Grade 3 atrophy (marked atrophy with or without shortening or 
narrowing) was reported in only 1 (<1%) patient receiving EBRT and four (2%) 
receiving VBT. 
Discussion 
The PORTEC-2 trial compared the efficacy and toxicity of EBRT and VBT for 
endometrial cancer of high-intermediate risk. At a median follow-up of 45 
months, very few vaginal recurrences occurred in both treatment groups, 
showing VBT to be very effective in ensuring of local control. The vaginal 
recurrence rate after EBRT is very similar to the rate of 2.2% at 5 years in the 
first PORTEC trial in patients at intermediate risk, showing consistency of this 
main finding in both trials.2 
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After PORTEC-1 and GOG#99, the indication for radiotherapy has become 
restricted to patients with features of high-intermediate risk, and thus 
most patients with endometrial cancer are treated with surgery alone (with 
radiotherapy as effective salvage treatment for the occasional patient with 
relapse). Use of radiotherapy has been justified for patients thought to be 
at high-intermediate risk, since radiotherapy reduces their 20% risk of 
locoregional recurrence to 5%, maximising initial local control and relapse-free 
survival. Even with no survival benefit, radiotherapy spares these patients the 
psychological stress of recurrence and the morbidity of intensive treatment 
for relapse. PORTEC-2 shows that patients at high-intermediate risk, about 
30% of all patients with endometrial cancer, can be safely treated with vaginal 
brachytherapy alone, with fewer side-effects and improved quality of life.11 
EBRT will thus be used only for the 15% of patients with high-risk or advanced 
disease.
A limitation of the trial design might be that we posed a non-inferiority 
question, but used a design that aimed to establish the actual difference in 
vaginal recurrence with sufficient precision, while choosing an absolute non-
inferiority margin of 6% - i.e., a power of 85% to exclude a difference in vaginal 
recurrence rate of 6% at 3 years. This margin of reduced efficacy of VBT was 
regarded as clinically acceptable in view of the absence of a survival benefit, 
the expected reduced toxic effects of VBT, and the fact that effective salvage 
treatment is available in case of vaginal recurrence. 
Almost all pelvic recurrences after VBT were part of widespread disease 
recurrence. The rates of distant metastases were low and similar in both 
groups. Locoregional recurrence rates in both groups were very similar to 
those reported in previous randomised trials in patients with intermediate risk, 
which varied between 2% to 4%.2, 3, 16, 17 
Both GOG#99 and PORTEC-1 trials showed that vaginal recurrences accounted 
for about 75% of recurrences in the control group.2, 3  PORTEC-2 has shown 
that vaginal brachytherapy can be as effectively used for patients at high-
intermediate risk to ensure vaginal control. This efficacy of VBT also explains 
the fairly low rate of isolated vaginal and pelvic recurrence in the control group 
(6.1% vs. 3.2% for EBRT) of the ASTEC/EN5 trial, the most recently reported 
randomised trial comparing EBRT with no additional therapy, in which 51% of 
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Figure 3. EORTC-RTOG early and late gastro intestinal (small/large intestine) and mucous membrane 
toxicity at pelvic examination. At every follow-up timepoint the toxicity rate represents the number 
of patients with toxicity as percentage of the total number of patients that have reached that follow-
up time point. There were no grade 4 or 5 toxicities. EBRT= external beam radiotherapy. VBT= 
vaginal brachytherapy. RT= at completion of radiotherapy. EORTC-RTOG= European Organisation 
of Research and Treatment of Cancer and Radiation Therapy Oncology Group. *Time points showing 
significant (p<0.05) difference between EBRT and VBT.
patients had received vaginal brachytherapy.17 Moreover, 30% of patients in 
ASTEC/EN5 and all in GOG#99 underwent a staging lymphadenectomy, whereas 
the low rates of locoregional recurrence in PORTEC-2 were obtained without 
routine lymphadenectomy, which accords with the findings of randomised 
trials showing no survival improvement with lymphadenectomy.18, 19
Rates of mild-to-moderate gastrointestinal toxic effects after EBRT in the 
PORTEC-2 trial were similar to other randomised trials. Gastrointestinal 
symptoms were most pronounced during and immediately after EBRT and 
gradually decreased - a pattern very similar to the quality-of-life diarrhoea 
score. However, effect on daily activities persisted with further follow-up. 
Patients assigned to VBT reported very few gastrointestinal symptoms.11 
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Assessment of vaginal toxicity is complex, and some grading systems include 
the impact on sexual functioning (common terminology criteria for adverse 
events v3.0), whereas others do not (EORTC/RTOG).14, 20, 21 For PORTEC-2 we 
decided to record mucosal atrophy and assess the effect of mucosal side-effects 
on sexual functioning with the quality-of-life sections on sexual activity and 
vaginal dryness. The vaginal mucosa surface dose is higher with VBT than with 
EBRT, leading to more grade 2 atrophy. Grade 3 atrophy (substantial atrophy 
with or without shortening of the vagina) was reported in only five patients 
(four in VBT group and one in EBRT group). Patient-reported rates of sexual 
activity increased during the first 6 months after treatment and remained stable 
thereafter, without significant differences between the treatment groups.11 
Sexual functioning and activity rates (40% at 12 months) were similar to those 
reported for elderly women in a population-based analysis.22 
Central pathology review was done because previous work of our group 
and others had shown discordances in pathological diagnoses, with 8% 
discrepancies altering patient management.4, 15 A poor reproducibility of the 
intermediate grade (grade 2) was confirmed. Additionally, 3% non-endometrioid 
histological types were diagnosed. On the basis of revised pathologic changes 
86% of the patients were true high-intermediate risk, whereas 6% had low-risk 
and 8% high-risk features. The results of this central pathology review did not 
change the main outcomes of the study. However, patients shown to be at high 
risk at review had a significantly higher rate of distant metastasis and lower 
survival rates, confirming the rationale for trials that include chemotherapy 
for patients at high risk. In the PORTEC-3 trial, pathology review is mandatory 
before randomisation, and high-risk patients are randomly assigned between 
EBRT alone and EBRT with concurrent and adjuvant chemotherapy.
In conclusion, VBT is very effective in ensuring local control, keeping to a 
minimum the risk of vaginal recurrence, which is the most frequent site of 
disease recurrence in patients with endometrial carcinoma of high-intermediate 
risk. VBT achieves excellent vaginal control and rates of locoregional recurrence, 
overall and disease-free survival that are similar to EBRT, and quality of life and 
gastrointestinal toxic effects are significantly better with VBT. VBT should be 
the adjuvant treatment of choice for patients with endometrial carcinoma of 
high-intermediate risk. 
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Abstract
Purpose: To determine the long-term outcome and health-related quality of 
life (HRQL) of patients with endometrial carcinoma treated with or without 
pelvic radiotherapy in the Post Operative Radiation Therapy in Endometrial 
Carcinoma 1 (PORTEC-1) trial.
Patients and Methods: Between 1990 and 1997, 714 patients with stage IC 
grade 1 to 2 or IB grade 2 to 3 EC were randomly allocated to pelvic external-
beam radiotherapy (EBRT) or no additional treatment (NAT). HRQL was 
evaluated with the Short Form 36-item (SF-36) questionnaire; subscales from 
the European Organisation for Research and Treatment of Cancer (EORTC) 
PR 25 module for bladder and bowel symptoms, and the CX 24 and OV28 
modules for sexual symptoms; and demographic questions. Analysis was by 
intention-to-treat.
Results: Median follow-up was 13.3 years. The 15-year actuarial locoregional 
recurrence rates were 5.8% for EBRT versus 15.5% for NAT (p<0.001), 
and 15-year overall survival was 52% versus 60% (p=0.14). Of the 351 
patients confirmed to be alive with correct address, 246 (70%) returned the 
questionnaire. Patients treated with EBRT reported significant (p<0.01) and 
clinically relevant higher rates of urinary incontinence, diarrhea and fecal 
leakage, leading to more limitations in daily activities. Increased symptoms 
were reflected by the frequent use of incontinence materials after EBRT (day 
and night use 42.9% vs. 15.2% for NAT, p<0.001). Patients treated with EBRT 
reported lower sores on the SF-36 scales ‘physical functioning’ (p=0.004) and 
‘role-physical functioning’ (p=0.003). 
Conclusions: EBRT for endometrial cancer is associated with long-term urinary 
and bowel symptoms, and lower physical and role-physical functioning, even 15 
years after treatment. Despite its efficacy in reducing locoregional recurrence, 
EBRT should be avoided in patients with low- and intermediate-risk EC.
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Introduction
Four randomized trials have established the role of radiotherapy in 
intermediate risk endometrial carcinoma (EC).1-4 The Post Operative Radiation 
Therapy in Endometrial Carcinoma 1 (PORTEC-1) trial (1990-1997) was among 
the first to randomly compare pelvic external beam radiotherapy (EBRT) to 
no additional treatment (NAT), and it showed that EBRT provides a highly 
significant improvement of local control, but without a survival advantage.3;5 
Furthermore, EBRT was associated with 26% risk of adverse effects, mainly 
grade 1-2 GI toxicity.6 
It was concluded that in view of the absence of survival benefit, EBRT would 
only be justified for patients at relatively high risk of recurrence. The risk 
factors identified were: grade 3, age 60 years or older, and deep myometrial 
invasion. Patients with at least 2 of these 3 risk factors were designated high-
intermediate risk (HIR). Patients with HIR features had 20% risk of locoregional 
recurrence (LRR) after NAT, which was reduced to 5% with EBRT.3;5 For 
these HIR patients the indication for radiotherapy (RT) was maintained after 
PORTEC-1, although EBRT was abandoned for the 50% of patients with stage I 
EC who were designated low-intermediate risk (LIR). 
The PORTEC-2 trial (2002-2006) confirmed that EBRT could safely be substituted 
by vaginal brachytherapy (VBT) for HIR patients.7;8 After a median follow-up 
of 24 months HRQL analysis showed that bowel symptoms such as diarrhea 
and fecal leakage were significantly increased after EBRT, leading to more 
limitation in daily activities and a significant lower level of social functioning.7
Only a few studies9-13 have investigated long-term HRQL of EC survivors, and 
most studies included few patients or had low (<40%) response rates. One 
retrospective study with an adequate response rate (75%) found that EBRT 
was negatively associated with vitality and physical and social well-being, but 
scores were similar to those of an age matched population.14 
The short-term PORTEC-2 findings prompted this analysis of long-term HRQL 
of EC survivors treated in the PORTEC-1 trial 11-18 years ago to investigate 
whether the impact of EBRT would have resolved over time. 
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Patients and Methods
Between 1990 and 1997, 714 patients with stage I EC participating in the 
PORTEC-1 trial were randomly allocated to EBRT or NAT. Information on patient 
selection and treatment have been provided in previous publications3;5;6 
and in the CONSORT diagram (Fig 1.). Surgery consisted of total extrafascial 
hysterectomy and bilateral salpingo–oophorectomy without lymphadenectomy 
(only biopsy of any suspicious lymph nodes). Women of any age with a WHO 
performance score 0 to 2; endometrial adenocarcinoma stage I, grade 1 with 
deep (³50%) myometrial invasion, grade 2 with any invasion, or grade 3 with 
superficial (<50%) invasion were eligible. Informed consent was obtained from 
all patients. Pelvic EBRT was administered with the target volume including the 
parametrial tissues, proximal two–thirds of the vagina, and lymphatic drainage 
regions along the internal iliac vessels up to the promontory. The superior field 
border was at the L5–S1 disc. Total dose was 46 Gy with 2 Gy daily fractions.
The original trial protocol was approved by the Protocol Review Committee of 
the Dutch Cancer Society and by the Ethics Committees of the participating 
centers. Because HRQL investigation was not included in the original protocol, 
ethics approval for the current study was sought and obtained in 2007 from 
the Ethics Committee of Leiden University Medical Center.
Patients were followed in their regional hospitals at least until 7 years after 
treatment. LRRs were confirmed by histology. Patterns of failure were recorded 
by sites of failure: locoregional, distant or both. LRRs were defined as vaginal 
and/or pelvic recurrences. Distant failures included para–aortic lymph node 
metastases, abdominal relapses, liver, lung, and bone metastases and diffuse 
metastatic disease. For this analysis, vital status of all patients considered 
to be alive and disease-free according to the trial database was checked 
with the Dutch Bureau for Genealogy and the governmental local population 
administration (GBA). Patients confirmed to be alive (N=428; January 2008) 
and for whom a correct mailing address was available (N=351) were sent a 
questionnaire to evaluate long-term HRQL. The questionnaire was accompanied 
by a letter written by each patient’s own radiation oncologist explaining the 
background and purpose of the questionnaire. A reminder 
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CONSORT diagram. TAH-BSO: total abdominal hysterectomy and bilateral salpingo–oo-
phorectomy; FIGO: International Federation of Gynecology and Obstetrics; EBRT: exter-
nal beam radiotherapy; NAT: no additional treatment; HRQL: health related quality of 
life. Follow–up and HRQL patient selection  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
715 patients randomly assigned 
(10 were not eligible) 
354 allocated to postoperative 
radiotherapy (EBRT) 
 (4 ineligible) 
339 received EBRT 
 15 did not receive EBRT 
 
361 allocated to no additional 
treatment (NAT) 
 (6 ineligible) 
355 received NAT 
   6 received EBRT 
   1 all records missing 
  
CONSORT diagram. TAH-BSO: total abdominal hysterectomy and bilateral salpingo–
oophorectomy; FIGO: International Federation of Gynecology and Obstetrics; EBRT: 
external beam radiotherapy; NAT: no additional treatment; HRQL: health related 
quality of life.  
Diagnosis and primary treatment 
Initial diagnosis by endometrial tissue biopsy. 
TAH-BSO performed by regional gynaecologist 
Eligibility  
FIGO stage based on surgical and pathological findings 
(diagnosis, typing and grading by regional pathologist). 
167 were alive with correct 
address; sent questionnaire. 
113 returned questionnaire 
For long-term analysis, trial database was frozen March 1, 2009: 48 patients were 
lost to follow-up (41 patients were lost after 5-years follow-up) 
354 Included in intention-to-treat 
analysis of primary and secondary 
end points  
360 Included in intention-to-treat 
analysis of primary and secondary 
end points  
184 were alive with correct 
address; sent questionnaire. 
133 returned questionnaire 
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was sent to patients who had not returned the questionnaire after 3 months. 
Patients who returned the questionnaire were noted alive with the date of 
completing their questionnaire. For patients who did not respond, vital status 
was noted as on the date of GBA confirmation. For patients who had died the 
date of death according to GBA registry was noted and local study coordinators 
were contacted to obtain causes of death. Follow-up information was updated, 
especially for patients with previously known recurrences and those who noted 
events on their questionnaires, by obtaining information from their local 
hospital or general practitioner.
HQRL assessment
General health status was measured with the Dutch version of the Medical 
Outcomes Study Short Form 36-item Health Survey (SF-36).16 The scores 
were standardized on a scale from 0 to 100, with higher scores indicating 
better health status. To compare the health status of survivors with a norm 
population, we used age matched SF-36 scores available from the general 
Dutch female population.17 
Although an EC module has recently been developed by the European 
Organisation for Research and Treatment of Cancer (EORTC) Quality of Life 
Group18, no EC-specific symptom questionnaire was available at the time of 
this study. With approval of the EORTC Quality of Life Group, relevant subscales 
from EORTC modules were combined into a symptom module, similar to that 
used in the PORTEC-2 trial.7 Subscales for bowel and bladder symptoms from 
PR25, for sexual functioning and symptoms from OV28, and additional single 
items from CX24 were used.19-21 For all items Likert-type response scales were 
used, with a 4 point response scale. All subscales and individual item responses 
were linearly converted to 0 to 100 scales. Higher scores for functioning items 
represent a better level of functioning. For the symptom items, a higher score 
reflects a higher level of symptoms and decreased quality of life. 
The impact of cancer (IOC) questionnaire, a specific questionnaire assessing 
the long-term impact of diagnosis and treatment of cancer, was also included 
in the survey.22;23 Since analysis of the IOC did not show differences between 
both treatment groups the results are not further discussed in this paper.
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Statistical methods
All statistical analyses were performed using SPSS, version 17.0 (SPSS, Inc, 
Chicago, IL). Primary endpoints for the study were LRR and overall survival 
(OS). The analysis was by intention to treat. All randomly assigned patients 
were kept in the analysis, including those who did not meet eligibility criteria 
(n=10) or with protocol violations (n=31). The Kaplan–Meier method, logrank 
test and Cox regression analysis were used for time–to–event analyses with 
the following endpoints: LRR and distant metastasis from randomization with 
censoring at date of last contact or death; OS from randomization with failure 
defined as death irrespective of the cause and censoring at the date of last 
contact for patients alive. 
Chi-square statistics or Fisher’s exact test for categorical variables and t test 
for continuous variables (p=0.05 was considered significant) were used to 
compare patient and tumor characteristics of EBRT with NAT and respondents 
with non-respondents. Explanatory comparison of HRQL scores was done 
with the t test; descriptive mean scores are presented in the Tables. To guard 
against false positive results due to multiple testing, a two sided p-value of 
0.01 was considered statistically significant. Differences between the groups 
were considered clinically relevant if they exceeded of 10 points on a scale 
of 100 points.24 Amount of variance explained (R2) by EBRT was analyzed in a 
linear regression model with age, co-morbidity and treatment arm entered in 
this order (Figure 2).
Results
Fifteen-year outcomes
The outcome analysis was done on data frozen on March 1, 2009. Of the 714 
evaluable patients, 48 patients were lost to follow–up (41 of them were lost 
after >5 years of follow-up); they were included in the analysis and censored at 
the date of last follow–up (Fig 1). Median follow–up for patients alive was 13.3 
years (range, 2.8 to 18.5 years). The study groups were well balanced with 
regard to patient and tumor characteristics.3 LRRs at 15-years were 5.8% in the 
RT group and 15.5% in the NAT group (hazard ratio [HR], 3.46; 95% CI 1.93 to 
6.18; logrank test p< 0.0001; Figure 3). Among 50 LRRs in the NAT arm, 37 
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Table 1. Scores on Medical Outcomes Study Short Form 36-item Health Survey (SF-36) 
and EORTC module
EBRT (n=113) NAT (n=133)
mean ± SD mean ± SD p-value* mean ± SD p-value†
SF-36
General Health 58 ± 22 62 ± 17 0.082 67 ± 18 0.311
Physical Function 50 ± 30 62 ± 27 0.004 62 ± 22 0.973
Role-Physical 40 ± 44 59 ± 45 0.003 66 ± 48 0.572
Bodily Pain 62 ± 27 70 ± 23 0.009 70 ± 22 0.999
Vitality 57 ± 30 62 ± 19 0.055 60 ± 17 0.744
Social Functioning 71 ± 29 79 ± 24 0.030 77 ± 24 0.817
Role-emotional 64 ± 47 77 ± 36 0.033 83 ± 24 0.579
Mental Health 71 ± 22 73 ± 18 0.526 81 ± 15 0.135
Physical Component Scale 38 ± 12 42 ± 11 0.014 42 ± 13 0.794
Mental Component Scale 51 ± 12 52 ± 10 0.614 53 ± 9 0.745
Urinary Symptoms
Frequency during the day 47 ± 31 37 ± 31 0.015 42 ± 29 0.601
Frequency during the night 48 ± 27 39 ± 27 0.017 45 ± 34 0.416
Urinary urgency 46 ± 33 32 ± 32 0.001 47 ± 33 0.078
Sleep deprivation because of US 21 ± 27 20 ± 30 0.716 27 ± 36 0.395
Need to remain close to toilet 26 ± 32 10 ± 20 <0.001 18 ± 31 0.392
Incontinence for urine 30 ± 31 16 ± 23 <0.001 27 ± 25 0.090
Dysuria  6 ± 16  6 ± 16 0.810 12 ± 22 0.344
Difficulty with voiding 16 ± 25 11 ± 22 0.121 12 ± 31 0.876
Limitation daily activities US 11 ± 21  4 ± 13 0.006 3 ± 10 0.755
Bowel Symptoms
Limitation daily activities BS 26 ± 34 15 ± 26 0.006 33 ± 36 0.062
Fecal urgency 44 ± 37 25 ± 33 <0.001 64 ± 32 <0.001
Fecal leakage 19 ± 30  8 ± 19 0.002 28 ± 30 0.021
Diarrhea 25 ± 33  10 ± 20 <0.001 21 ± 29 0.165
Rectal blood loss  2 ± 11 1 ± 5 0.416 3 ± 10 0.441
Bloated feeling 18 ± 27 13 ± 23 0.199 9 ± 16 0.505
Flatulence 30 ± 29 26 ± 29 0.240 45 ± 43 0.129
Abdominal cramps 20 ± 28 12 ± 21 0.011 15 ± 26 0.512
Vaginal Symptoms
Vaginal irritation  9 ± 19  9 ± 19 0.993 22 ± 30 0.112
Vaginal discharge  5 ± 15  4 ± 13 0.523 18 ± 31 0.136
Vaginal blood loss 1 ± 5 1 ± 4 0.816 6 ± 13 0.167
Sexual Functioning
Sexual interrest 14 ± 20 10 ± 18 0.212 3 ± 11 0.079
Sexual activity 11 ± 18 8 ± 17 0.393 4 ± 11 0.394
Sexual Symptoms
Sexual enjoyment 36 ± 28 31 ± 27 0.532 17 ± 33 0.255
Vaginal dryness 33 ± 38 26 ± 30 0.384 8 ± 17 0.229
Body Image
Decreased feeling of attractiveness 9 ± 22 5 ± 15 0.093 6 ± 19 0.888
Less feminine 6 ± 18 3 ± 11 0.180 0 ± 0 0.002
Dissatisfied with body 17 ± 27 11 ± 19 0.094 15 ± 23 0.481
Remaining Single Items
Lymphoedema 22 ± 30 20 ± 26 0.590 21 ± 31 0.882
Pain lower back 33 ± 36 24 ± 30 0.054 24 ± 34 0.978
Hot flushes 16 ± 28  9 ± 22 0.060 11 ± 22 0.758
Recurrence after NAT (n=14)
EBRT: external beam pelvic radiotherapy; NAT: no additional treatment; US: urinary symptoms; BS: 
bowel symptoms; EORTC: European Organistation for Research and Treatment of Cancer; SD: stand-
ard deviation. *EBRT vs NAT, there were no differences when excluding patients with a recurrence 
and/or with second cancer.P-values <0.01 are shown in bold, <0.05 in italic. †patients with a recur-
rence after NAT vs patients without a recurrence after NAT     
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(74%) were located in the vagina. The 15-year rate of distant metastases was 
similar in the treatment groups: 9.3% for EBRT and 7.1% for NAT (HR, 0.73; 95% 
CI 0.43 to 1.25; logrank test p=0.25). Overall survival (OS) rate at 15 years was 
52% after EBRT vs. 60% after NAT (HR, 0.84; 95% CI 0.67 to 1.06; logrank test 
p=0.94; Figure 1).
HRQL population and compliance
Quality-of-life questionnaires were sent to 351 patients of whom the correct 
address could be confirmed. In all, 246 patients (70%) responded to the 
questionnaire. Median follow-up of the respondents was 13.3 years (range 
9.4-18.3 years). Nonrespondents were slightly older; all other tumor and 
treatment characteristics were equally balanced between responders and non-
respondents and between the EBRT and NAT groups (Table 2). As expected, 
more respondents in the NAT arm had been diagnosed with a locoregional 
recurrence (N=14) than in the EBRT arm (N=1; p=0.007); there were no 
significant differences in the rates of second cancers or distant metastases 
between respondents in both arms.
Six patients returned the questionnaire only responding to the demographic 
questions. Excluding these six patients, the rate of missing data was 8.7% 
for the SF-36, 5.3% for EORTC items, and 7.4% for IOC. Patients were more 
reluctant in responding to questions about their sexual functioning (activity 
and interest: 29% missing). Among the patients who indicated they were 
sexually active, 91% responded to the items on sexual symptoms. Overall, 
the treatment groups did not differ significantly with regard to questionnaire 
response rates and missing items. 
General health status (SF-36) 
Patients treated with EBRT reported lower scores on all scales of the SF-36 
(Table 1 and Fig 4). These differences were significant and clinically relevant 
for physical functioning (EBRT, 50.5 vs. NAT, 61.6, p=0.004) and role-physical 
(EBRT, 40.3 vs. NAT, 58.5, p=0.003). 
EBRT was a significant explanatory variable for deteriorated score on the 
physical functioning scale (R2 change, 3.0%; p=0.002) and role-physical scale 
(R2 change, 3.1%; p=0.006) after correction for age and co-morbidity (Fig 2).
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Figure 2. Percentage of explained variance in scores for all patients on Short Form 36-item (SF-36) 
Role-Physical (RP) and Physical Functioning (PF). Light-blue represents the percentage of variance in 
the SF-36 score that is explained by the addition of radiotherapy, after correction for age and co-
morbidity (arthropathy and diabetes as significantly explanatory variables).
There were no clinically relevant differences between the SF-scores of either 
of the treatment groups and those of an age-matched Dutch norm population 
(data not shown). 
Symptom items (EORTC modules) 
Compared with patients in the NAT arm, patients treated with EBRT reported 
significantly higher levels of urinary urgency (mean, 45.6 vs. 31.7; p<0.001), 
and of urinary incontinence, a higher need to remain close to the toilet and 
more limitations in daily activities due to bladder symptoms (Table 1 and 
Figure 5). 
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Figure 4. Scores of both treatment groups on Medical Outcomes Study Short Form 36-item Health 
Survey. EBRT, external beam pelvic radiotherapy; NAT, no additional treatment; PF, physical func-
tioning; SF, social functioning; RP, role-physical; RE, role-emotional; MH, mental health; VT, vitality; 
BP, bodily pain; GH, general health; PCS, physical component scale; MCS, mental component scale. * 
p-values ≤0.01, ‡ p-values ≤0.05
As for bowel symptoms, patients treated with EBRT reported increased levels 
of diarrhea, fecal leakage and more limitations in daily activities due to bowel 
symptoms (25.8 vs. 14.6; p=0.006). As a result of these increased symptoms, 
significantly more patients treated with EBRT indicated they used incontinence 
materials. “Day and night usage” was reported by 42.9% of patients treated 
with EBRT, in contrast to 15.2% of patients who had NAT, and “never use” was 
reported by 39.0% vs. 60.0% (overall p<0.001).
There were no significant differences in vaginal symptoms, body image, 
lymph edema, lower back pain or menopausal symptoms between the groups. 
Among the patients that answered questions on their sexual functioning 
and symptoms, 24.3% reported being sexually active, with no differences in 
functioning or symptoms between the EBRT and NAT group.
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Figure 3. Probability of locoregional (vaginal and/or pelvic) relapse (left) and overall survival (right) 
for patients assigned to postoperative radiotherapy (RT) or no additional treatment (no RT). N, num-
ber of patients; F, number of events
HRQL after having survived a locoregional recurrence or a second cancer
Patients who had survived a locoregional recurrence in the NAT-arm (n=14) 
reported significantly more fecal urgency and fecal leakage, with a trend 
towards more urinary urgency and urinary incontinence on the EORTC items, 
compared with the other patients who had NAT, although there were no 
significant differences between the patients who had a recurrence after NAT 
and the EBRT patients (Table 1). 
A sensitivity analysis was undertaken to estimate a possible effect of having 
survived a recurrence or a second cancer on the main HRQL analysis. In this 
analysis, HRQL outcomes were compared between both treatment arms after 
exclusion of patients with a recurrence and/or a second cancer. This analysis 
did not alter the previously described findings.
Discussion 
This analysis of the long-term outcomes of the PORTEC-1 trial confirms the 
highly significant reduction of locoregional recurrence obtained by pelvic 
EBRT, but any survival benefit is absent. EBRT was found to be associated with 
a clinically relevant increase of patient reported long-term bowel and bladder 
symptoms, most notably urinary urgency, incontinence, diarrhea and fecal
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 Table 2. Patient, tumor and treatment characteristics of HRQL respondents.
N % N % p-value
113 46 133 54
Age, mean (range) 75.5 (56-94) 76.0 (59-93) 0.64
≤70 36 32 28 21 0.02
71-80 38 34 68 51
>80 39 34 37 28
Maritial status
Married 54 50 57 44 0.54
Not Married 12 11 14 11
Divorced 6 6 5 4
Widow 35 33 54 41
Partner and living together
Yes, together 42 46 54 45 0.68
Yes, living apart 0 0 1 1
No 50 54 66 54
Children
Yes 81 76 91 72 0.41
No 25 24 36 28
Living with children
Yes 7 8 8 8 0.98
No 77 92 87 92
Comorbidities
Asthma 15 14 9 7 0.08
Heart disease 10 9 7 6 0.26
Hypertension 44 41 66 52 0.10
Stroke 6 6 3 2 0.20
Kidney disease 4 4 1 1 0.12
Diabetes 26 24 23 18 0.26
Malignancy 5 5 2 2 0.17
Arthropathy 48 44 53 41 0.64
Skin disease 3 3 9 7 0.14
Liver disease 1 1 1 1 0.90
Thyroid disease 8 7 6 5 0.38
No comorbidity 17 16 14 11 0.28
Medication for comorbidity
Yes 79 76 97 81 0.59
No 25 24 23 19
Grade
1 90 80 103 77 0.13
2 14 12 10 8
3 9 8 20 15
Myometrial infiltration
<50% 45 40 61 46 0.34
>50% 68 60 72 54
FIGO stage and grade
IB grd 2 40 35 52 39 0.53
IB grd 3 5 4 9 7
IC grd 1 21 19 28 21
IC grd 2 47 42 44 33
Age and demografic characteristics at time of questionnaire; tumor characteristics at time
of randomisation (before central pathology review). 
EBRT: external beam pelvic radiotherapy; NAT: no additional treatment
EBRT NAT
urgency and leakage, compared with surgery alone. These symptoms resulted 
in more limitations of daily activities. The increased symptom rates are reflected 
by the frequent use of incontinence materials after EBRT. Moreover, patients 
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treated with EBRT reported significant and clinically relevant lower physical 
and role-physical functioning (the extent to which role-related activities are 
limited by physical functioning). 
As expected, there were more patients in the NAT group who had survived a 
locoregional recurrence and had undergone salvage therapy.25 These patients 
reported higher levels of fecal urgency and fecal leakage, with a trend towards 
more urinary urgency and urinary incontinence, similar to the patients in the 
EBRT group. 
Randomized controlled trials on adjuvant RT for EC have published acute 
toxicity rates after EBRT of approximately 60% (predominantly grade 1-2 GI), 
although late toxicity rates show a decline to approximately 20% grade 1-2 
symptoms at 5 years and overall 3% grade 3-4 late complications.4;6;26 Patient-
reported toxicity outcomes that providing insight in the impact of low-grade 
toxicity on HRQL are lacking in these trials, and follow-up of reported toxicity 
generally does not exceed 5 years.  
The 2-year HRQL results of the PORTEC-2 trial showed that bowel symptoms 
(diarrhea, fecal leakage) were significantly increased in patients treated with 
EBRT, leading to a higher need to remain close to a toilet and a higher level 
of limitation of daily activities due to bowel problems, which resulted in a 
significant lower level of social functioning for these patients compared with 
patients who received brachytherapy.7 These short-term results reflect the 
long-term HRQL findings of PORTEC-1, suggesting that although the negative 
impact of EBRT decreases in the first 6 months after treatment, there is a long-
term component that persists during subsequent years. The few retrospective 
studies that evaluated long-term patient reported symptoms after pelvic 
radiotherapy confirm the increased rate of prolonged bowel and bladder 
symptoms after radiotherapy.15;27;28  The increase of urinary incontinence and 
fecal leakage after EBRT are suggestive for a decreased pelvic floor function, 
although the exact etiology remains unclear. In addition to the chronic effects 
of radiation to the gastro intestinal epithelium, a recent study in prostate 
cancer patients found that besides dose volume parameters regarding the anal 
sphincter, colonic dismotility resulting in a faster colonic transit and reduced 
rectal compliance contribute to anorectal dysfunction.29;30 
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Figure 5. Patient responses to single-item symptom scores of urinary urgency, urinary incontinence, 
need to remain close to the toilet due to urinary symptoms (US), limitation in daily activities due to 
US and bowel symptoms (BS), diarrhea, fecal urgency and fecal leakage. EBRT, external beam pelvic 
radiotherapy; NAT, no additional treatment.
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Techniques for radiation therapy have improved over the last two decades, 
first the introduction of 3D-conformal RT as a standard, and the more recent 
introduction of intensity-modulated RT (IMRT), with significantly improved 
bowel sparing.31 Approximately 52% of the patients in PORTEC-1 were treated 
with a four-field box technique and 18% with a 3-field technique with some 
form of individualized shielding, although 30% were treated with parallel 
opposing fields. The use of multiple fields was associated with a lower rate of 
late complications compared to parallel opposing fields.6 Standard use of IMRT 
might further decrease the rate of late radiation toxicity. However, even with 
sophisticated IMRT techniques the target volume for gynecological cancers 
remains relatively large, with significant exposure of bowel, rectum, bladder 
and pelvic floor muscles to the full radiation dose. This necessitates research 
into etiology and preventive measures.32;33  
One of the most illustrative results of this long-term HRQL analysis is the 
increased use of incontinence materials among patients treated with EBRT. The 
prevalence of incontinence among the general population of elderly women 
in the Netherlands is 30-40%, with higher rates among women with comorbid 
conditions such as diabetes.34  In our study,  urinary incontinence was reported 
by 38.2% of the patients in the NAT arm, much in line with the general 
population, in contrast to 57.8% of the EBRT patients. After EBRT significantly 
more women used incontinence materials during the day and at night (EBRT, 
42.9% vs. NAT, 15.2%; p<0.001).
Sexual functioning has long been identified as an important part of quality 
of life after cancer treatment.35 In this group of elderly women (median age 
76 years), 24.3% reported to be sexually active, which is in accordance with 
population data.36 There were no differences between both treatment groups 
with regard to sexual functioning or symptoms.
The abandonment of EBRT for the 55% patients who had EC and LIR features 
has been confirmed to be a correct decision. Adverse effects of EBRT have a 
long-term negative impact on HRQL and EBRT can therefore not be justified in 
absence of survival benefit and in presence of effective salvage RT for the very 
few LIR patients who develop locoregional recurrence.
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For patients with HIR features the indication for RT was maintained. For 
these patients the subsequent PORTEC-2 trial has shown that VBT was highly 
effective, with fewer side effects and better HRQL.8 As a result of the PORTEC-2 
trial, HIR patients are currently treated with VBT, thus sparing a further 30% of 
patients with EC the risks and morbidity of EBRT. 
According to the PORTEC-1 and PORTEC-2 data, EBRT has remained indicated 
as adjuvant therapy only for the 15% of patients with EC who have high-risk 
features. Several randomized trials (PORTEC-3, Gynecologic Oncology Group 
[GOG]-249, GOG-258) are currently investigating the role of chemotherapy for 
patients with high-risk EC.
In conclusion, pelvic EBRT for EC is associated with long-term urinary and 
bowel symptoms, leading to lower physical and role-physical functioning, even 
15 years after treatment. Combined with the 15-year outcome results of the 
PORTEC-1 trial, it is clear that EBRT should be avoided in patients with low- and 
intermediate-risk EC. 
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Abstract
Purpose: To evaluate the very long-term results of the randomized Post 
Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-1 trial for 
patients with stage I endometrial carcinoma (EC), focusing on the role of 
prognostic factors for treatment selection and the long-term risk of second 
cancers.
Patients and methods: The PORTEC trial (1990-1997) included 714 patients 
with stage IC grade 1-2 or IB grade 2-3 EC. After surgery, patients were 
randomly allocated to external beam pelvic radiotherapy (EBRT) or no additional 
treatment (NAT). Analysis was by intention-to-treat. 
Results: 426 patients were alive at the date of analysis. The median follow-
up time was 13.3 years. The 15-year actuarial locoregional recurrence (LRR) 
rates were 6% for EBRT vs. 15.5% for NAT (p<0.0001). The 15-year overall 
survival (OS) was 52% vs 60% (p=0.14), and failure-free survival 50% vs 54% 
(p=0.94). For patients with high-intermediate risk criteria (HIR), 15-year OS was 
41% vs. 48% (p=0.51), and 15-year EC-related death 14 vs 13%. Most LRR in the 
NAT group were vaginal recurrences (11% out of 15.5%). The 15-year rates of 
distant metastases were 9% vs 7% (p=0.25). Second primary cancers had been 
diagnosed over 15 years in 19% of all patients; 22% vs 16% for EBRT vs. NAT 
(p=0.10), with observed versus expected ratios of 1.6 (EBRT) and 1.2 (NAT) 
compared with a matched population (p=NS). Multivariate analysis confirmed 
the prognostic significance of grade 3 for LRR (hazard ratio [HR] 3.4, p=0.0003) 
and for EC death (HR 7.3, p<0.0001), of age >60 (HR 3.9, p=0.002 for LRR and 
HR 2.7, p=0.01 for EC death), and myometrial invasion >50% (HR 1.9, p=0.03 
and HR 1.9, p=0.02).
Conclusions: The 15-year outcomes of PORTEC-1 confirm the relevance of 
high-intermediate risk criteria for treatment selection, and a trend for long-
term risk of second cancers. EBRT should be avoided in patients with low- and 
intermediate-risk endometrial carcinoma. 
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Introduction
The Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-1 
trial was one of four randomized trials that have established the role of 
radiotherapy (RT) in intermediate risk endometrial carcinoma (EC), showing 
that pelvic external-beam radiotherapy (EBRT) provides a highly significant 
improvement of local control, but without a survival advantage.1-4 The majority 
(75%) of the locoregional (vaginal and/or pelvic) recurrences were located in 
the vagina, and treatment for vaginal recurrence was effective with 5-year 
survival of 70%, while outcomes after pelvic and distant relapse were poor.5 
EBRT was associated with 26% risk of side effects, mainly grade 1-2 gastro-
intestinal (GI) toxicity.6 
As a result of these trials, the indication for EBRT has become limited to patients 
with a relative high risk of recurrence. Risk factors have been identified: grade 
3; age 60 years or older; and deep myometrial invasion. Patients with at least 
2 of these 3 risk factors have been designated high-intermediate risk (HIR). 
Patients with HIR features have a 20% risk of locoregional recurrence (LRR) 
after no additional treatment (NAT), which is reduced to 5% with EBRT. For 
these HIR-patients the indication for radiotherapy has been maintained after 
PORTEC-1, and EBRT was abandoned for the 55% patients with stage I EC who 
were designated as low-intermediate risk (LIR). 
In the Gynecology Oncology Group (GOG) 99 trial, which included patients 
with stage I-IIA EC after surgery which including lymphadenectomy (LA) with 
negative nodes, a similar HIR group was identified.4 EBRT resulted in a hazard 
reduction of 58% both for LIR and HIR, but this reduction was clinically relevant 
only in the HIR group. The 4-year isolated local relapse rate was reduced from 
13% to 5% in the HIR group.4 These results were essentially the same as those 
from PORTEC-1, showing that both with and without LA, the risk factors grade 
3, deep invasion, older age, and lymphovascular space invasion are associated 
with local recurrence. 
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The subsequent randomized PORTEC-2 trial for International Federation of 
Gynecology and Obstetrics (FIGO) 1988 stage I-IIA EC patients with HIR factors 
confirmed that EBRT could safely be substituted by vaginal brachytherapy 
(VBT), with less toxicity and better quality of life.7,8 However, for high-risk EC 
-FIGO 20099 stages IB grade 3, II, III; or stages IB-III with serous/clear cell 
histology, EBRT continues to be the most effective adjuvant treatment for 
pelvic control.10-12  The present analysis was done to evaluate very long-term 
outcomes of the PORTEC-1 trial, to investigate whether patients with HIR EC 
benefited more from EBRT than those without HIR factors, and to analyze the 
long-term risk of second cancers.
Patients and Methods 
Patient selection and treatment
The PORTEC-1 trial was a multicenter trial accruing in 1990-1997. Details on 
patient evaluation and treatment have been described in previous publications.3,6 
Surgery consisted of total extrafascial hysterectomy and bilateral salpingo–
oophorectomy without LA (only biopsy of any suspicious lymph nodes). 
Women of any age, World Health Organisation performance score 0-2, with 
endometrial adenocarcinoma stage I, grade 1 with deep (³50%) myometrial 
invasion, grade 2 with any invasion, or grade 3 with superficial (<50%) invasion 
were eligible. The protocol was approved by the Protocol Review Committee of 
the Dutch Cancer Society and by the Ethics Committees of the Daniel den Hoed 
Cancer Center and of the participating centers.
Radiation therapy
Pelvic EBRT was administered with a target volume that included the parametrial 
tissues, the proximal two–thirds of the vagina, and lymphatic drainage regions 
along the internal iliac vessels up to the promontory. The superior field border 
was at the L5–S1 disc. Total dose was 46 Gy in 2-Gy daily fractions. The PORTEC 
trial was done before 3-D conformal treatment planning techniques had been 
introduced. Radiation was delivered by AP-PA parallel opposed fields (30%), 
three–field (18%) or four–field techniques (52%) with calculation of the dose 
distribution on the central axis and specification at isocentre or midplane.6
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Pathology review
Central pathology review was done after patient inclusion.13 Histopathological 
slides of 567 patients (79%) were obtained. The diagnosis of endometrial 
carcinoma was confirmed in all patients. The histological grade was determined 
at review according to the FIGO 1988 grading criteria.14,15 Systematic grading 
according to these criteria led to the assignment of grade 1 to significantly 
more tumors: 60% of the tumors were grade 1, 32% grade 2, and 8% were 
grade 3, in contrast to the initial assignment of 21% grade 1, 68% grade 2 and 
11% grade 3. The outcomes in patients with grade 1 or 2 tumors were similar, 
in contrast to grade 3.13 In the present analysis, histological grades determined 
at review have been used. In cases without pathology review the grade was 
assigned ‘not done’. For determination of HIR and LIR groups, patients with 
review grade ‘not done’ were assigned grade 2. 
Follow–up 
Patients were followed in their regional hospitals until 7 years after treatment. 
The LRRs were confirmed by histology. LRR was defined as vaginal and/or pelvic 
recurrences. Distant failures included para–aortic lymph node metastases, 
abdominal relapses, liver, lung, and bone metastases and diffuse metastatic 
disease. For the present analysis, vital status of all patients considered to 
be alive and disease-free according to the trial database was checked with 
the Dutch Bureau for Genealogy and the Governmental local population 
administration (GBA). The analysis of long-term HRQL has been addressed in 
a separate publication.16 The current analysis was done to evaluate prognostic 
factors, to establish the role of HIR factors for treatment selection, and to 
evaluate the long-term risk of second cancers after EBRT.
Statistical methods
The primary endpoints for the study were LRR and overall survival (OS). 
Secondary endpoints were morbidity and survival after relapse. 
The analysis was by intention-to-treat. All randomized patients were kept in 
the analysis, including those who did not meet eligibility criteria (n=10) and 
those with protocol violations (n=31). The Kaplan–Meier method, log-rank 
test and Cox regression analysis were used for time–to–event analyses.3,5 
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Competing risk probabilities of failure were calculated with the following 
competing risks of first failure type: LRR, distant metastasis and death without 
relapse. If metastases were detected together with LRR, the failure type was 
metastases. Competing risk analysis was also applied to calculate probabilities 
of risk of death split by cause of death, and LRR split by type (vaginal or pelvic). 
Combined vaginal and pelvic recurrences were scored as pelvic recurrence. 
The observed numbers of secondary cancers and deaths were compared with 
the expected numbers based on Dutch sex and age specific incidence rates of 
cancer and death16 using the subject–years method.
Prognostic factors considered in the analysis were: age, depth of myometrial 
invasion, and (review) grade. Age (at randomization) was classified a priori in 
three groups (<60, 60–70 and >70 years). Differences between the treatment 
groups in risk of relapse or death were tested with the log-rank test without 
adjustment for prognostic factors, and with the likelihood ratio test in Cox 
regression analysis with adjustment. All reported p–values are based on two–
sided tests with p–values <0.05 considered statistically significant. 
Results
Outcomes
A total of 715 eligible patients with stage I EC were enrolled; 354 patients were 
randomly assigned to EBRT, and 361 to no additional treatment (NAT). One 
patient was excluded because all information was irretrievably missing. Thus, 
714 patients were evaluated. The study groups were well balanced with regard 
to patient and tumor characteristics (Table 1). 
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Table 1: Patient characteristics after central pathology review  
Characteristic  
  
RT  
(n  =  354)  
NAT  
(n  =  360)  
   number  of  patients  (%)  
Age  (years)  
<60  
60–70  
>70  
mean  (sd)  
range  
  
93    (26)  
136    (38)  
125    (35)  
66.3  (sd  9)  
41–85  
  
108    (30)  
134    (37)  
118    (33)  
          65.7  (sd  9)  
43–90  
Myometrial  invasion  
<  50%  
≥  50%  
  
138    (39)  
216    (61)  
  
156    (43)  
204    (57)  
Revised  histologic  grade      
1  
2  
3  
nd*  
  
198    (56)  
49    (14)  
32    (09)  
75  (21)  
  
197    (55)  
39    (11)  
54    (15)  
70  (19)  
Revised  FIGO  1988  stage  
IB  grade  1#  
IB  grade  2**  
IB  grade  3  
IC  grade  1  
IC  grade  2**  
IC  grade  3  
  
60    (17)  
56    (16)  
22    (06)  
138    (39)  
68    (19)  
10    (03)  
  
74    (21)  
47    (13)  
35    (10)  
123    (34)  
62    (17)  
19    (05)  
Vascular  space  invasion  
present  
  
22    (06)  
  
19    (05)  
HIR  
no  
yes  
  
170    (48)  
184    (52)  
  
178    (49)  
182    (51)  
*nd  =  no  review  grade;  #  at  review  ineligible;  **  includes  grade  nd;    
RT=  radiotherapy;  NAT=  no  additional  treatment;  sd=  standard  deviation;    
HIR  =  high-­‐intermediate  risk    
The present analysis was done on data frozen on March 1, 2009. Forty-eight 
patients were lost to follow–up (41 of whom were lost after >5 years’ follow-
up); they were included in the analysis and censored at the date of last follow–
up. Median follow–up for patients alive was 13.3 years (range, 2.8-18.5 years). 
Table 2 shows the 15-year rates of LRR, metastases, OS and failure-free survival 
(FFS) by treatment group. The 15–year LRR rates were 5.8% in the RT group 
and 15.5% in the NAT group (hazard ratio [HR] for NAT 3.46; 95% CI 1.93-6.18; 
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log-rank test p< 0.0001). For comparison, the 5-year, 10-year and 15-year LLR 
rates were 4.2% vs. 13.7%; 4.6% vs. 14.3% and 5.8% vs. 15.5%. Among 50 
LRR in the NAT arm, 37 (74%) were located in the vagina. The 15-year rate of 
distant metastases was similar in the treatment groups: 9.3% for EBRT and 
7.1% for NAT (p=0.25). In both treatment arms some very late recurrences were 
diagnosed (Fig 1). All late recurrences were histologically confirmed, showing 
adenocarcinoma similar to the previous endometrial carcinoma. In one patient 
in the RT group, a large (6 cm) abdominal recurrence was diagnosed 16 years 
after treatment. She was started on hormonal therapy and is currently alive 
with partial remission. In two patients in the NAT group, vaginal recurrence and 
vaginal and pelvic recurrences were found after 9 and 14 years, respectively. 
These were treated with EBRT, and are currently without evidence of disease.
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Table 2: Long-term outcomes at 15 years (actuarial probabilities) by treatment arm
Table  2:  Long-­‐term  outcomes  at  15  years  (actuarial  probabilities)  by  treatment  arm  
Outcome   RT  
(n  =  354)  
NAT  
(n  =  360)  
   Events   15-­‐yr  %  (SE)   Events   15-­‐yr  %  (SE)  
Survival    
Alive  
Death  EC  
Death  other  causes  
  
202  
      37  
115  
  
  
52%    (3)  
11%    (2)  
38%    (3)  
  
224  
    30  
106  
  
60%    (3)  
    8%    (1)  
31%    (3)  
Survival  -­‐  HIR  
Alive  
Death  EC  
Death  other  causes  
  
85  
25  
74  
  
  
41%    (4)  
14%    (3)  
45%    (4)  
  
93  
24  
65  
  
48%    (4)  
13%    (3)  
39%    (4)  
Recurrence  
Vaginal  
Pelvic  
Distant  
    
      8  
      7  
32  
  
2.5%    (0.6)  
3.4%    (1.6)  
9.3%    (1.6)  
  
37  
13  
24  
  
11.0%    (1.3)  
    4.5%    (1.4)  
    7.1%    (1.4)  
  
First  failure  
No  failure  
Death  NED  
Vaginal  recurrence  
Pelvic  recurrence  
Distant  recurrence  
  
  
  
198  
115  
        8  
        7      
    26  
  
  
50.1%    (3.3)  
38.1%    (3.2)  
      2.3%    (0.8)  
      2.5%    (1.0)      
      7.1%    (1.4)  
  
  
  
203  
    94  
    37  
    13  
    13  
  
  
54.4%    (3.0)  
27.7%    (3.0)  
10.3%    (1.6)  
    4.0%    (1.1)    
    3.6%    (1.0)  
  
Second  cancer    
Breast  
GI  
Other  
  
11  
19  
25  
  
    4.8%    (1.6)  
    6.2%    (1.4)  
10.6%    (2.3)  
  
18  
10  
14  
  
  6.6%    (1.6)  
    3.2%    (1.0)  
    6.0%    (1.7)  
RT=  radiotherapy;  NAT=  no  additional  treatment;  EC=  endometrial  carcinoma;    
NED=no  evidence  of  disease;  HIR=  high-­‐intermediate  risk;  GI  =  gastro-­‐intestinal;    
se=  standard  error  
 
A total of 288 patients had died: 67 due to EC (13 pelvic disease; 47 metastases; 
1 related to primary treatment; 3 related to treatment of metastases; and 3 of 
unknown cause, but with previous diagnosis of relapse); and 221 due to other 
causes (51 second cancers; 165 intercurrent diseases; 5 unknown). The rates 
of death were compared with those of an age-matched population. Observed 
versus expected ratios were 1.14 for the total group; 1.22 in the EBRT group 
vs. 1.06 in the NAT group (p=N.S.).
In Fig. 2 the FFS rates by treatment group are shown for all patients and for 
those with HIR features. The FFS at 15 years was 50 vs. 54% (p=0.94), and 
among HIR patients FFS was nonsignificantly slightly higher in the EBRT group.
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Fig. 1. Probability of locoregional (vaginal and/or pelvic) relapse for patients assigned to postopera-
tive radiotherapy (RT) or no additional treatment (NAT) for the total group (left) and for patients with 
high-intermediate-risk (HIR) features (right).
Survival after recurrence 
The 5- and 10-year survival rates after recurrence were significantly better in 
the NAT group: 48% (NAT) vs. 12% (EBRT) at 5 years, and 35% vs. 7% at 10 years 
(p<0.01). Survival rates after vaginal recurrence were 70% (NAT) vs. 38% (EBRT) 
at 5 years, and 51% vs. 25% at 10 years. Estimated 10-year survival rates for 
NAT vs EBRT were 18% vs 0% for pelvic relapse; and 8% vs 4% for distant relapse. 
Three patients with distant metastases were still alive and progression-free 
after 14, 12 and 10 years: two after surgical excision of a solitary pulmonary 
metastasis and a solitary omental metastasis, respectively; the third after 
salvage RT for vaginal recurrence and complete prolonged response on 
hormonal treatment of histologically verified pulmonary metastasis which had 
occurred 3 years after vaginal recurrence.
Second cancers
Second cancers were diagnosed in 97 patients, with 15-year rates of 22% in 
the EBRT group vs. 16% in the NAT group (p=0.10). The incidence rates were 
compared with those of an age-and sex-matched population: the observed vs. 
expected ratios were 1.40 for the total group; 1.62 for EBRT and 1.20 for NAT 
(p=N.S.). 
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Fig. 2. Probability of failure-free survival for patients assigned to postoperative radiotherapy (RT) or 
no additional treatment (NAT) for the total group (left) and for patients with high-intermediate-risk 
(HIR) features (right).
Second cancer types were breast cancer (6% at 15 years), cancers of the GI 
tract (5%), and any other types (8%). The predominant cancer type among EBRT 
patients was GI cancer (6.2% vs. 3.2% among NAT patients), and breast cancer 
was most frequent in the NAT group (6.6% vs. 4.8% in the EBRT group). These 
differences did not reach statistical significance (p=0.10).
Prognostic factors 
Table 3 shows multivariate analysis of prognostic factors for LRR and EC-related 
death. The HR for LRR, adjusted for major prognostic factors, were 3.46 for 
NAT compared to EBRT (p<0.0001), 3.35 for review grade 3 (p<0.001) and 
1.66 for grade 2 (p=0.19) as compared to grade 1; and 3.90 for age ³60 years 
compared to <60 years (p=0.0017). Figure 3 shows OS split by prognostic 
factors. The risk of EC–related death was significantly higher for patients ³60 
years and especially for patients with grade 3 tumors (HR 7.3, p<0.0001). After 
adjustment for age, grade and invasion there was no evidence of benefit of 
EBRT for OS or EC-specific survival. 
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Discussion
The recent publication of the results of the ASTEC trial included a meta-
analysis of the ASTEC, GOG#99 and PORTEC-1 data, which excluded a survival 
benefit of EBRT in intermediate-risk endometrial cancer of more than 3%.2 
Moreover, the results of previous meta-analyses suggested that EBRT may even 
be harmful for patients with features of low to intermediate risk, given that 
these patients have a low risk of recurrence after surgery alone, and EBRT adds 
toxicity and risks without improving survival.17,18 This was confirmed in the 
current analysis, with results showing a trend for lower OS after EBRT, whereas 
FFS curves overlapped. However, for patients with HIR features the OS rates 
were similar, and FFS was slightly (but nonsignificantly) higher after EBRT. 
The abandonment of EBRT for patients with LIR features has been confirmed 
to be a correct decision. EBRT causes side effects6, and has been shown in 
our recent analysis to have a very long-term negative impact on HRQL.16 
Moreover, we found a trend towards more second cancers among EBRT 
patients, especially cancers of the GI tract. EBRT can therefore not be justified 
in absence of survival benefit, and in presence of effective salvage RT for the 
very few LIR patients who develop locoregional recurrence. Although current 
sophisticated EBRT planning techniques (intensity-modulated RT) may be 
expected to have lower GI toxicity rates19, the irradiated volume in the lower 
pelvis remains large, and the long-term risks of pelvic floor dysfunction, GI 
symptoms, and second cancers cannot be disregarded.
For patients with HIR features the indication for RT was maintained, because 
their 5-year risk of LRR risk was 20%, which was considered sufficiently high 
to justify adjuvant treatment significantly improving local control. For these 
patients the subsequent PORTEC-2 trial showed that vaginal brachytherapy 
(VBT) was highly effective, with fewer side effects and better HRQL than after 
EBRT.8 Patients who received VBT did not have the increased bowel symptoms 
reported by EBRT patients, most notably diarrhea and urgency, resulting in 
higher need to remain close to a toilet.7 As a result of the PORTEC-2 trial, 
patients with HIR EC are currently treated with VBT. 
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Table 3. Cox regression analysis
  
  
  
  
Locoregional  relapse  
  
  
Death  related  to  endometrial  cancer  
Variable   HR   95%  CI   p–value   HR   95%  CI   p–value  
  
NAT  arm    
  
3.46  
  
1.93  -­‐  6.18  
  
<0.0001  
  
  
0.71  
  
0.43  -­‐  1.16  
  
0.17  
  
  
Age    ≥   60  
  
  
3.90  
  
  
1.67  -­‐  9.11  
  
  
0.0017  
  
  
2.66  
  
  
1.26  -­‐  5.61  
  
0.010  
  
  
Review  grade  2  
Review  grade  3  
  
1.66  
3.35  
0.78  -­‐  3.52  
1.75  -­‐  6.41  
0.19  
0.0003  
2.20  
7.30  
1.07  -­‐  4.51  
3.94  -­‐  13.53  
0.032  
<0.0001  
  
Invasion  >50%  
  
  
1.86  
  
1.07  -­‐  3.24  
  
0.027  
  
1.86  
  
1.09  -­‐  3.17  
  
0.024  
  
HIR  patients  
  
NAT  arm  
  
Review  grade  2  
Review  grade  3  
  
  
  
3.31  
  
1.53  
2.15  
  
  
  
1.73  -­‐  6.35  
  
0.62  -­‐  3.79  
1.10  -­‐  4.21  
  
  
0.0003  
  
0.35  
0.026  
  
  
0.87  
  
1.93  
4.31  
  
  
0.50  -­‐  1.50  
  
0.81  -­‐  4.60  
2.28  -­‐  8.12  
  
  
0.61  
  
0.14  
<0.0001  
NAT=  no  additional  treatment;  CI=  confidence  interval;  HIR=  high-­‐intermediate  risk  
  
External-beam RT has remained indicated only for the 15% of EC patients with 
high-risk features (grade 3 with deep invasion and/or lymph-vascular space 
invasion (LVSI), serous or clear cell histology) or advanced stages. Omitting 
EBRT for those patients has been shown to result in significantly lower pelvic 
control rates and may even affect survival.10,12 The use of high-risk and HIR 
factors for decisions on adjuvant treatment underlines the critical importance 
of complete and reproducible pathology evaluation in the treatment of EC 
patients. 
Adjuvant chemotherapy might be considered in view of the higher risk of distant 
metastases among patients with high-risk EC. Although two randomized trials 
comparing chemotherapy alone to pelvic EBRT alone did not show differences 
in OS, progression-free survival, or relapse rates20,21, the Nordic Society of 
Gynaecological Oncology / European Organisation fo Research and Treatment 
of Cancer (NSGO9501/EORTC55991) trial comparing EBRT alone with EBRT 
preceded or followed by chemotherapy showed a 7% increase in progression-
free survival (p=0.03), and a trend for improved overall survival (p=0.08) in 
the combined arm.22 The current international randomized PORTEC-3 trial for 
patients with high-risk and advanced-stage EC investigates survival benefit, 
toxicities, and impact on quality of life of EBRT +chemotherapy compared 
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with EBRT alone. Both treatments are started early (2 cycles of cisplatin during 
EBRT and 4 cycles of carboplatin and paclitaxel after the completion of EBRT), 
which obviates the need to decide which treatment should be given first.23 
Two current ongoing GOG trials (GOG 249 and 258) investigate the role of 
chemotherapy for early-stage HIR and high-risk EC (three cycles of carboplatin 
and paclitaxel and VBT vs. EBRT), and advanced stage EC (EBRT plus two cycles 
of cisplatin followed by four cycles carboplatin and paclitaxel vs. six cycles of 
carboplatin and paclitaxel). 
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Fig. 3. Probability of overall survival according to prognostic factors: depth of myometrial invasion 
(<50% vs. $50%, top left), patient age (<60 vs. 60–70 vs. >70 years, top right), revised International 
Federation of Gynecology and Obstetrics (FIGO) Grade (1 vs. 2 vs. 3 vs. ND grade, bottom left), and 
presence vs. absence of high-intermediate-risk (HIR)features (bottom right).
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PORTEC-1 and 2, GOG 99, and ASTEC trials2-4,8 have resulted in a 
significant reduction of the treatment burden for a large number of patients 
with endometrial carcinoma, abandoning EBRT for 85% of EC patients, and 
introducing VBT as adjuvant treatment for the 30% EC patients with HIR features. 
It should be noted that the favorable results in the control arm of PORTEC-1 
and VBT arm of PORTEC-2 were obtained in the absence of LA, whereas only 
30% of patients in the ASTEC trial underwent LA. These results were very 
similar to those of GOG 993, which required LA and only included patients who 
were node-negative. Two recent large randomized trials investigated the role 
of LA and did not find survival benefit or any differences in patterns and sites 
of relapse.24,25 The Italian trial24, which had median node count of 23 to 30 in 
the LA arm, showed identical rates of vaginal (2.6% for LA vs 2.4% for no-LA), 
lymph node recurrence (1.5% vs 1.6%) and intraperitoneal (3% vs 2.8%) relapse 
in both arms. The abandonment of EBRT for 85% of EC patients should thus not 
encourage increased use of LA to identify the 9% of patients with microscopic 
node metastases. This will not affect their survival and add morbidity: 18.6% 
vs. 8.8% risk of late complications for LA vs no LA, most notably 10.2% vs. 1.6% 
lymphedema.24,26 Lymphedema has been shown to affect HRQL, and women 
with LA reported more clinically relevant edema symptoms (25.6% vs. 16.9%, 
p<0.001).27 Powerful prognostic factors, especially grade 3 (with HR of 7.3 for 
EC death in the current analysis), and lymphovascular space invasion28,29 are 
available at histologic examination and are associated with increased risk of 
distant spread. These factors can be used to select patients who might benefit 
from systemic treatments reaching areas that neither radiation nor the surgical 
knife can effectively treat. 
In conclusion, 15-year results of the PORTEC-1 trial have confirmed the highly 
significant improvement of local control obtained by EBRT, but an absence 
of survival benefit. HIR features were shown to be useful for selection for RT 
(currently VBT). In view of the long-term negative impact of EBRT, the absence 
of survival benefit and presence of effective salvage treatment, the rationale 
for the abandonment of EBRT for intermediate-risk EC has been confirmed.
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Abstract 
Background: The PORTEC-2 trial showed efficacy and reduced side-effects of 
vaginal brachytherapy (VBT) compared with external beam pelvic radiotherapy 
(EBRT) for patients with high-intermediate risk endometrial cancer. The current 
analysis was done to evaluate long-term health related quality of life (HRQL), 
and compare HRQL of patients to an age-matched norm population.
Methods: Patients were randomly allocated to EBRT (n=214) or VBT (n=213). 
HRQL was assessed using EORTC QLQ-C30 and subscales from PR25 and OV28 
(bladder, bowel, sexual symptoms); and compared to norm data. 
Findings: Median follow-up was 65 months; 348 (81%) patients were evaluable 
for HRQL (EBRT n=166, VBT n=182). At baseline, patient functioning was 
at lowest level, increasing during and after radiotherapy to reach a plateau 
after 12 months, within range of scores of the norm population. VBT patients 
reported better social functioning (p=0.005) and lower symptom scores for 
diarrhoea, faecal leakage, need to stay close to a toilet, and limitation in daily 
activities due to bowel symptoms (p≤0.001), compared to EBRT. There were no 
differences in sexual functioning or symptoms between the treatment groups; 
however, sexual functioning was lower and sexual symptoms more frequent in 
both treatment groups compared to the norm population. 
Interpretation: Patients who received EBRT reported clinically relevant higher 
levels of bowel symptoms and related limitations in daily activities with lower 
social functioning, 5 years after treatment. VBT provides a better HRQL, which 
remained similar to that of an age-matched norm population, except for sexual 
symptoms which were more frequent in both treatment groups.
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Introduction
Endometrial carcinoma (EC) is the most common gynaecological malignancy 
among postmenopausal women in Western countries.1 Surgery, consisting 
of total abdominal (or laparoscopic) hysterectomy and bilateral salpingo-
oophorectomy (TAH-BSO) is the cornerstone of treatment. 
Randomised trials have shown that pelvic external beam radiotherapy (EBRT) 
significantly reduced locoregional relapse, but without survival benefit, and at 
the cost of more (predominantly mild) gastro-intestinal toxicity.2-6 Risk factors 
for locoregional recurrence were tumour grade 3, outer 50% myometrial 
invasion, age over 60 years, and lymph-vascular space invasion. Patients with 
these high-intermediate risk features had the largest benefit from EBRT (20% 
locoregional relapse without radiotherapy vs. 5% with EBRT). As most (75%) 
locoregional relapses were located in the vagina, the randomised PORTEC-2 
trial was initiated to investigate if vaginal brachytherapy (VBT) would be equally 
effective for vaginal control, while reducing treatment toxicity and improving 
health related quality of life (HRQL) as compared to EBRT. Final results showed 
that VBT was indeed very effective in preventing vaginal recurrence with 
an estimated vaginal recurrence rate of 2% at 5 years, similar to the results 
obtained with EBRT.7 Short-term HRQL results up to two years after treatment 
showed that rates of bowel symptoms such as diarrhoea and faecal leakage 
were significantly lower among women treated with VBT, with better social 
functioning compared to women treated with EBRT.8 Symptom levels among 
VBT patients were very low. These results prompted adoption of VBT as 
standard of care for patients with high-intermediate risk EC in the Netherlands.
Analysis of HRQL among PORTEC-1 patients 15 years after treatment showed 
that EBRT is associated with long-lasting symptoms impacting on patient 
functioning.9 This finding underscores the importance of longitudinal HRQL 
analysis and reporting of late outcomes. 
The current analysis was done to evaluate 5-year HRQL after EBRT and VBT of 
PORTEC-2 trial patients and compare their HRQL with that of an age-matched 
Dutch norm population. 
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Patients and Methods
Patient selection, treatment and study design of the PORTEC-2 trial
The multicenter PORTEC-2 trial randomly allocated EC patients with high-
intermediate risk features to EBRT or VBT. Details on patient selection, 
treatment and HRQL have been described in previous publications.7,8 In short, 
surgery consisted of TAH-BSO; clinically suspicious pelvic and/or periaortic 
lymph nodes were removed, but no routine lymphadenectomy was performed. 
FIGO 1988 staging was assigned on the basis of surgical and pathological 
findings.10 Patients were eligible if they had one of the following combinations 
of age, grade and FIGO stage: (1) Age ≥60 years and stage 1C grade 1 or 
2, or stage 1B grade 3; (2) stage 2A, any age (except grade 3 with outer 
50% myometrial invasion). Written informed consent was obtained from all 
patients. The protocol was approved by the Dutch Cancer Society and the 
Ethics Committees of participating centres.
EBRT was given to a total dose of 46 Gy in 2 Gy daily fractions, 5 fractions/
week. VBT was delivered to the upper half of the vagina using a vaginal cylinder. 
Brachytherapy dose schedules were used, equivalent to 45-50 Gy to the vaginal 
mucosa: high-dose-rate (90% of patients) 21 Gy at 5 mm depth in 3 fractions 
of 7 Gy over 2 weeks; low-dose-rate (10%) 30 Gy at 5 mm depth, in one session 
at 50-70 cGy/hr.
The primary endpoint was 5-year vaginal relapse (VR) as cumulative incidence, 
accounting for death as competing risk.11 Secondary endpoints were HRQL, 
treatment related toxicity, pelvic lymph node and distant relapse and overall 
survival. 
Quality-of-Life Assessment
Cancer-specific HRQL was measured with the EORTC (European Organization 
for Research and Treatment of Cancer) Core questionnaire (QLQ-C30 version 
3.0).12 No endometrial cancer-specific symptom questionnaire was available at 
the time; with approval of the EORTC Quality of Life Group, relevant subscales 
from existing published EORTC modules were combined into a symptom 
module (subscales for bowel and bladder symptoms from PR25 and subscale 
for sexual functioning and symptoms from OV28).13,14 For all items Likert-type 
response scales were used, with response scales ranging from 1-4 points for 
all items except for items 29 and 30 (response scale 1-7). All subscales and 
individual item responses were linearly converted to 0 to 100 scales. A higher 
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score for a functional and global quality of life scale represents a better level of 
functioning. For the symptom scales and items, a higher score reflects a higher 
level of symptoms and decreased HRQL. 
Baseline HRQL questionnaires were handed out at first consultation with the 
radiation oncologist 3-4 weeks after surgery, and were returned prior to RT. 
The end-of-treatment HRQL questionnaire was completed 2-4 weeks after RT. 
With consent, subsequent questionnaires were sent directly to the patient 
home address at 6, 12, 18, 24, 36, 48 and 60 months from randomization. 
Patients were considered evaluable for the HRQL assessment if they had returned 
the baseline questionnaire and at least one of the follow-up questionnaires 
(‘responders’).
Statistical methods
All statistical analyses were performed using SPSS, version 17.0 (SPSS, Inc, 
Chicago, IL). Chi-square statistics or Fisher’s exact test for categorical variables 
and t test for continuous variables were used to compare patient and tumour 
characteristics (significance p-value < 0.05). 
HRQL analysis was done according to the guidelines provided by the EORTC 
Quality of life Group.15 Descriptive median scores are presented in the 
tables. Baseline scores of both treatment groups were compared with a t 
test, or Armitage trend test for single items. In order to exclude a treatment 
effect on baseline scores, baseline forms completed later than the first day 
of radiotherapy were excluded for this comparison. To obtain estimates of 
the EORTC QLQ-C30, PR25 and OV28 subscales at each of the fixed time 
points, a linear mixed model was used with patient as random effect and time 
(categorical), randomization and their interaction as fixed effects. Single items 
were analyzed using (ordinal) logistic regression with random effects. The 
difference in HRQL between the two treatment groups was tested by Wald’s 
test in the linear or ordinal logistic mixed model (p-randomization), excluding 
the baseline value. The same test was applied to look for significant changes 
of QOL scores over time (p-time), and score changes over time were compared 
between both treatment groups (p-time by randomization), including the 
baseline value. Age-matched Dutch norm population means16 were compared 
with both treatment groups at each time point using the t test. To guard 
against false positive results due to multiple testing, a two sided p-value of 
0.01 was considered statistically significant.
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Recently published guidelines on the interpretation of clinical relevant 
changes of EORTC QLQ-C30 scores were applied (trivial, small, medium or 
large differences per scale).17 For scales not included in the guideline, changes 
were evaluated according to Osoba, who found for the EORTC QLQ-C30 that 
patients valued a change of 5-10% as ‘little’, 10-20% as ‘moderate’ and more 
than 20% as ‘very much’ difference.18  
Results
Study population and compliance
The PORTEC-2 trial accrued 427 patients between 2002 and 2006; 214 patients 
were allocated to EBRT and 213 to VBT. Baseline questionnaires and at least 
one follow-up questionnaire were received from 348 patients (81%), hereafter 
referred to as ‘responders’. At the time of analysis (June 30th 2011), 268 of the 
348 responders were alive, disease free and had reached the 5-year follow-
up time point, of whom 206 (76%) returned the 5-year questionnaire (Web 
Appendix A). The median follow-up was 65 months (range 18-106 months), 
both for the whole trial population and for the responders.
All returned questionnaires were complete for all items of the QLQ-C30 in 82% 
of the responders, and for PR25 items in 92%; when allowing up to two missing 
items, these rates were 95% and 97%. In contrast, the sexual functioning 
subscale was complete for all items in 65%, and the sexual symptom subscale 
could be calculated for 81% of responders who were sexually active. The 
treatment groups did not differ with regard to questionnaire response rates 
and missing items. Although there were more EBRT patients among the non-
responders (51 EBRT vs. 31 VBT patients p=0.02), patient characteristics were 
equally balanced between the EBRT and VBT group and between responders 
and non-responders (Table 1). 
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Tabel 1. Patient characteristics of responders and non-responders
Responders (n=348) Non-responders (n=79)
EBRT (n=166) VBT (n=182) No. of 
Patients %
p-Value*
No. of Patients % No. of Patients % p-Value‡
Age, years
   mean 69.5 70.1 0.45 71,3 0.16
   range 52-88 46-86 52-89
   <60 years 7 4.2 6 3.3 0.29 3 3.8 0.33
   ≥60 years 159 95.8 176 96.7 75 96.2
FIGO-stage 0.73 0.99
   1B 11 6.1 13 7.2 8 9.2
   1C 137 82.9 147 80.7 58 75
   2A 18 11 22 12.2 9 11.8
Histologic 
Grade 0.83 0.42
   Grade 1 77 46.4 89 48.9 36 46.1
   Grade 2 78 47 79 43.4 34 43.4
   Grade 3 11 6.6 14 7.7 9 10.5
KPS 0.18 0.10
   0 118 71.1 119 65.4 61 78.2
   1 47 28.3 59 32.4 16 20.5
   2 1 0.6 4 2.2 1 1.3
Comorbidity
   IBD 2 1.2 2 1.1 0.93 2 2.6 0.34
   Diabetes 19 11.4 31 17 0.14 12 15.4 0.82
   Hypertension 61 37 63 34.8 0.68 26 33.3 0.68
   Cardiovascular 38 23 42 23.1 0.99 18 23.4 0.95
   Other 24 14.5 28 15.5 0.79 14 17.9 0.51
EBRT: external beam radiotherapy; VBT: vaginal brachytherapy. KPS: Karnofski Performance Score; 
IBD: inflammatory bowel disease. FIGO: International Federation of Gynaecology and Obstetrics. 
‡: p-Value for comparison EBRT vs. VBT. *: p-Value for comparison responders vs. non-responders.
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Table 2. Patient functioning scores from EORTC QLQ-C30 and sexual functioning and 
symptom scores from OV-28.
Patient functioning
For both treatment groups, global heath status and functioning scales were low 
at baseline and showed a medium to large improvement during radiotherapy 
and in the first 6 months, reaching a plateau within range of the scores of the 
norm population at 6-12 months (Fig. 1 and Table 2). Cognitive functioning 
remained unchanged from baseline onwards.
Patients treated with vaginal brachytherapy (VBT) reported significantly better 
social functioning scores, both at completion of VBT and during follow-up, than 
patients treated with EBRT. The maximum difference in mean social functioning 
scores between the groups was small (EBRT 83 vs. VBT 89, p-randomization = 
0.005); this difference remained during the first year of follow-up. 
Sexual activity and interest were lowest at baseline (i.e. after surgery), when 
15% of the patients indicated that they were sexually active. There was a large 
increase of both interest and activity increased during the first 6 months 
to reach a plateau (39% active), without significant differences between 
the treatment groups (Fig. 1 and Table 2). For both EBRT and VBT patients 
however, mean sexual interest and activity scores were significantly lower than 
those of the age-matched norm-population. The maximum difference between 
EBRT or VBT patients and the norm population in mean sexual interest after 
12 months was small and ranged between 6-10 points, and in sexual activity 
between 4-8 points. Among the patients who indicated they were active, 81% 
reported on their sexual symptoms. There were no significant differences in 
sexual symptoms between patients treated with EBRT or VBT. However, the 
norm population reported significantly less vaginal dryness and higher levels 
of sexual enjoyment.
Five-year quality of life PORTEC-2
127
B
a
se
li
n
e
p
*
A
ft
e
r 
R
T
6
1
2
1
8
2
4
3
6
4
8
6
0
T
im
e
R
a
n
d
o
m
iz
a
ti
o
n
E
O
R
T
C
 Q
L
Q
-C
3
0
G
lo
b
a
l 
h
e
a
lt
h
 s
ta
tu
s
EB
R
T
6
9
.3
0
.5
5
7
3
.4
7
6
.3
7
6
.1
7
7
.2
7
6
.9
7
7
.5
7
5
.9
7
6
.7
<
0
.0
0
1
0
.4
6
0
.8
5
V
B
T
7
0
.4
7
5
.4
7
8
.7
7
6
.7
7
7
.6
7
8
.4
7
7
.7
7
8
.7
7
7
.0
N
o
rm
7
5
.4
₣‡
7
5
.4
7
5
.4
7
5
.3
7
5
.3
7
5
.2
7
5
.1
7
5
.1
7
5
.0
F
u
n
ct
io
n
a
l 
sc
a
le
s
Ph
ys
ic
al
 f
u
n
ct
io
n
in
g
EB
R
T
7
2
.0
0
.4
2
7
6
.5
7
9
.3
7
8
.4
7
8
.8
7
7
.8
7
6
.4
7
6
.6
7
5
.2
<
0
.0
0
1
0
.2
3
0
.9
7
V
B
T
7
3
.7
7
9
.5
8
1
.7
8
0
.3
8
0
.3
7
9
.3
7
8
.7
7
7
.2
7
7
,7
N
o
rm
8
2
.0
₣‡
8
2
.0
₣
8
2
.0
8
1
.7
8
1
.7
8
1
.4
8
1
.0
8
1
.0
8
0
.7
₣
R
o
le
 f
u
n
ct
io
n
in
g
EB
R
T
6
1
.0
0
.4
9
7
1
.8
7
9
.4
8
0
.5
8
2
.2
8
1
.1
8
0
.1
8
1
.5
7
7
.0
<
0
.0
0
1
0
.2
7
0
.2
6
V
B
T
5
9
.1
7
6
.8
8
3
.3
8
1
.6
8
3
.3
8
1
.5
8
3
.3
8
1
.6
8
1
.5
N
o
rm
8
2
.1
₣‡
8
2
.1
₣
8
2
.1
8
1
.9
8
1
.9
8
1
.6
8
1
.3
8
1
.3
8
1
.1
Em
o
ti
o
n
al
 f
u
n
ct
io
n
in
g
EB
R
T
7
5
.6
0
.7
7
8
2
.0
8
3
.6
8
3
.7
8
5
.1
8
6
.0
8
4
.6
8
5
.4
8
3
.0
<
0
.0
0
1
0
.3
9
0
.5
8
V
B
T
7
6
.3
8
3
.5
8
4
.4
8
4
.3
8
7
.0
8
5
.3
8
7
.6
8
5
.8
8
7
.2
N
o
rm
8
7
.2
₣‡
8
7
.2
₣
8
7
.2
8
7
.2
8
7
.2
8
7
.2
8
7
.1
8
7
.1
8
7
.1
C
o
g
n
it
iv
e 
fu
n
ct
io
n
in
g
EB
R
T
8
4
.3
0
.2
6
8
6
.0
8
5
.9
8
6
.5
8
6
.4
8
6
.1
8
6
.1
8
7
.6
8
3
.4
0
.2
8
0
.2
4
0
.6
6
V
B
T
8
6
.7
8
7
.5
8
9
.2
8
8
.7
8
8
.8
8
7
.4
8
7
.9
8
7
.0
8
7
.8
N
o
rm
9
0
.0
₣
9
0
.0
9
0
.0
8
9
.9
8
9
.9
8
9
.8
8
9
.7
8
9
.7
8
9
.6
₣
So
ci
al
 f
u
n
ct
io
n
in
g
EB
R
T
7
7
.6
0
.8
4
8
2
.7
8
6
.6
8
7
.6
9
0
.7
9
0
.1
9
2
.2
9
0
.8
8
7
.8
<
0
.0
0
1
0
.0
0
5
0
.0
9
V
B
T
7
8
.1
8
9
.1
9
2
.6
9
3
.1
9
3
.7
9
1
.9
9
3
.7
9
2
.2
9
2
.4
N
o
rm
9
0
.4
₣‡
9
0
.4
₣
9
0
.4
9
0
.3
9
0
.3
9
0
.2
9
0
.1
9
0
.1
8
9
.9
E
O
R
T
C
 O
V
-2
8
S
e
x
u
a
l 
fu
n
ct
io
n
in
g
Se
x
u
al
 i
n
te
re
stE
B
R
T
8
.0
0
.0
8
1
0
.0
1
4
.4
1
3
.6
1
5
.0
1
4
.2
1
4
.9
1
4
.2
1
4
.0
<
0
.0
0
1
0
.3
5
0
.4
0
V
B
T
4
.9
9
.9
1
5
.2
1
4
.4
1
3
.3
1
0
.6
1
1
.4
1
0
.3
1
1
.8
N
o
rm
2
2
.3
₣‡
2
2
.3
₣‡
2
2
.3
₣‡
2
1
.7
₣‡
2
1
.7
₣‡
2
1
.1
₣‡
2
0
.5
‡
2
0
.5
‡
2
0
.0
‡
Se
x
u
al
 a
ct
iv
it
yE
B
R
T
5
.4
0
.0
7
9
.6
1
2
.9
1
2
.8
1
2
.1
1
1
.1
1
2
.8
1
0
.8
8
.3
<
0
.0
0
1
0
.4
6
0
.8
6
V
B
T
2
.9
6
.6
1
2
.5
1
1
.8
1
2
.0
1
0
.3
1
0
.2
8
.6
8
.7
N
o
rm
1
8
.2
₣‡
1
8
.2
₣‡
1
8
.2
1
7
.6
1
7
.6
1
7
.1
‡
1
6
.5
‡
1
6
.5
‡
1
5
.9
₣‡
S
e
x
u
a
l 
sy
m
p
to
m
s
EB
R
T
4
6
.8
0
.0
2
4
0
.6
4
4
.3
4
9
.1
4
8
.9
4
6
.5
4
7
.8
4
9
.2
5
0
.7
0
.0
6
8
0
.2
7
0
.0
2
5
V
B
T
2
1
.0
4
5
.5
4
7
.2
4
2
.8
4
9
.9
4
0
.6
3
6
.1
4
2
.7
4
2
.4
N
o
rm
5
7
.1
‡
5
7
.1
₣
5
7
.1
₣
5
6
.5
‡
5
6
.5
5
6
.0
‡
5
5
.4
‡
5
5
.4
5
4
.8
V
ag
in
al
 d
ry
n
es
s
EB
R
T
3
1
.5
0
.2
1
3
2
.4
3
3
.4
3
4
.3
4
0
.8
3
5
.4
3
9
.2
3
0
.3
3
0
.4
0
.8
9
0
.7
3
0
.0
6
3
V
B
T
3
8
.3
3
7
.3
3
9
.8
4
0
.6
2
5
.0
3
1
.7
3
7
.6
3
8
.0
3
7
.2
N
o
rm
1
9
.4
1
9
.4
‡
1
9
.4
‡
1
9
.8
₣‡
1
9
.8
₣
2
0
.3
2
0
.7
₣‡
2
0
.7
2
1
.2
‡
Q
u
e
st
io
n
n
a
ir
e
 T
im
e
 P
o
in
ts
p
-V
a
lu
e
M
o
n
th
T
im
e
 b
y
 
R
a
n
d
o
m
iz
a
ti
o
n
T
o
 w
h
at
 
ex
te
n
t 
w
as
 
se
x
 
NOTE: for functioning scales a higher score indicates higher functioning, for symptom scales a high-
er score indicates more symptoms. EORTC: European Organisation of Research and Treatment of 
Cancer, QLQ-C30: Core Questionnaire, OV-28: ovarian cancer module. EBRT: external beam radio-
therapy, VBT: vaginal brachytherapy, Norm: age matched Dutch population.  After RT: after radio-
therapy. * p-Value for baseline comparison, t test for comparing means, Armitage trend test for 
single items.₣: p<0.01 for EBRT vs Norm; ‡: p<0.01 for VBT vs Norm.    
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Fig. 1 - Patient functioning on subscales from European Organization for Research and Treatment of 
Cancer C30 questionnaire (EORTC QLQ-C30) and sexual activity score of the ovarian cancer question-
naire module (EORTC OV-28). A higher score indicates a higher level of functioning or activity. For 
EBRT and VBT error bars represent 99% Confidence Interval (CI), for Norm the error bars represent 
the 95% CI. The vertical axis is in the (A-C) upper-50% range; and (D) lower-50% range. VBT, vaginal 
brachytherapy; EBRT, external-beam radiotherapy; Norm, age-matched Dutch norm population; RT, 
radiation therapy.
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Symptom scores 
Patients treated with EBRT reported a large increase of diarrhoea scores 
at completion of RT, in contrast to VBT patients (31 EBRT vs. 10 VBT, 
p-randomization <0.001, Table 3 and Fig. 2). Diarrhoea scores of EBRT patients, 
although decreasing, remained at significantly higher levels throughout the 
5-year follow-up period, whereas diarrhoea scores in the VBT group remained at 
baseline level (p-time < 0.001). There were no significant differences between 
diarrhoea scores of VBT patients and those of the norm population, whereas 
the diarrhoea scores of EBRT patients remained increased throughout 5 years 
after treatment. In addition, EBRT patients reported a little increase of faecal 
leakage 6 months after radiotherapy (11% EBRT vs. 3% VBT, p-randomization 
<0.001), remaining stable with further follow-up. Among the bowel symptoms, 
the item ‘limitations of daily activities due to bowel problems’ showed the 
largest difference between the treatment groups, in favour of VBT (23% EBRT 
vs. 7% VBT, p-randomization: <0.001). Moreover, EBRT patients reported a 
moderately increased need to remain close to the toilet.
Fatigue scores of both EBRT and VBT patients returned to levels in range with 
the norm-population after 6 months, while pain scores of both treatment 
groups were lower than those of the norm population. 
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Table 3.  Symptom scores of EORTC QLQ-C30 and PR-25.
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Fig. 2 - Single item symptom scores from European Organization for Research and Treatment of 
Cancer C30 questionnaire (EORTC QLQ-C30) and prostate cancer questionnaire module (EORTC PR-
25). A higher score indicates a higher level of symptoms. For EBRT and VBT error bars represent 
99% Confidence Interval (CI), for Norm the error bars represent the 95% CI. The vertical axis is in 
the (A-F) lower-50% range. VBT, vaginal brachytherapy; EBRT, external-beam radiotherapy; Norm, 
age-matched Dutch norm population; RT, radiation therapy.
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Discussion 
The current analysis of long-term HRQL of patients treated in the PORTEC-2 trial 
with a median follow-up of 65 months found a continuing long-term impact 
of EBRT on HRQL. Especially diarrhoea and faecal leakage were increased after 
EBRT, leading to a higher need to remain close to a toilet; more limitations of 
daily activities due to bowel problems; and a lower level of social functioning. 
HRQL of patients treated with VBT remained very similar to that of a healthy 
age-matched norm population. In contrast, sexual aspects of HRQL after 
treatment for endometrial cancer were lower than that of the norm population, 
irrespective of the type of adjuvant radiotherapy.16 
Diarrhoea scores of VBT patients remained at the norm population level, while 
the scores of EBRT patients remained significantly increased up to 5 years 
after treatment. Furthermore, scores on the global health status scale and 
functioning scales of both EBRT and VBT patients were significantly lower than 
norm data at baseline (after surgery), and recovered in the first 6 months to 
reach a plateau within range of the age-matched norm population. A similar 
pattern was found for fatigue scores. These results indicate that for most 
women the stressful period of diagnosis and treatment for endometrial cancer 
has a clear but transient influence on their general functioning.
The persisting increased rates of bowel symptoms after EBRT  are consistent 
with the increased gastrointestinal toxicity rates after EBRT found in 
randomised trials and retrospective studies on long-term morbidity after pelvic 
radiotherapy.19-21 In the HRQL analysis of PORTEC-1 trial survivors 15 years after 
treatment, increased bowel symptom rates were reported by EBRT patients as 
compared to those treated with surgery alone, indicating the persistence of 
these symptoms over time.9 
Reported late side effects of vaginal brachytherapy include atrophic changes 
in the vaginal mucosa leading to vaginal dryness, painful intercourse, and 
vaginal fibrosis leading to tightening and/or shortening. Analysis of vaginal 
mucosal changes as assessed at gynaecological examinations showed an 
increase of grade 1 and 2 mucosal atrophy from 6 months onwards (at 3 years 
17% after EBRT vs. 35% after VBT).7 Despite the increased rate of grade 1-2 
mucosal atrophy, there were no significant differences in sexual functioning 
and sexual symptoms between patients treated with EBRT or VBT. However, 
sexual functioning (activity and interest) scores of both EBRT and VBT were 
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lower than those of the age-matched norm-population, and sexual symptoms 
were increased. The rates of sexual activity and symptom scores reported 
by PORTEC-2 trial patients were similar to the long-term scores of PORTEC-1 
trial survivors, also those treated with surgery alone, suggesting an impact of 
cancer diagnosis and treatment on sexual aspects of HRQL.9 Limitations to any 
conclusion are the low rate of sexual activity in this elderly population, and the 
lower completion rate of the sexual functioning questions. 
A striking finding of the 15-year HRQL analysis of the PORTEC-1 trial was the 
increase rate of urinary urgency and incontinence. In the current analysis 
of 5-year HRQL in the PORTEC-2 trial, there were no differences in urinary 
symptoms between the groups. However, from 12 months onwards a trend 
towards higher incontinence and urgency scores after EBRT seemed to emerge. 
Possibly, these late urinary symptoms develop as a result of added long-term 
impact of EBRT upon normal ageing changes of the pelvic floor muscles. A 
future analysis of very long-term HRQL in PORTEC-2 will include questions 
on incontinence pad usage. Future studies should investigate preventive 
measures to maintain pelvic floor functioning to diminish the added effect of 
RT on normal ageing.
In conclusion, up to 5 years after treatment, EBRT has a clinically relevant, bowel 
symptom-related negative impact on HRQL, with limitation of daily activities. 
Global health status and functioning scores of all patients returned to levels 
of an age-matched Dutch norm population after 6-12 months, indicating that 
for most women diagnosis and treatment for endometrial cancer has a clear 
but transient influence on their general functioning. Compared to the norm 
population, EC patients reported lower levels of sexual functioning and more 
sexual symptoms after treatment, without differences between patients who 
received EBRT or VBT. 
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Abstract
Objective: To investigate if analysis of genetic alterations in the main 
pathways involved in endometrioid type carcinogenesis (PI3K-AKT, Wnt/β-
catenin, P53-activation and MSI) improves the current risk assessment based 
on clinicopathological factors.
Methods: Formalin fixed paraffin embedded (FFPE) primary tumor samples 
of 65 patients with FIGO-stage I endometrioid type endometrial cancer (EEC) 
were selected from the randomized PORTEC-2 trial. Tumors were stained by 
immunohistochemistry for P53, PTEN and ß-catenin. Tumor DNA was isolated 
for sequence analysis of TP53 (exons 4 to 8), hotspot mutation analysis of KRAS 
(exon 1) and PI3K (exon 9 and 20) and microsatellite-instability (MSI) analysis 
including MLH1 promotor-methylation status. Univariate and multivariate 
analyses for disease-free survival (DFS) using Cox regression models were 
performed.
Results: P53 status (HR 6.7, 95%CI 1.75 – 26.0, p=0.006) and MSI were the 
strongest single genetic prognostic factors for decreased DFS, while high PI3K-
AKT pathway activation showed a trend and ß-catenin was not prognostic. 
The combination of multiple activated pathways was the most powerful 
prognostic factor for decreased DFS (HR 5.0; 95%CI 1.59 – 15.6 p=0.006). 
Multiple pathway activation, found in 8% of patients, was strongly associated 
with aggressive clinical course. In contrast, 40% of patients had no alterations 
in the investigated pathways and had a very low risk of disease progression. 
Conclusions: Activation of multiple oncogenic pathways in EEC was the most 
powerful prognostic factor for decreased DFS, resulting in an individual risk 
assessment superior to the current approach based on clinicopathological 
factors. 
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Introduction
Endometrial cancer (EC) is the most common gynecological cancer in Western 
countries.1 Surgery alone (hysterectomy and bilateral salpingo-oophorectomy) 
is a curative treatment for the majority of patients.2,3  
This study focuses on type 1 EC (EEC), the most frequent subtype (80-85%), 
characterized by endometrioid morphology. The remaining 15-20% are type 2 
cancers with a non-endometrioid morphology (NEEC), mostly serous or clear 
cell cancers having a far more aggressive clinical behavior than type 1 cancers. 
Adjuvant treatment for EEC has become increasingly tailored to 
clinicopathological risk factors.4 In low-risk EEC patients adjuvant treatment is 
not indicated, while high-risk EEC patients receive adjuvant radiotherapy and/
or chemotherapy. The (high)intermediate risk category of EEC patients has at 
least two high-intermediate risk (HIR) features; advanced age, grade 3, deep 
invasion, and LVSI.5,6 The PORTEC-2 trial, in which HIR patients were randomly 
allocated to external beam radiotherapy or vaginal brachytherapy, concluded 
that vaginal brachytherapy is an effective therapy to prevent local recurrence 
with <2% vaginal recurrence at 5 years and 8% distant metastasis.7 Despite 
tailoring adjuvant therapy to clinicopathological factors, considerable over- 
and undertreatment still exists. Approximately 7 HIR patients need to receive 
brachytherapy to prevent 1 vaginal recurrence. 
The signaling pathways currently known to drive EEC development are 
activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, Wnt/β-
catenin-signaling, microsatellite-instability (MSI) and, although typically 
described in NEEC, mutational activation of TP53.8-10 The PI3K-AKT pathway 
can be deregulated by many different mechanisms, including inactivation of 
PTEN or mutations in PI3K and KRAS.11 A recently investigated marker of PI3K-
AKT pathway activation, Stathmin (STMN1), was shown to have independent 
prognostic capacity and may reflect the degree of PI3K-AKT pathway activation.12 
As in other cancers, endometrial carcinogenesis is likely to be the result of a 
complex interaction of pathway alterations. Concomitant PI3K-AKT and P53 
alterations were found to be associated with poor prognosis.13 Most studies 
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have however focused on single oncogenic pathway alterations in EEC and 
were performed in a heterogenic population containing both EEC and NEEC 
and both early and advanced FIGO stage tumors. 
The aim of the present study was to investigate whether combined analysis 
of genetic alterations in the main pathways involved in endometrioid type 
carcinogenesis can help to improve the current clinicopathological risk 
assessment of patients with EEC. 
Methods
Patient and tissue selection
The current analysis was undertaken in a sample size of 65 EEC patients 
selected from the PORTEC-2 trial population (427 participants). Written 
informed consent was obtained from all patients and included consent for 
collection of a tumor sample. The trial protocol was approved by the Dutch 
Cancer Society (CKTO 2001-04) and the ethics committees of all participating 
centers. Eligible trial patients had EEC with HIR factors based on the original 
pathology report of the treatment center. At central pathology review some EC 
were diagnosed to have low-risk (LR, 6%) or high-risk (HR, 8%) features.7 In order 
to detect a trend in the incidence of alterations in oncogenic pathways in the 
LR, HIR and HR risk groups, all patients who were found to have LR (N=23) or 
HR features (N=16) at review and of whom tissue samples were available, were 
included in the current selection. In addition, sufficient disease-related events 
were required to correlate the pathway alterations with disease recurrence. For 
this purpose, from the subgroup of patients with HIR features, with grade 1-2 
tumors with deep (>50%) myometrial invasion, confirmed after review (true-
HIR, 366 patients) tissue samples of 26 patients were selected with the aim to 
include 50% of patients with disease recurrence during follow-up.  
Formalin fixed paraffin-embedded (FFPE) blocks containing representative 
tumor were selected. Hematoxylin-eosin stained slides were viewed by an 
experienced gynecopathologist (V.S.), in order to select an area of tumor tissue 
containing at least 70% tumor cells. From this area two to three 0.6 mm cores 
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were extracted and used to isolate tumor DNA after proteinase K digestion. For 
the immunohistochemistry (P53, β-catenin, PTEN, Stathmin) procedures 4µm 
whole slide sections were used.  
Mutational analysis
All samples were analyzed using a custom made panel of hydrolysis probe 
assays, designed to detect hotspot mutations in PIK3CA (PI3K) and KRAS.14 
The hotspot mutations investigated for PI3K were exon 9, c.1624G>A; p.E542K 
and c.1633G>A; p.E545K and in exon 20 the c.3140A>G; p.H1047R and for 
KRAS exon 1, c.34G>A; p.G12S, c.34G>C; p.G12R, c.34G>T; p.G12C, c.35G>A; 
p.G12D, c.35G>C; p.G12A, c.35G>T; p.G12V and c.38G>A; p.G13D. Real 
time qPCR was performed by allelic discrimination using primers and probes 
designed and ordered by Applied Biosystems (Applied Biosystems, Nieuwerkerk 
aan de IJssel, the Netherlands).  
Microsatellite instability (MSI) and Methylation-specific PCR
The microsatellite status of each tumor was determined using the Promega 
MSI analysis system (version 1.2, Promega, Madison, WI, US) , following the 
recommendation of the National Cancer Institute/ICG-HNPCC.15 Tumors were 
classified as microsatellite instable (MSI) when two or more markers showed 
an instable pattern. The MSI tumors were selected for further testing for 
methylation status of the 5’ regulatory region of MLH1, using methylation-
specific PCR (MSP), with primers that have been previously described.16 
TP53 Mutation Analysis
Primers were designed to amplify exons 4-8 of TP53 by PCR. TP53 primers were 
designed to avoid amplification of a pseudogene, and have been described 
previously.17 Sanger sequencing was performed on purified PCR products  
(Macrogen, Amsterdam, the Netherlands). Sequences were analyzed with 
Mutation SurveyorTM DNA variant analysis software (version 3.97 Softgenetics). 
A mutation was only accepted once it was identified in both forward and 
reverse strands.
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Immunohistochemistry
Slides were deparafinated in xylene, rehydrated though a graded ethanol series, 
and washed with phosphate-buffered saline. Antigen retrieval was achieved 
by microwave oven treatment for 10 min in 10mmol/L citrate buffer, pH6.0 
(ß-catenin in 10 mmol/L Tris-EDTA, pH9.0). Sections were incubated overnight 
with monoclonal p53 antibody (clone D0-7, 1:1000 dilution; NeoMarkers), 
polyclonal Stathmin antibody (3352, 1:100 dilution, Cell Signaling), PTEN 
(clone 6.H2.1, 1:200 dilution; DAKO), ß-catenin (cat. 610154; 1:1600; BD 
Transduction) and monoclonal MLH-1 (clone ES05, 1:200 dilution; DAKO). The 
sections were incubated and stained with a secondary antibody (Poly-HRP-GAM/
R/R; DPV0110HRP; ImmunoLogic). Diaminobenzidine tetrahydrocholoride was 
used as a chromogen for all antibodies. The slides were counterstained with 
hematoxylin. 
Evaluation of staining
Slides were evaluated by two pathologists (T.B. and V.S), blinded for patient 
characteristics and outcome. Evaluations were done independently, and 
discrepancies were resolved at simultaneous viewing. P53 was scored positive 
if >50% of the tumor cells showed strong positive nuclear staining, or when 
discrete geographical patterns showed >50% tumor cell positivity.18 Activated 
Wnt-signaling was defined as nuclear staining of ß-catenin. For Stathmin and 
PTEN a semi quantitative grading system incorporating staining intensity 
(score 0-3) and area of tumor with positive staining was used, as described by 
Trovik et. al.19: 0, no staining; 1, <10%; 2, 10-50%, and 3, >50% of tumor cells. 
Staining index was calculated as the product of staining intensity and staining 
area, range 0-9. Values defined by the upper quartile for the data set were 
considered positive. 
Statistics
The distribution of patient and tumor characteristics of the different risk 
groups was tested for significance using the Chi-square test for categorical 
variables and the student T-test for continuous variables. Disease free survival 
(DFS) was defined as the time between date of randomization and date of 
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disease recurrence or death from any cause; all other patients were censored 
at the date of last follow-up. DFS was calculated with the Kaplan Meier method 
including Log rank test. Multivariate analysis of prognostic factors for disease 
free survival was performed using Cox regression models. All variables with 
a univariate Log rank p-value less than 0.1 were included in the model. SPSS 
software version 17.0 was used for statistical analysis.
Results
Patient characteristics
Patient characteristics are shown in Table 1. Median follow-up was 88 months 
(range 4 – 106 months) and was not significantly different from the main trial 
population (p=0.29). 
Despite the disease free survival (DFS) rate being lower in the true-HIR 
population (N=26) due to selection of patients with recurrent disease, DFS in 
the total population (N=65) did not differ significantly from that of the original 
trial population (N=427) (Appendix 1 ). In total 15 of 65 (23.1%) patients 
recurred during follow-up, while 12 of 26 (46.2%) true-HIR patients recurred 
during follow-up (Table 1). 
In univariate analysis both age (p=0.03) and deep myometrial invasion 
(p=0.02) were prognostic factors for decreased DFS, and were included in the 
subsequent Cox regression analysis, in contrary to grade (p=0.26) and lymph 
vascular invasion (p=0.15).
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Table 1. Patient, tumor and treatment characteristics of endometrioid type tumors. 
No. % No. % No. % No. % p-value*
Total 23 35.4 26 40.0 16 24.6 65 100
Age at Diagnosis
Mean 0.04
Range
Myometrial Invasion
<50% 23 100 0 0 0 0 23 35.4 <0.001
>50% 0 0 26 61.9 16 38.1 42 64.6
Grade
1 21 55.3 17 44.7 0 0 38 58.5 <0.001
2 2 18.2 9 81.8 0 0 11 16.9
3 0 0 0 0 16 100 16 24.6
Lymph Vascular Invasion
Abstent 21 39.6 22 41.5 10 18.9 53 81.5 0.07
Present 2 16.7 4 33.3 6 50.0 12 18.5
Treatment arm
EBRT 10 32.3 13 41.9 8 25.8 31 47.7 0.88
VBT 13 38.2 13 38.2 8 23.5 34 52.3
Site of First Recurrence
No Recurrence 22 44.0 14 28.0 14 28.0 50 76.9 0.01
Pelvic Lymph Node Recurrence 0 0 1 100 0 0 1 1.5
Distant Metastasis 1 7.1 11 78.6 2 14.3 14 21.5
70.1 68.8 67.9
Low Risk High-intermediate Risk High Risk Total
51.6 - 84.6 56.0 - 82.0 60.7 - 82.7 51.6 - 84.6
64.7
EBRT: external beam radiotherapy; VBT: vaginal brachytherapy.
*p-value by χ2 method, p-values <0.05 in bold and between 0.05 and 0.10 in italic.
PI3K-AKT pathway activation
PI3K mutations were found in 7 tumors (11%) of which 5 had a mutation in 
exon 20 (H1047R). KRAS mutations in exon 1 were found in 14 tumors (22%) 
of which 11 were located at position 35. Loss of PTEN expression was found 
in 45% of the tumors. Both PI3K and KRAS mutation status alone were not 
predictive for decreased DFS, while loss of PTEN expression showed a trend 
for decreased DFS (Table 2). 
PI3K-AKT pathway activation was classified as high when two or more altered 
genetic factors (PI3K and KRAS mutation status and loss of PTEN) were found 
(12/65 tumors, 19%), moderate in case of one altered genetic factor and no 
pathway activation if none of the factors were altered (26/65 tumors, 40%). 
High PI3K-AKT pathway activation was more frequently seen in patients with 
low and high-intermediate risk tumors and was mainly caused by a combination 
of KRAS mutation and complete loss of PTEN expression (Figure 1). Although 
not significant, DFS of patients with high PI3K-AKT pathway activation seemed 
decreased compared to those with no or moderate activation (Figure 1). High 
Stathmin expression was more frequently found in high risk tumors without 
an association with DFS. No correlation between the degree of Stathmin 
expression and the degree of PI3K-AKT pathway activation was found (Table 2 
and Figure 1).
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A 
C 
B 
D 
No. Patients PI3K KRAS Loss of PTEN
PI3K 5 1 1
KRAS 3 10
Loss of PTEN 18
Total 7 14 29
PI3K-AKT pathway activation Total
PI3K-Akt pathway No. % No. % No.
No activation 18 66.7 9 33.3 27
Moderate activation 16 61.5 10 38.5 26
High activation 8 66.7 4 33.3 12
Total 42 64.6 23 35.4 65
Stathmin negative Stathmin positive
Figure 1A-D. PI3K-Akt pathway activation and the role of Stathmin. (A) Cross correlation table of 
components of the PI3K-AKT pathway. High PI3K-AKT pathway activation (red fields): tumors hav-
ing 2 or more altered components of the pathway, moderate activation: 1 altered component and 
no activation: none of the components showed alterations. In 7 patients a PI3K mutation was found 
of whom 1 had a simultaneous mutation in KRAS and 1 patient had loss of PTEN. (B) No correlation 
between the degree of PI3K-AKT pathway activation and Stathmin expression on immunohistochem-
istry. (C) Degree of PI3K-AKT pathway activation is not significantly associated with DFS, with trend 
that high Pi3K-AKT pathway activation is indicative for a worse DFS. (D) Stathmin protein expression 
shows positive cytoplasmic staining of the tumor cells and negative normal endometrial glands for 
comparison.
ß-catenin / Wnt-signaling pathway
Nuclear staining of ß-catenin as a marker for an activated Wnt-signaling pathway 
was found in 9 tumors (14%) and infrequently found in combination with other 
alterations (Figure 4). Staining was only seen in low and high-intermediate risk 
tumors without any relation to DFS.
P53 pathway 
P53 protein overexpression, assessed by immunohistochemical staining, 
was found in 17% of the tumors and was highly predictive for decreased 
DFS (Table 2 and Figure 2). Sequencing of TP53 (exons 4-8) succeeded in 48 
patients and revealed 9 (14%) functional and 4 (6%) non-functional mutations 
(Figure 2 and Table Web Appendix 2). There was high agreement between 
immunohistochemical staining and sequencing of TP53 (Kappa 0.86). 
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Microsatellite Instability (MSI)
MSI was found in 12 tumors (19%), with a significantly higher frequency of 
MSI with increasing depth of myometrial invasion and increasing tumor grade 
(Table 2). The methylation status of the MLH-1 promoter region was successfully 
assessed in 9 patients and was hypermethylated in 8 patients. One patient 
was found to have a MSH6 germline mutation (confirming Lynch syndrome) 
and developed a colon carcinoma during follow-up. MSI was predictive for 
decreased DFS (Figure 3), and was found to be mutually exclusive with P53 
overexpression (Figure 4).
Accumulation of alterations in oncogenic pathways
An alteration in one of the four main mechanisms of endometrioid type 
carcinogenesis (PI3K-AKT, Wnt/ß-catenin, P53 pathways and MSI) was found in 
60% (39/65). In a Cox regression model that included age and deep myometrial 
invasion, P53 status was found to be the strongest (HR 6.7, 95%CI 1.75 – 26.0, 
p=0.006) single alteration to predict for a decreased disease free survival, 
followed by MSI (Figure 4). 
In order to analyze the prognostic impact of the accumulation of alterations in 
the oncogenic pathways, three groups were defined: no altered pathway; one 
altered pathway; two or more altered pathways. When the factor accumulated 
altered oncogenic pathways was entered in the regression analysis (including 
age and deep myometrial invasion) followed by P53 overexpression and MSI, 
it was the only factor that remained significantly predictive for decreased DFS 
(HR 5.0; 95%CI 1.59 – 15.6 p=0.006, Figure 4). This finding was confirmed in 
the subgroup of true-HIR patients (Figure Appendix).  Five out of 65 (8%) EEC 
patients had two or more activated pathways, and all died due to early disease 
recurrence (Figure 4). In contrast, 24 patients (40%) had no activated pathway 
of whom only one patient developed a recurrence. 
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Table 2. Alterations in the most common mechansms of endometrioid type tumor car-
cinognesis.
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Discussion
Over the past decades prospective randomized trials have provided a solid 
basis for the use of clinicopathological prognostic factors such as age, 
grade and myometrial invasion for risk-based adjuvant therapy.5,6 The vast 
majority of patients with EEC have either low (55%) or high-intermediate risk 
features (30%) and have a good prognosis. The present study was undertaken 
to investigate whether combined analysis of genetic alterations in the main 
involved pathways of endometrioid type carcinogenesis improved the current 
risk assessment on an individual basis, with the ultimate goal to further reduce 
both over- and undertreatment. 
Although all PORTEC-2 trial patients were randomized under the condition of 
having HIR features at central pathology review diagnosed a subset of 14% 
was diagnosed with low-risk (LR) or high-risk (HR) features.7 Incorporation of 
these patients into this study enabled the detection of alterations in oncogenic 
mechanisms in all three risk groups (LR, true-HIR, HR). In addition, patients with 
HIR features confirmed at central review (true-HIR) were selected for disease-
related events in order to correlate the alterations in oncogenic pathways with 
disease recurrence. An obvious advantage of using this trial population is the 
relative homogeneity of the study cohort. All patients were diagnosed with EEC 
and were treated in a comparable manner with a long and well documented 
follow-up (median 7.3 years). 
Although TP53 mutations have frequently (80-90%) been found in non-
endometrioid endometrial cancer (NEEC), they are found in 10-15% of the EEC.9,10 
In this study 17% of the EEC tumors showed P53 overexpression. For validation 
purposes, TP53 (exons 4-8) was sequenced and showed a high agreement with 
the immunohistochemical staining (Kappa 0.86). P53 overexpression was the 
strongest independent prognostic pathway for decreased DFS. This finding 
supports the assumption that P53-positive endometrial cancers, independent 
of their morphology, should be considered as intrinsically aggressive tumors. 
Microsatellite instability (MSI) was demonstrated in 19% of the tumors and 
correlated with depth of myometrial invasion and grade. Although this frequency 
is in line with other studies (20%-45%)9,10, its relation with other pathological 
factors remains controversial. In many previous MSI studies20-23, patient cohorts 
including both early and advanced FIGO stages, and cancers of different 
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histological subtypes, may have blurred the evaluation of the prognostic 
value of MSI. In our cohort, MSI was mainly caused by hypermethylation of 
the promoter region of MLH-1. MSI as an oncogenic mechanism was found 
to be mutually exclusive with P53 overexpression and clearly associated in 
our study with decreased DFS. A similar inverse relationship between TP53 
mutations and MSI status was recently found in gastric cancer.24 The authors 
hypothesized that this may be explained by alterations in an emerging tumor 
suppressor gene, ARID1a (component of the SWI/SNF chromatin remodeling 
complex), that may constitute an alternative pathway of carcinogenesis strongly 
associated with MSI and independent of TP53 that drives cancer development 
through epigenetic modifications. Recent studies have shown frequent ARID1a 
mutations in gynecologic cancers, including endometrial cancer.25 
The accumulation of molecular alterations in the PI3K-AKT pathway showed 
a trend toward a worse clinical outcome (Figure 1). It did not reach statistical 
significance probably due to the small sample size. The PI3K-AKT pathway 
is one of the most frequent deregulated pathways in cancer and has been 
associated with aggressive tumor behavior in endometrial cancers.12 The 
well known oncogen KRAS and tumorsuppressor PTEN converge on the PI3K-
AKT pathway, resulting in growth, proliferation and survival signaling.26,27 In 
addition, ‘hot spot’ mutations in the kinase and helical domains of PI3K confer 
constitutive kinase activity and thereby directly activate PI3K-AKT signaling.28 
Our data show considerable coexistence between these molecular alterations, 
suggesting that individual mutations are not completely redundant. These 
independent alterations activate the PI3K-AKT pathway differently, and 
cumulative molecular alterations may have a selective advantage.29 It may 
be possible that loss of PTEN results in circumvention of negative feedback 
loops which result in an additive effect on PI3K-AKT pathway activation, as was 
found in knock-out mice experiments.30 Based on these data, it is likely that 
the magnitude of PI3K-AKT pathway activation is influenced by the underlying 
molecular alteration(s), and that this impacts on oncogenicity. 
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Figure 4 A-D. Accumulation of altered oncogenic mechanisms. (A) Cox regression model for effect 
on disease free survival of alterations in single oncogenic mechanisms. In a second model the ac-
cumulation of altered oncogenic mechanisms was entered together with oncogenic mechanisms (P53 
and MSI) that were significantly associated with a decreased disease free survival on univariate 
analysis (Log rank p<0.1), showing that the factor accumulation of oncogenic mechanisms remained 
significant. (B) Table showing cross correlations between investigated oncogenic mechanisms, in red 
patients with 2 or more altered mechanisms and in green patients with 1 altered mechanism. PI3K-
AKT pathway was activated in 12 patients of whom 2 had a P53 overexpression and 1 MSI. (C) DFS of 
patients selected for the current study (green, N=65) and of all unselected PORTEC-2 patients (blue, 
N=362). (D) DFS by accumulation of genetic alterations in PI3K-AKT, Wnt/β-catenin and P53 pathways 
and MSI including all patients selected for the current study (N=65). 
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In light of this discussion, indentifying a marker for PI3K-AKT pathway 
activation would be of major interest. Recently Stathmin (STMN1), a micro-
tubule destabilizing protein, was postulated as a putative surrogate marker 
of the PI3K-AKT pathway with independent prognostic significance.12,19,31 Our 
data do not support a clear relationship between Stathmin overexpression and 
PI3K-AKT pathway activation. This discrepancy may be partly explained by the 
difference in definition of PI3K-AKT activation. Another explanation may be 
that Stathmin is not only expressed in the context of activated PI3K-AKT, but 
also overexpressed when the TP53 tumor suppressor function is lost. This is 
supported by studies that show that wild-type P53 transcriptionally represses 
STMN1, and mutant TP53 can impair this negative regulation, leading to 
increased Stathmin levels.32-34  
Mutations of multiple genes that participate in different pathways or functions 
may be additive or even synergistic in conferring a survival advantage to the 
tumor.35 Patients with multiple activated pathways had significantly worse 
DFS (Figure 4). The most frequent co-occurrence was the combination of P53 
and PI3K-AKT activation, which previously has been reported to be associated 
with a poor prognosis.13 Taken together, these combined carcinogenic 
pathway alterations may better reflect the oncogenicity of tumors than their 
morphology, and prove to be the strongest prognostic factors. 
In summary, analysis of multiple molecular genetic alterations in tissue samples 
of patients with EEC showed that P53 and MSI status are important independent 
prognostic factors for decreased DFS. The simultaneous activation of multiple 
oncogenic pathways was the most powerful factor predicting decreased 
DFS, resulting in a superior individual risk prediction as compared to the 
current clinicopathological approach. Although larger (prospective) series are 
necessary to validate these findings, our results support a biologically driven 
approach for individual risk assessment and treatment selection.
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Appendix 1. 
Figure 1A-B. Disease Free Survival. (A) DFS 
of all patients selected for the current study 
(N=65) by risk group based on clinicopatho-
logic factors, see text for definitions. For this 
study High-intermediate risk (HIR) patients 
with recurrence during follow-up were se-
lected (approximately 50%), explaining the 
lower than expected disease free survival of 
HIR patients compared to low and high risk 
patients in this figure. (B) DFS by accumula-
tion of alterations in PI3K-AKT, Wnt/β-catenin 
and P53 pathways and MSI in patients whose 
HIR status was confirmed by central pathol-
ogy review (N=26). 
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The main purpose of the Post Operative Radiotherapy in Endometrial Carcinoma 
(PORTEC) trials has been to provide evidence with regards to risks (short 
and long-term treatment related morbidity) and benefits (disease control) of 
adjuvant radiotherapy and by doing so, further define both the indications and 
methods of radiotherapy with the ultimate goal to improve the overall outcome 
and quality of life of endometrial cancer patients. In this thesis results from 
the first and second PORTEC trials are presented. In the PORTEC-1 trial (1990-
1997), stage I EC patients with intermediate risk features were randomized after 
surgery between no additional therapy and pelvic external beam radiotherapy. 
In the subsequent PORTEC-2 trial (2002-2006), patients with high-intermediate 
risk features were randomized between pelvic external beam radiotherapy and 
vaginal brachytherapy. In this chapter the main findings of this thesis and their 
implications for current patient management are discussed, focusing on future 
perspectives for research and treatment of endometrial cancer. 
Optimal treatment for endometrial cancer 
patients with high-intermediate risk features
In order to decide on optimal treatment for patients with high-intermediate 
(HIR) features, risks (treatment related morbidity) and benefits (disease 
control) of different treatment strategies should be evaluated. Before reaching 
a conclusion, the following paragraphs discuss the key issues concerning three 
possible strategies after surgery: pelvic external beam radiotherapy (EBRT), 
vaginal brachytherapy (VBT), and no additional therapy (NAT).
Risk of disease recurrence
Evidence for the role of adjuvant radiation therapy for intermediate risk EC 
patients has come from four large randomised trials and a meta-analysis 
(Table 1).1-5 All of these trials reached the same conclusion, that EBRT reduces 
the risk of locoregional (vagina and/or pelvic) recurrence approximately three-
fold, but this does not lead to a decrease in the rate of distant metastasis or a 
benefit in overall survival. Both PORTEC-1 and GOG#99 trials have identified a 
subgroup of patients with HIR features that had the highest risk of locoregional 
recurrence without additional therapy. Based on these outcomes, the indication 
for adjuvant radiotherapy was only maintained for patients with HIR features. 
This led to a major decrease in indications for radiotherapy, sparing low-
intermediate risk patients the risk of radiotherapy related morbidity.
Discussion
163
Table 1. Randomized trials establishing the role of postoperative radiotherapy in inter-
mediate risk endometrial cancer.
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The very long-term analysis of the PORTEC-1 trial confirmed the importance 
of the prognostic factors age, grade and depth of myometrial invasion for 
selection of HIR patients. In patients with HIR features the risk of developing 
a locoregional recurrence was reduced from approximately 20% after NAT to 
5% after EBRT. The majority (75%) of locoregional recurrences in the NAT-arm 
were isolated vaginal recurrences. Salvage treatment, usually consisting of 
EBRT combined with VBT, was most effective in patients with isolated vaginal 
recurrences; in 80-90% a complete remission was achieved, with 70% 5-year 
survival after recurrence.6 This explains in part why upfront EBRT does not 
improve overall survival. In contrast, patients with isolated pelvic or combined 
pelvic and vaginal recurrences are at high risk of developing distant metastasis 
and their survival rate is similar to that of patients who initially present with 
distant metastasis. EBRT does not seem to prevent the development of distant 
metastasis, which occurred in approximately 8% of the patients in both 
treatment arms. Overall survival rates at 5, 10 and 15 years after treatment 
were approximately 80%, 65% and 50%, irrespective of receiving adjuvant 
radiotherapy or not. The vaginal recurrence risk of 2% at 5 years after VBT in 
the PORTEC-2 trial was strikingly similar to that obtained after EBRT both in 
PORTEC-2 and in PORTEC-1, demonstrating the efficacy of VBT in preventing 
vaginal recurrences. At 5 years the rate of total pelvic recurrences was 0.5% 
after EBRT vs. 3.8% after VBT. However, first failure analysis showed that most 
patients (5 of 8) with a pelvic recurrence had simultaneous distant metastases 
and the pelvic recurrence rate as first failure was 0.5% after EBRT vs. 1.5% 
after VBT, with similar rates of distant metastasis and overall survival in both 
arms. These findings were confirmed in a recently published Swedish trial 
in which 527 patients with intermediate risk EC were randomized between 
VBT and combined EBRT and VBT. The rate of vaginal recurrences was low 
in both arms of the trial (crude rates 2.7% vs. 1.9%), while in the VBT alone 
arm a higher rate of locoregional recurrences was found (5.0% vs 1.5% at 
5 years, p=0.01) without differences in 5-year relapse-free (86 vs 87%) and 
overall survival (89 vs 90%), results very similar to those of PORTEC-2.7 For 
approximately 3% of patients EBRT might be beneficial compared to VBT in 
preventing both vaginal and pelvic lymph node recurrences, but as distant 
Discussion
165
metastasis will ultimately dictate their prognosis and overall survival is not 
improved, this benefit is debatable.Due to the low total number of vaginal and 
pelvic events in PORTEC-2, a multivariate analysis of prognostic factors for 
pelvic recurrence was not included in the publication of the outcome analysis. 
The GOG99 trial investigators identified lymph vascular space invasion (LVSI) 
as an independent prognostic factor for any relapse and included LVSI in their 
HIR definition.4 Other authors have confirmed the strong adverse prognostic 
impact of LVSI, both in presence and absence of nodal metastases8,9 In the 
PORTEC-1 analysis which included the registered group with grade 3 EC with 
deep invasion, LVSI was also found to be a risk factor, especially for distant 
relapse.10 The Swedish trial included DNA-aneuploidy in their definition and 
did not include LVSI or age.7 Despite the differences in HIR definitions, testing 
of the GOG HIR definition in the PORTEC-1 analysis yielded very similar results. 
In clinical practice, LVSI should be considered an adverse factor and as such, 
grade 3 EC with superficial invasion but with clear LVSI is considered high-
risk, and these patients receive EBRT and are eligible for trials investigating 
chemotherapy, such as PORTEC-3 and GOG249. Similarly, grade 2 with very 
deep invasion close to the serosa and clear LVSI represents the upper end of 
the HIR spectrum and might also be considered high risk. 
Overall survival and recurrence rates for patients with HIR features in PORTEC-2 
were remarkably similar to those obtained in all of the randomized trials in 
patients with intermediate risk EC (Table 1). From a clinical point of view, 
given that low-intermediate risk patients do not receive adjuvant treatment 
and are in fact regarded low risk, patients with HIR features have become the 
intermediate group. Thus, it would seem more appropriate to group current 
low-risk and low-intermediate risk features as low risk EC, and designate those 
with HIR features as intermediate risk EC, which would be in line with the 
prognosis and therapeutic consequences.  
   
Radiotherapy related morbidities and their impact on health-related 
quality of life
In the randomised trials (Table 1) increased early and late (physician-reported) 
adverse event rates were reported after EBRT, as compared to NAT.1-4 In 
PORTEC-1 late toxicity was reported in 6% of patients in the NAT arm and 
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in 25% after EBRT. Approximately two-thirds of adverse events (AE) in the 
EBRT arm were mild (grade 1), while 3% were grade 3 complications, with the 
vast majority of AE related to the gastro-intestinal (GI) tract. In PORTEC-2 the 
increased gastro-intestinal acute toxicity in the EBRT arm decreased from 6 
months onwards, and the difference between the EBRT and VBT arms lost 
its significance after 24 months. Both HRQL analyses in the PORTEC-1 and 
PORTEC-2 trials have provided unique insight into the impact these symptoms 
have on patient-reported health related quality of life (HRQL), and how long 
this impact persists in the years following treatment.
With HRQL studies the question always remains what size of difference 
between scores reflects a clinical meaningful or relevant difference. Studies on 
the magnitude of clinically relevant differences agree on a minimum difference 
of 5% to 10% of the instrument range as being clinically relevant.14-16 For the 
EORTC Core questionnaire, Osoba et al. found that patients valued a change 
of 5-10% as ‘little’, 10-20% as ‘moderate’ and more than 20% as ‘very much’ 
difference.15 These descriptions are used to value the observed differences in 
HRQL scores.
In the PORTEC-2 trial, EBRT was associated with an early increase of patient 
reported bowel symptoms (very much diarrhea and little fecal leakage), while 
scores after VBT remained at baseline level in range of those of an age-matched 
Dutch norm-population. In the years following treatment the bowel symptoms 
gradually decreased but remained moderately to a little higher than those of 
VBT patients and the norm-population. Even in patients treated 12 to 19 years 
ago with EBRT in PORTEC-1, bowel symptoms were still moderately increased 
compared to NAT patients. Interestingly, after the longer follow-up period 
in PORTEC-1, urinary urgency and incontinence were moderately increased 
after EBRT. While the bladder is known to be a late responding organ, the 
combination of increased rates of fecal leakage and urinary incontinence 
are suggestive for a decrease in pelvic floor function.17-20 In terms of clinical 
relevance perhaps the most straightforward finding in the long-term PORTEC-1 
analysis was the increased use of incontinence materials day and night after 
EBRT (43% vs 15%), thus very much difference.  
Importantly there were clear relationships between increased bowel and 
bladder symptoms and the moderately increased need to remain close to 
the toilet, and between increased limitation in daily activities due to these 
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symptoms and decreased social and (role-) physical functioning. This pattern 
of combined bowel symptoms and decreased social and (role-) physical 
functioning was also observed in the Swedish trial that compared VBT alone 
with the combination of EBRT and VBT.21 In the PORTEC-1 HRQL questionnaire 
there was space at the end of the questionnaire for additional comments, 
several patients commented in there own words on this relationship: ‘frequent 
and unpredictable bowel movements make me uncertain, so I don’t leave the 
house’, ‘radiotherapy gave me irritated bowels, so I have to keep in mind if 
there is a toilet in my direct vicinity’ and ‘when I leave the house for a day 
trip I always take a loperamide for my stool‘.  Finally, both from 6 months 
after treatment onwards in PORTEC-2 and in PORTEC-1 the general functioning 
scores of both treatment groups did not differ from those of an age-matched 
Dutch norm population, indicating that for most women the diagnosis and 
treatment for endometrial cancer has a clear but transient influence on their 
general functioning. 
Both in PORTEC-1 and PORTEC-2 there was no difference in patient reported 
sexual functioning and symptoms between both treatment arms. In both 
trials quite a few patients indicated on the questionnaire forms that they were 
widowed, did not have a partner, or that their partner had a medical condition 
that withheld them from being sexually active, resulting in a lower response 
rate to these questions. In PORTEC-2 sexual activity increased from 15% at 
baseline after surgery to 39% at 6 months, reaching a plateau at a slightly lower 
level in both treatment arms compared to the age-matched norm population. 
The increase in sexual activity in the 6 months following treatment was most 
apparent in patients younger than 65 years, while very few patients older than 
75 years were sexually active which did not change over time. In PORTEC-1 
there was no difference in sexual activity between both treatment arms, 
suggesting that the slight decrease in sexual activity in PORTEC-2 patients 
compared to the age-matched norm population is not radiotherapy related. A 
statement on one of the returned questionnaires provides meaningful insight: 
‘for me it was important my spouse had consideration for my situation; sexual 
changes need adjustment and creativity’.
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Advances in pelvic external beam radiotherapy
As with all studies looking at the late effects of treatment, important progress 
has been made in the delivery of EBRT since 1990 when the first patients 
were treated in the PORTEC-1 trial. Intensity modulated and image-guided 
radiotherapy (IMRT, IGRT), have led to a more conformal dose distribution with 
increased sparing of normal (bowel and bladder) tissues (Figure 1).22-24 
Figure 1. Dose distribution of pelvic external beam radiotherapy; in yellow 95% isodose of 46 Gy. 
(A) 3-dimensional conformal radiotherapy dose distribution (B) Intensity modulated radiotherapy 
(IMRT).
Approximately 52% of the patients in PORTEC-1 were treated with a four-
field box technique and 18% with a 3-field technique with some form of 
individualized shielding, while 30% were treated with parallel opposing fields. 
The use of multiple fields significantly reduced the rate of late complications 
compared to parallel opposing fields, which increased exposure of bowel 
structures to high dose levels.25 Nonetheless, a four-field box technique with 
individual shielding was required in PORTEC-2 and still led to increased gastro-
intestinal toxicity and related sequelae at least up to 5-years after treatment. 
Studies using IMRT for gynaecological cancer have shown that this leads 
to more bowel and bladder sparing and less early and late bowel toxicity 
compared to historic controls. Early results of the RTOG-0418 in which 58 EC 
patients were included from 25 institutions found a non-significant reduction 
of short-term bowel adverse event rate of 28% after IMRT compared to 40% in 
historic controls.26 Mundt et al. have reported a reduction in early (40 patients, 
GI grade 2: 60% vs 91% for IMRT vs conventional historic controls) and late (36 
patients, median follow-up 19 months, GI all grades: 11% vs 50%) GI toxicity 
in patients treated for cervical cancer.27,28 Due to interfraction motion of the 
target volume due to differences in bladder and rectal filling, even with IMRT 
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considerable margins are needed to ensure adequate target coverage during 
the whole period of external beam treatment.29,30 Further improvement is 
expected from strategies that incorporate interfraction motion of the target 
volumes and organs at risk (i.e. IGRT), resulting in reduced margins.24 Results 
of studies using IGRT, including daily online soft tissue position verification 
protocols and a ‘treatment plan of the day’ concept are being awaited. In the 
mean time IMRT is an important step forward in reducing treatment related 
toxicity in patients that need EBRT. 
Vaginal brachytherapy: current issues
VBT has been used as adjuvant treatment for EC patients for several decades. A 
wide variety of dose and fractionation schedules and treated length of the vagina 
have been reported, resulting in low rates of vaginal recurrences and treatment 
related toxicity (Table 2).31-42 However, most studies were retrospective and 
most included a significant proportion of low to low-intermediate risk patients, 
which makes it difficult to draw definite conclusions with regard to efficacy. 
With increasing dose and increasing irradiated vaginal length, the risk of 
associated toxicity such as atrophy and shortening of the vagina increases.36 
In a randomized trial reported by Sorbe et al, 290 low-risk EC patients were 
allocated to receive either 15 Gy in 2.5 Gy fractions, or 30 Gy in 5 Gy fractions 
of HDR brachytherapy specified at the surface over a period of 8 days.40 The 
mean vaginal shortening measured by colpometry was 0.3 cm in the 15 Gy 
group (ns), and 2.1 cm in the 30 Gy group (p < 0.001) at 5 years. In addition, 
mucosal atrophy and bleeding were significantly more frequent in the 30 Gy 
group, demonstrating a clear dose-effect relationship.
In PORTEC-2 a dose and fractionation schedule was chosen with the aim to 
give a similar biological effective dose to the proximal vagina as with EBRT. 
The dose was specified at 5 mm depth from the surface and top of the cylinder 
in order to include the full vaginal wall. Due to the steep dose gradient with 
brachytherapy, the dose from the specification isodose at 5 mm depth towards 
the surface of the cylinder increases considerably, which can explain the 
increase rate of grade 2 in mucosal atrophy observed during gynaecological 
examination after VBT compared to EBRT.43
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Table 2. Results of postoperative vaginal brachytherapy for endometrial cancer.
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More recently a study examining vaginal wall specimens found that most 
lymph vessels are located in the superficial 3 mm of the vaginal wall.44 While 
3-dimensional delineation and treatment planning are mainstay in virtually 
all tumor sites in radiation oncology, VBT planning has largely remained 
2-dimensional. Few studies have used CT for analysis of dose to organs at risk, 
but CT fails in visualizing the target volume since the vaginal wall cannot be 
clearly distinguished from the bladder and rectal wall on CT.45-48 In a pilot study 
of 10 patients for whom MRI scans were obtained with the vaginal cylinder in 
treatment position, the maximal distance from the surface of the cylinder to 
the outer border of the vaginal wall did not exceed 3 mm in dorso-ventral 
direction, while in the lateral directions the distance was 5 mm on average 
(Figure 2).49 However, in the upper (proximal) third of the vagina on the lateral 
sides, folds of the vaginal wall were observed where the distance from the 
applicator surface to the outer border of the vaginal wall exceeded 5 mm. 
Although excellent vaginal control was seen using a standardized treatment 
prescription in PORTEC-2, underdosage in these lateral vaginal folds can 
provide a possible explanation for the very few vaginal recurrences seen after 
brachytherapy. These results suggest that the brachytherapy prescription dose 
in the doso-ventral direction could be reduced compared to the lateral sides, 
and support a more individualized image guided approach. Although such 
asymmetrical dose distributions can be obtained using multichannel cylinders, 
care must be taken with regard to an increased mucosal surface dose.50 Future 
studies examining the most optimal dose and fractionation schedule as well 
as target definition and type of applicator ensuring optimal target coverage 
are warranted. 
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Figure 2. Axial, coronal and sagittal MRI scan of vaginal brachytherapy cylinder in treatment posi-
tion. A clinical target volume was contoured by two observers (red, orange), organs at risk by one 
(bladder in blue, rectum in brown). 
Optimal treatment for patients with high-intermediate risk features
Taken together, both PORTEC-1 and PORTEC-2 have provided evidence with 
regard to risks and benefits of three adjuvant treatment strategies for HIR 
patients: EBRT, VBT or NAT. EBRT leads to an important reduction in the risk 
of locoregional recurrence, without leading to a reduction in the rate distant 
metastasis or a benefit in overall survival compared to NAT. Both EBRT and VBT 
offer similar rates of vaginal control, distant metastasis and overall survival. 
However, as discussed above, for approximately 3% of patients EBRT might 
be beneficial in preventing both vaginal and pelvic lymph node recurrences 
compared to VBT. Since the majority of patients with a pelvic lymph node 
recurrence have simultaneous distant metastases, overall survival is not 
improved, and this potential benefit of EBRT is debatable. 
Despite the fact that EC patients in general are elderly with frequent co-morbid 
conditions such as obesity, diabetes and hypertension, patients with HIR 
features have a good prognosis and given the increasing population of long-
term survivors, both short and long-term treatment related symptoms and 
their impact on quality of life should be taken into account when deciding 
Chapter 8 
174
on optimal treatment for these patients. EBRT is associated with long-lasting 
bowel and bladder symptoms that impact on patient functioning up to 15 years 
after treatment. VBT is clearly more favourable, with equal vaginal control and 
HRQL results similar to an age-matched norm population.  
When opting for no additional treatment, only the 15-20% patients that develop 
a recurrence are exposed to salvage treatment. Salvage treatment usually 
consists of combined EBRT and VBT and offers a high probability of local 
control but with a risk of increased toxicity compared with EBRT alone.51-53 
However, HRQL and symptom outcome of 14 patients who received salvage 
treatment for a recurrence in the NAT arm of PORTEC-1 was very similar to that 
of patients initially treated with EBRT alone. VBT (18-24 Gy in 3-6 fractions) 
has only been compared to observation in a single, small randomized trial 
that only included low risk patients.54 There was no significant difference in 
the vaginal recurrence rate (VBT 1.2% vs observation 3.1%, p=0.11) and there 
were few and mild (grade 1-2) side effects. Potential risks of this strategy 
that remain unquantified are the psychological impact of a watchful waiting 
policy, and the burden, stress and anxieties of experiencing a recurrence 
and subsequent more intensive treatment.55 Finally, there is a lack of data on 
patient preferences with regard to risks versus benefits of NAT vs VBT. 
With the aim to provide both an answer to the question if VBT is more favorable 
than NAT in terms of reduction of overtreatment, health impact and costs, 
and ultimate vaginal control, and if a lower dose of VBT is equally effective 
compared to the standard dose, the PORTEC-4 has been initiated.56 The recently 
started PORTEC-4 trial is a multicenter randomized trial in which patients 
with HIR features are randomly allocated (2:1) to vaginal brachytherapy and 
observation after surgery, and in the VBT arm 1:1 to the standard dose of 
21 Gy in 3 fractions of 7 Gy and the lower dose level (3 fractions of 5 Gy). 
The primary endpoint is vaginal recurrence and the second primary endpoint 
is the 5-year probability of vaginal control, including treatment for vaginal 
relapse. The objective of the brachytherapy dose comparison is to estimate 
the differences in vaginal relapse, toxicity and quality of life (with emphasis 
on sexual symptoms and functioning) with sufficient precision. Imaging with 
CT or MRI with the vaginal cylinder inserted will be performed to provide more 
detailed data on target volume and doses to rectum and bladder. Importantly, 
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both patient and health care provider preferences with regard to risks versus 
benefits of VBT or observation are being investigated in a medical decision 
making side study to PORTEC-4. 
At present, vaginal brachytherapy offers a highly effective therapy to prevent 
vaginal recurrences and maximize relapse-free survival with a favorable toxicity 
and HRQL profile and is therefore currently the treatment of choice.
Current issues and future perspectives in 
adjuvant treatment of endometrial cancer
Improving the outcome of high risk patients
The prognosis of the 15% of EC patients with high risk features, being those 
with grade 3 and deep invasion, with more advanced stages, or serous or 
clearcell histology, is predominantly determined by the higher risk of distant 
metastases.10,57,58 Improvement of the prognosis of these patients depends 
on systemic therapy that is effective in preventing the development of distant 
metastases. Therefore, ongoing trials focus on establishing the role of 
chemotherapy, either given alone or in combination with radiotherapy. In the 
ongoing PORTEC-3 trial EBRT alone is compared with combined chemotherapy 
and EBRT (two cycles of cisplatin during radiotherapy followed by four 
adjuvant cycles of carboplatin and paclitaxel) in high risk patients.59 In this 
trial upfront pathology review is mandatory to ensure only high risk patients 
are included. Quality of life is assessed which will play an important role in 
the weighing of risks versus benefits of more intensified treatment in these 
elderly patients. In the GOG#249 trial stage I-II patients with high-intermediate 
or high risk features are randomized between EBRT alone and VBT followed by 
adjuvant chemotherapy (3 cycles of carboplatin and paclitaxel).60 This trial will 
potentially answer two questions: if VBT followed by adjuvant chemotherapy 
can further decrease the relatively low risk of pelvic and distant recurrences 
in high-intermediate risk patients (and at which cost); and how the toxicity 
profile of EBRT compares to the combination of VBT and short-course adjuvant 
chemotherapy. The GOG#258 trial compares the same combined radiotherapy 
and chemotherapy schedule used in the PORTEC-3 trial with chemotherapy 
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alone (6 cycles of carboplatin and paclitaxel alone) in patients with stage III and 
IVA endometrial cancer.61 This trial will answer the question if there is a role for 
EBRT at all in patients with advanced stage disease, who are mainly at risk of 
distant relapse. It is expected that the implementation of technical advances in 
EBRT such as IMRT and IGRT (discussed in the previous section) will decrease 
external beam radiotherapy related morbidity. Outcomes of ongoing phase II 
and III randomized trials comparing IMRT with 3D conformal EBRT including 
quality of life analysis are awaited.62,63 
While ongoing trials all use the combination of carboplatin and paclitaxcel 
chemotherapy, knowledge of the biology of endometrial cancer and the 
underlying pathways that play a role in the development and disease progression 
is accumulating. Drugs targeting specific pathways known to be of importance 
in EC have mainly been tested as single agents in phase I and II trials.64 Since 
targeted therapies are in clinical use in several types of cancer, more evidence 
has emerged that a major mechanism of targeted therapy resistance lies in 
the propensity of tumors to use alternative pathways.65 Similar to the use of 
different classical chemotherapeutic agents during a course of chemotherapy, 
it is expected that multiple targeted agents will need to be used that block 
several alternative pathways simultaneously.66 An alternative approach that is 
being investigated is to target pathways further downstream where alternating 
routes converge. 
Can we further decrease over- and undertreatment in endometrial cancer 
in the future?
Implementation of the high-intermediate risk criteria to select patients for 
radiotherapy has led to a substantial reduction of indications for radiotherapy. 
Nonetheless, there still remains considerable overtreatment and to a lesser 
extent undertreatment: approximately 5% of the low or low-intermediate risk 
patients develop recurrent or metastatic disease; approximately 7 patients 
with HIR features need to be receive VBT to prevent 1 vaginal recurrence and 
this does not prevent the development of distant metastasis in approximately 
8% of the patients; and finally a substantial proportion of high risk patients do 
not develop metastases and might not have needed adjuvant treatment. An 
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attractive way to further refine the currently used system for risk assessment 
is to incorporate new molecular prognostic factors that may better predict the 
biology, risk of recurrence and metastatic propensity of individual tumours. 
Several studies have investigated the prognostic capacity of genetic alterations 
involved in endometrial carcinogenesis.64,67-69 For endometrioid type tumors, 
the majority of studies indicate that activation of the Wnt/ß-catenin signaling 
pathway is associated with a good prognosis, while mutation of TP53 and 
activation of the PI3K-AKT pathway are indicators of tumors with a more 
aggressive clinical course. Conflicting results have been reported with regard 
to the prognostic significance of MSI and mutations in PTEN and KRAS as 
components of the PI3K-AKT pathway. However, most studies are relative 
small, retrospective and include a heterogenous group of patients including 
both higher FIGO stages and a combination of endometrioid type and non-
endometrioid type tumors and focus on one or two pathways. For these reasons 
genetic alterations are not yet used as prognostic factors to tailor treatment.
In the pilot study undertaken in 65 selected PORTEC-2 patients, the aim 
was to investigate these four important pathways simultaneous in a 
relative homogenous cohort of patients with a similar prognosis based on 
clincopathologic factors. The combination of multiple activated pathways was 
the most powerful prognostic factor for decreased disease free survival in 
a multivariate analysis that included depth of myometrial invasion and age. 
The most frequent co-occurrence was the combination of TP53 mutation and 
PI3K-AKT activation, which has previously been reported to be associated 
with a poor prognosis.70 Multiple pathway activation, found in 8% of patients, 
was strongly associated with aggressive clinical course. In contrast, 40% of 
patients had no alterations in the investigated pathways and had a very low 
risk of disease progression. These results indicate that molecular prognostic 
factors can potentially refine the currently used system for risk classification 
and lead to a further decrease of over- and undertreatment. Confirmation and 
further refinement of these findings in a large sample of patients including un-
irradiated controls is pivotal. For this purpose a future study is planned using 
tumor samples of patients from both the PORTEC-1 and PORTEC-2 trials. In 
future, analysis of tumor samples of patients treated in the PORTEC-3 trial will 
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provide insight alterations that are predictive for response to chemotherapy, 
both in endometrioid and non-endometrioid types, and provide rationale for 
patient selection and future trials incorporating targeted therapies. 
Despite their older age at diagnosis and frequent comorbid conditions, the 
overall prognosis of endometrial cancer patients is good. Improved selection 
of patients at risk of recurrent and metastastic disease will decrease over- 
and undertreatment and will be pivotal for future studies applying targeted 
therapies. In the process of shared decision making on optimal adjuvant therapy, 
patients need to be informed not only on benefits concerning risk reduction, 
but also on risks of treatment related morbidity. Quality of life analysis plays 
a critical role in the interpretation of physician-reported adverse events, and 
knowledge of the impact treatment related symptoms have on the everyday 
life of patients. In the near future, the use of postoperative radiotherapy and 
brachytherapy will be increasingly tailored to the individual patient’s needs, 
sparing many low and intermediate risk patients unnecessary toxicities while 
identifying the few who need adjuvant treatment, and improving outcomes for 
patients with high risk disease.
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Introduction
Chapter 1 provides a general introduction into the background and treatment 
of endometrial cancer (EC). This thesis presents results of two randomized 
trials investigating the role of Post Operative Radiation Therapy in Endometrial 
Carcinoma (PORTEC). The PORTEC-1 trial (1990-1997) randomly allocated 714 
EC patients with intermediate risk features to postoperative external beam 
radiotherapy (EBRT) or no additional treatment (NAT). After completion of 
PORTEC-1, the indication for RT was restricted to patients with 2 of the so-
called high-intermediate risk (HIR) factors (age >60, grade 3 or deep invasion). 
In the subsequent PORTEC-2 trial (2002-2006) the role of vaginal brachytherapy 
(VBT) was investigated. In PORTEC-2, 427 EC patients with HIR features were 
randomly allocated to EBRT or vaginal brachytherapy (VBT). 
The aims of this thesis were:
1) To establish the role of VBT in terms of efficacy, treatment related morbidity 
and patient-reported health related quality of life (HRQL) as compared to EBRT 
for patients with HIR features. 
2) To analyze the long-term outcomes of the PORTEC-1 trial, especially with 
regard to HRQL of the long-term cancer survivors. 
3) To investigate whether adverse molecular prognostic factors can improve 
the current risk assessment based on clinicopathological factors.
The role of postoperative vaginal brachytherapy in high-intermediate risk 
endometrial cancer; results of the PORTEC-2 trial.
The final efficacy analysis of the PORTEC-2 trial is reported in chapter 3. With 
a median follow-up of 45 months there were very few vaginal recurrences in 
both treatment arms: estimated 5-year vaginal recurrence rates were 1.6% 
after EBRT vs. 1.8% after VBT (p=0.74). There was no significant difference in 
the 5-year locoregional (vaginal and/or pelvic) recurrence rate (2.1% vs. 5.1%, 
p=0.17), despite a higher total pelvic recurrence rate after VBT (0.5% vs. 3.8%, 
p=0.02). First failure analysis showed that most patients (5 of 8) with a pelvic 
recurrence had simultaneous distant metastases and the 5-year rate of pelvic 
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recurrence as first failure were 0.5% after EBRT vs. 1.5% after VBT (p=0.30). 
There were no differences in the five-year rates of distant metastasis (5.7% vs. 
8.3%) and overall survival (79.8% vs. 78.6%).
An initial increase of physician-reported grade 1 and 2 gastro-intestinal (GI) 
morbidity was observed directly after EBRT (53% vs. 12% for VBT) that decreased 
during further follow-up, while for VBT there was no increase compared to 
baseline. Morbidity of the vaginal mucosa was assessed during gynaecological 
examination and showed an increase of grade 1 to 2 mucosal atrophy in both 
treatment arms, with more grade 2 atrophy from 6 months onwards after 
VBT, as compared to EBRT. There were few serious (grade 3) adverse events 
(GI bowel obstruction requiring surgery in 4 EBRT patients vs. 1 VBT patient; 
marked vaginal atrophy with or without shortening or narrowing in 1 vs. 4 
patients).
Patient-reported HRQL during the first two years after treatment is described in 
chapter 2 and the subsequent analysis up to five years, including a comparison 
with an age-matched Dutch norm population, is described in chapter 6. With a 
high response rate of 81%, marked differences in HRQL between both treatment 
groups were found. Bowel symptoms such as diarrhea and fecal leakage were 
significantly increased after EBRT as compared to VBT. After EBRT, 15.4% and 
7.3% of the patients reported “quite a bit” or “very much” diarrhea, whereas 
after VBT these rates were 2.8% and 2.8%. Fecal leakage was reported by 3.4% 
(quite a bit) and 1.7% (very much) patients who had EBRT, vs. 0.7% and 0% for 
VBT, respectively. Although these bowel symptoms showed a decline during 
further follow-up, they remained increased in patients treated with EBRT, both 
compared to patients who had VBT and to the age-matched norm population. 
Among VBT patients, bowel symptoms did not increase over baseline and 
remained similar to those of the norm population. Importantly, for patients 
treated with EBRT the increased bowel symptoms led to a higher need to 
remain close to a toilet, more limitations of daily activities and a lower social 
functioning, which persisted up to five years after treatment. Global health and 
functioning scales were lowest at baseline after surgery, and recovered during 
the first 6 months to reach a plateau within range of the norm population. 
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These results indicate that for most women the stressful period of diagnosis 
and treatment for endometrial cancer has a clear but transient influence on 
their general functioning.
In this population of elderly women reported sexually activity rates increased 
during the first 6 months after treatment, without differences in sexual 
functioning or symptoms between the treatment groups. However, sexual 
activity rates of both groups were a little lower than those of the age-matched 
norm population.
Fifteen-year results of the PORTEC-1 trial and health related quality of life 
of the long-term cancer survivors.
In chapter 4 the HRQL analysis of life of the long-term cancer survivors from 
the PORTEC-1 trial is reported. The questionnaire response rate was 70%, 
with a median follow-up of 13 years. Patients treated with EBRT reported 
significantly increased bowel and bladder symptoms, most notably urinary 
urgency and incontinence, diarrhea with frequency and urgency and fecal 
leakage, as compared to those who had surgery alone (NAT). The increased 
symptom rates are reflected by the frequent use of incontinence materials 
after EBRT: 43% of patients reported day and night use of incontinence pads, in 
contrast to 15% of patients who were observed after surgery. Patients treated 
with EBRT reported more limitations of daily activities due to bowel and urinary 
symptoms and lower physical and role-physical functioning. There were no 
differences between both treatment groups with regard to sexual functioning 
or symptoms. As expected, there were more patients in the NAT group who 
had survived a locoregional recurrence and had undergone salvage therapy. 
These patients reported higher levels of fecal urgency and fecal leakage, with 
a trend towards more urinary urgency and urinary incontinence, similar to the 
patients in the EBRT group. 
The very long-term outcomes with regard to the primary and secondary 
endpoints of the PORTEC-1 trial are reported in chapter 5. At the time of 
analysis 426 patients were alive with a median follow-up of 13 years. Fifteen-
year locoregional recurrence rates were 6% for EBRT vs. 16% for NAT (p<0.0001), 
while 15-year rates distant metastasis (9% vs 7%, p=0.25) and overall survival 
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(52% vs 60%, p=0.14) were similar. Most (74%) of the locoregional recurrences 
in the NAT group were vaginal recurrences. Multivariate analysis confirmed 
the prognostic significance of grade 3, age >60 years and deep myometrial 
invasion for locoregional recurrence and endometrial cancer related death, 
confirming the relevance of HIR criteria for treatment selection. For patients 
with HIR features the locoregional recurrence rate without radiotherapy was 
approximately 20% at 5 and 10 years, compared to 5% after EBRT. Again, there 
were no differences in rates of distant metastases and overall survival for 
patients with HIR features. Estimated 10-year survival after vaginal recurrence 
was 51% vs. 25% for NAT vs EBRT; 18% vs 0% after pelvic relapse and 8% vs 4% 
after distant relapse. These results indicate that salvage therapy for vaginal 
recurrences is effective, while pelvic recurrences have a more dismal outcome, 
similar to patients with distant metastasis.
The role of molecular prognostic factors in the refinement of the current 
risk based strategy for adjuvant therapy in endometrial cancer.
The results of a pilot study investigating the prognostic significance of 
alterations in the main pathways involved in endometrioid type carcinogenesis 
(PI3K-AKT pathway, Wnt/β-catenin-signaling, microsatellite-instability and 
mutational activation of TP53) are described in chapter 7. Formalin-fixed 
paraffin embedded tissue samples of 65 selected patients who participated in 
the PORTEC-2 trial were analysed. P53 status and MSI were the strongest single 
genetic prognostic factors for decreased disease free survival, while high PI3K-
AKT pathway activation showed a trend and β-catenin was not prognostic. 
However, the combination of multiple activated pathways was the most 
powerful prognostic factor for decreased disease free survival in multivariate 
analysis. Activation of multiple pathways, found in 8% of patients, was strongly 
associated with an aggressive clinical course. In contrast, 40% of patients had 
no alterations in the investigated pathways and had a very low risk of disease 
progression. These results indicate that molecular prognostic factors can be 
used to refine the currently used system for risk classification and may lead to 
a further decrease of over- and undertreatment. 
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Discussion
Chapter 8 discusses the main findings presented in this thesis and their 
implications, including a future outlook for the treatment and research for 
EC. The 15-year results of the PORTEC-1 trial confirm the importance of the 
prognostic factors age, grade and depth of myometrial invasion for selection 
of HIR patients (approximately 30% of EC patients). EBRT leads to an important 
reduction in the risk of locoregional recurrence (mainly due to a decrease in 
vaginal recurrences), without a survival benefit compared to NAT. The PORTEC-2 
trial has shown that EBRT and VBT offer excellent rates of vaginal control and 
similar overall survival for patients with HIR features, while VBT has a clearly 
more favourable treatment related morbidity and HRQL profile, with results 
similar to an age-matched norm population. It has become clear that EBRT is 
associated with long-lasting bowel symptoms that impact on patients’ daily 
lives and physical functioning, even 10-15 years after treatment. Therefore, 
VBT is currently the treatment of choice for patients with HIR features.
It can be argued that VBT is still overtreatment, since approximately 7 HIR 
patients need VBT to prevent 1 recurrence and postoperative radiotherapy 
does not lead to a survival benefit. When opting for no additional treatment 
after surgery, only the 20% patients that develop a recurrence are exposed 
to salvage treatment, usually a combination of EBRT and VBT, that has more 
treatment related morbidity and impact on HRQL than VBT alone. In order to 
provide both an answer to the question if NAT is more favorable than VBT in 
terms of reduction of overtreatment, health impact and costs, with similar 
ultimate vaginal control, and to the question if a lower VBT dose is equally 
effective compared to the standard dose, the PORTEC-4 has been initiated. 
In PORTEC-4, EC patients with HIR features are randomly allocated (2:1) to 
vaginal brachytherapy and observation after surgery, and in the VBT arm 1:1 
to the standard dose of 21 Gy in 3 fractions of 7 Gy and the lower dose level 
(3 fractions of 5 Gy).
EBRT has remained only indicated in the 15% EC patients with high risk features. 
Ongoing trials (PORTEC-3, GOG#249 and GOG#258) focus on establishing the 
role of chemotherapy either alone or in combination with radiotherapy in these 
patients. 
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Another attractive way to further decrease over- and undertreatment in EC 
is to incorporate new molecular prognostic factors in the currently used 
system for risk classification based on clinicopathological factores. The pilot 
study in 65 selected PORTEC-2 patients showed that P53 status and MSI were 
the strongest single genetic prognostic factors. However, the combination 
of multiple activated pathways was the most powerful prognostic factor 
for decreased disease free survival in multivariate analysis, indicating that 
molecular prognostic factors can potentially refine the currently used system 
for risk classification. Confirmation of these findings in a large sample of 
patients including unirradiated controls is pivotal. For this purpose a future 
study is planned using tumor tissue samples of patients from both PORTEC-1 
and PORTEC-2 trials. In addition, future analysis of tumor samples of patients 
treated in the PORTEC-3 trial will provide insight in molecular alterations 
that are predictive for response to chemotherapy, both in endometrioid and 
non-endometrioid types, and provide rationale for future trials incorporating 
targeted agents.
In the near future both the use and technique of postoperative radiotherapy 
and image-guided VBT will be increasingly tailored to the individual patient’s 
needs, sparing low risk patients unnecessary treatment related toxicity and 
improving outcomes for high risk EC patients.
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Introductie
In Hoofdstuk 1 wordt een algemene inleiding gegeven over de achtergrond 
en behandeling van endometriumcarcinoom (baarmoederkanker). In 
dit proefschrift worden de resultaten van twee gerandomiseerde trials 
naar de rol van Post-Operatieve RadioTherapie in de behandeling van 
EndometriumCarcinoom (PORTEC) beschreven. In de PORTEC-1 trial (1990-
1997) werden 714 endometriumcarcinoom patiënten met intermediaire 
risicofactoren gerandomiseerd tussen postoperatieve uitwendige radiotherapie 
en geen aanvullende behandeling na de operatie. Uitwendige radiotherapie gaf 
een significante verlaging van het risico op het optreden van een locoregionaal 
recidief (in de vagina en/of lymfklieren in het bekken); dit leidde echter 
niet tot een verbetering in de 5-jaars overleving. Er werden drie belangrijke 
risicofactoren gevonden voor het optreden van een locoregionaal recidief: 
leeftijd 60 jaar of ouder, graad 3 en diepe myometriuminvasie. Voor patiënten 
met twee van deze drie risicofactoren was de verlaging in het risico op een 
locoregionaal recidief het grootst. Na afloop van deze trial werd de indicatie 
voor radiotherapie dan ook beperkt tot patiënten met twee van de drie 
risicofactoren: de zogenaamde ‘hoog-intermediaire’ risicogroep. Omdat de 
meeste (75%) recidieven in het diepst gelegen deel van de vagina optraden 
werd in de daaropvolgende PORTEC-2 trial (2002-2006) de waarde van vaginale 
brachytherapie (inwendige bestraling) onderzocht. In PORTEC-2 werden 427 
endometriumcarcinoom patiënten met hoog-intermediare risicofactoren 
gerandomiseerd tussen uitwendige radiotherapie of vaginale brachytherapie.
De doelstellingen van dit proefschrift zijn:
1) Onderzoeken van de waarde van vaginale brachytherapie in vergelijking 
met uitwendige radiotherapie voor patiënten met endometriumcarcinoom met 
hoog-intermediaire risicofactoren in de PORTEC-2 studie, zowel wat betreft 
de effectiviteit, behandelingsgerelateerde morbiditeit als door de patiënt 
gerapporteerde kwaliteit van leven.
2) De lange termijn uitkomsten van de PORTEC-1 studie te analyseren, met 
name wat betreft de kwaliteit van leven van de lange termijn overlevenden.
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3) Te onderzoeken of moleculaire prognostische factoren de huidige op klinisch-
pathologische factoren gebaseerde risico-inschatting (en indicatiestelling voor 
adjuvante behandeling) kunnen verbeteren.
De rol van postoperatieve vaginale brachytherapie in hoog-intermediair 
risico endometriumcarcinoom patiënten: resultaten van de PORTEC-2 trial.
Hoofdstuk 3 beschrijft de uitkomsten van de analyse van de effectiviteit van 
de behandeling in de PORTEC-2 trial. Met een mediane follow-up duur van 45 
maanden waren er zeer weinig vaginale recidieven in beide behandelingsarmen: 
het geschatte 5-jaars vaginaal recidief risico bedroeg 1.6% na uitwendige 
radiotherapie en 1.8% na vaginale brachytherapie (p=0.74). Ondanks het hogere 
totaal risico op een lymfklier recidief in het bekken na vaginale brachytherapie 
(0.5% vs. 3.8%, p=0.02), leidde dit niet tot een significant verschil in het 5-jaars 
locoregionaal recidief risico. Analyse van het eerste recidief toonde aan dat 
de meeste patiënten (5 van de 8) met een lymfklier recidief in het bekken ook 
afstandsmetastasen hadden, en dat het 5-jaars risico op een lymfklier recidief 
in het bekken als enige (solitaire) recidief 0.5% na uitwendige radiotherapie en 
1.5% na vaginale brachytherapie (p=0.30) bedroeg. Er was geen verschil tussen 
de behandelingsgroepen in de kans op afstandsmetastasen na 5 jaar (5.7% vs. 
8.3%) of de 5-jaars kans op overleving (79.8% vs. 78.6%).
Direct na afloop van de uitwendige radiotherapie werd een toename 
van de door de artsen gerapporteerde graad 1 en 2 gastro-intestinale 
morbiditeit gevonden (53% na uitwendige radiotherapie vs. 12% na vaginale 
brachytherapie), die vervolgens afnam tijdens de verdere follow-up, terwijl 
er na vaginale brachytherapie geen toename gevonden werd in vergelijking 
met het uitgangsniveau voor start van de behandeling. Veranderingen in 
het vaginaslijmvlies door de radiotherapie werd geobjectiveerd tijdens het 
gynaecologisch onderzoek, en liet een toename zien van graad 1 en 2 atrofie 
in beide behandelingsarmen, met meer graad 2 atrofie vanaf 6 maanden na 
vaginale brachytherapie in vergelijking met uitwendige radiotherapie. Er waren 
weinig ernstige (graad 3) bijwerkingen (darmobstructie waarvoor operatief 
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ingrijpen in 4 uitwendig bestraalde patiënten vs. 1 patiënt na vaginale 
brachytherapie; uitgesproken vaginale atrofie met of zonder verkorting of 
vernauwing in 1 vs. 4 patiënten).
De resultaten van de door de patiënten zelf gerapporteerde kwaliteit van leven 
tijdens de eerste twee jaar na de behandeling zijn beschreven in hoofdstuk 2, 
en de vervolg analyse tot 5 jaar na de behandeling inclusief een vergelijking 
met een voor leeftijd gecorrigeerde Nederlandse normpopulatie is beschreven 
in hoofdstuk 6. Met een hoge (81%) respons op de kwaliteit van leven 
vragenlijsten werden markante verschillen gevonden in de kwaliteit van leven 
tussen beide behandelgroepen. Darm symptomen zoals diarree en verlies van 
beetjes ontlasting waren significant toegenomen na uitwendige radiotherapie 
in vergelijking met vaginale brachytherapie. Na afloop van uitwendige 
radiotherapie rapporteerden 15.4% en 7.3% van de patiënten “nogal” en “heel 
erg” diarree, terwijl dit na vaginale brachytherapie 2.8% en 2.8% bedroeg. 
Verlies van beetjes ontlasting werd na uitwendige radiotherapie door 3.4% van 
de patiënten als “nogal“ en door 1.7% als “heel erg” gerapporteerd, vergeleken 
met 0.7% en 0% na vaginale brachytherapie. Alhoewel de darmsymptomen 
afnamen tijdens de verdere follow-up, bleef een hoger percentage van 
de uitwendige bestraalde patiënten hier last van houden vergeleken met 
vaginale brachytherapie en de normpopulatie. Na vaginale brachytherapie 
werd geen toename in darmsymptomen gerapporteerd in vergelijking met 
de uitgangssituatie voor de start van de behandeling, en de darmsymptomen 
bleven op het niveau van de normpopulatie. Van belang hierbij is dat bij 
uitwendig bestraalde patiënten de darmsymptomen leidden tot een sterkere 
noodzaak om in de buurt van een toilet te blijven, tot meer beperkingen van 
dagelijkse activiteiten en tot lager sociaal functioneren, hetgeen aanhield tot 
5 jaar na de behandeling. Algemene kwaliteit van leven en functioneren waren 
op het laagste niveau bij de uitgangsmeting na de operatie (voor de start 
van de bestraling), en herstelden in de eerste 6 maanden na de behandeling 
tot het niveau van de normpopulatie. Deze resultaten tonen aan dat voor de 
meeste vrouwen de stressvolle periode van diagnose en behandeling voor 
endometriumcarcinoom een duidelijke maar voorbijgaande invloed heeft op 
het algemeen functioneren.
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Door deze populatie van oudere vrouwen werd een toename van seksuele 
activiteit (ten opzichte van kort na de operatie) gerapporteerd tijdens de eerste 
6 maanden na de behandeling, zonder verschillen in seksueel functioneren 
of symptomen tussen de behandelgroepen. Desondanks was de seksuele 
activiteit in beide groepen lager dan die van de voor leeftijd gecontroleerde 
normpopulatie.
Vijftien-jaars resultaten van de PORTEC-1 trial en kwaliteit van leven van 
de lange termijn overlevenden. 
In hoofdstuk 4 wordt de kwaliteit van leven analyse van de lange termijn 
overlevenden van de PORTEC-1 trial beschreven. De respons op de kwaliteit 
van leven vragenlijst was 70% met een mediane follow-up duur van 13 jaar. Na 
uitwendige radiotherapie rapporteerden significant meer patiënten darm- en 
blaassymptomen vergeleken met patiënten die geen aanvullende behandeling 
kregen. Deze darm- en blaassymptomen bestonden uit een toegenomen 
aandrang voor urine, verlies van beetjes ontlasting of urine, en diarree. Deze 
toename in symptomen bleek ook duidelijk uit het toegenomen gebruik van 
incontinentiemateriaal: na uitwendige radiotherapie droeg 43% van de patiënten 
dag en nacht incontinentiemateriaal, vergeleken met 15% van de patiënten die 
alleen de operatie hadden ondergaan. Patiënten die waren behandelend met 
uitwendige radiotherapie rapporteerden meer beperkingen in de dagelijkse 
activiteiten door darm- en blaas symptomen, en scores voor lichamelijk 
functioneren waren lager. Er was geen verschil tussen de behandelingsgroepen 
met betrekking tot seksueel functioneren en symptomen.
Zoals verwacht waren er in de groep patiënten die geen aanvullende 
behandeling hadden ondergaan, meer patiënten die een locoregionaal recidief 
hadden overleefd en daar een meer uitgebreide behandeling voor hadden 
ondergaan. Deze patiënten rapporteerden vaker aandrang en verlies van 
beetjes ontlasting, met een trend voor frequentere aandrang en ongewild 
verlies van urine, met scores die vergelijkbaar waren met die van de patiënten 
die uitwendig bestraald waren.
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De zeer lange termijn uitkomsten met betrekking tot de primaire en secundaire 
eindpunten van de PORTEC-1 trial zijn beschreven in hoofdstuk 5. Ten tijde 
van de analyse waren 426 patiënten in leven, met een mediane follow-up 
van 13 jaar. Het 15-jaars locoregionale recidief risico was 6% na uitwendige 
radiotherapie versus 16% na geen aanvullende behandeling na de operatie 
(p<0.0001), terwijl zowel het 15-jaars risico op afstandsmetastasen (9% vs 7%, 
p=0.25) en de 15-jaars overleving (52% vs 60%, p=0.14) gelijk waren. De meeste 
(74%) locoregionale recidieven in de groep patiënten die geen aanvullende 
behandeling na de operatie hadden ondergaan waren gelokaliseerd in het 
diepst gelegen deel van de vagina, en de meeste werden alsnog succesvol 
behandeld. Multivariate analyse bevestigde het prognostische belang van 
leeftijd ouder dan 60 jaar, graad 3 en diepe myometriuminvasie voor het risico 
op locoregionaal recidief en endometriumcarcinoom gerelateerd overlijden, 
waarmee het belang van de hoog-intermediaire risico criteria voor patiëntselectie 
bevestigd werd. Voor patiënten met hoog-intermediare risicofactoren die geen 
radiotherapie hadden ondergaan was het locoregionaal recidief risico 20% na 
5 en 10 jaar, vergeleken met 5% na uitwendige radiotherapie. Ook voor de 
patiënten met hoog-intermediare risicofactoren was er geen verschil tussen de 
behandelingsgroepen in risico op afstandsmetastasen en kans op overleving. 
De 10-jaars overleving na een vaginaal recidief was 51% in de groep die 
geen aanvullende behandeling na de operatie had ondergaan (en dus alsnog 
bestraald kon worden), versus 25% in de groep die uitwendige radiotherapie 
had ondergaan na de operatie. 10-jaars overlevingspercentages na een lymfklier 
recidief in het bekken waren 18% vs. 0%, en na afstandsmetastasen 8% vs. 4%. 
Deze resultaten geven aan dat behandeling van vaginale recidieven effectief 
is met goede genezingskansen, terwijl lymfklier recidieven in het bekken een 
slechtere uitkomst hebben, vergelijkbaar met afstandsmetastasen.
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De rol van moleculaire prognostische factoren voor risicobepaling en 
indicatiestelling voor adjuvante therapie bij het endometriumcarcinoom. 
De resultaten van een pilotstudie die het prognostische belang onderzocht van 
veranderingen in de voornaamste signaaltransductieroutes (PI3K-AKT, Wnt/β-
catenin, microsatelliet-instabiliteit en TP53 mutatie) die betrokken zijn bij de 
carcinogenese van het endometrioide type endometriumcarcinoom, worden 
beschreven in hoofdstuk 7.
Paraffine blokjes met in formaline gefixeerd tumormateriaal van 65 geselecteerde 
patiënten die in de PORTEC-2 trial hadden deelgenomen werden geanalyseerd. 
P53 expressie en microsatelliet-instabiliteit waren de sterkste individuele 
moleculaire prognostische factoren voor een lagere kans op ziektevrije 
overleving, terwijl sterke PI3K-AKT signaaltransductie een trend voor een lagere 
ziektevrije overleving liet zien en β-catenine geen prognostisch effect liet zien. 
Echter, de combinatie van meerdere geactiveerde signaaltransductieroutes 
was de sterkste onafhankelijke prognostische factor voor een lagere kans op 
ziektevrije overleving. Activatie van meerdere signaaltransductieroutes werd 
gevonden in 8% van de patiënten en was sterk geassocieerd met een agressief 
ziektebeloop. In tegenstelling tot deze groep hadden de 40% patiënten 
zonder een verandering in de onderzochte signaaltransductieroutes een zeer 
lage kans op ziekteprogressie. Deze resultaten geven aan dat moleculaire 
prognostische factoren gebruikt kunnen worden om het huidige systeem voor 
risicoclassificatie te verfijnen, en zo in de toekomst tot een verdere afname van 
zowel over- als onderbehandeling kunnen leiden, door een meer individuele 
risicovoorspelling en therapiebepaling.
Discussie
Hoofdstuk 8 bespreekt de voornaamste bevindingen van de studies die in 
dit proefschrift worden gepresenteerd, inclusief een toekomstvisie voor de 
behandeling van en onderzoek naar endometriumcarcinoom. De 15-jaars 
resultaten van de PORTEC-1 trial bevestigden het belang van de hoog-
intermediaire risicofactoren leeftijd, graad en myometriuminvasie, die bij 
ongeveer 30% van de endometriumcarcinoom patiënten aanwezig zijn. 
Uitwendige bestraling leidt tot een belangrijke reductie in het risico op een 
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locoregionaal recidief (met name door het voorkomen van vaginale recidieven), 
zonder dat dit leidt tot overlevingswinst vergeleken met geen aanvullende 
behandeling na de operatie. De PORTEC-2 trial heeft laten zien dat uitwendige 
radiotherapie en vaginale brachytherapie beide tot een zeer laag risico op 
een vaginaal recidief leiden, met gelijke overlevingskansen. Tegelijkertijd 
had vaginale brachytherapie duidelijk gunstigere uitkomsten met betrekking 
tot behandelingsgerelateerde morbiditeit en kwaliteit van leven, zonder 
verslechtering ten opzichte van een leeftijdsgecontroleerde normpopulatie. 
Het is duidelijk geworden dat uitwendige radiotherapie geassocieerd is met 
lange termijn darmklachten die een impact kunnen hebben op het dagelijks 
leven en lichamelijk functioneren bij een kwart van de (ex-)patiënten, zelfs 
10-15 jaar na de behandeling. Vaginale brachytherapie is derhalve de huidige 
behandeling van keuze voor patiënten met hoog-intermediaire risicofactoren.
Men kan stellen dat vaginale brachytherapie nog steeds overbehandeling is, 
omdat ongeveer 7 patiënten met hoog-intermediaire risicofactoren vaginale 
brachytherapie moeten ondergaan om 1 recidief te voorkomen, terwijl 
postoperatieve radiotherapie niet leidt tot een verbetering in de overlevingskans. 
Indien voor geen aanvullende behandeling na de operatie wordt gekozen, 
worden alleen de 20% patiënten die een recidief ontwikkelen blootgesteld 
aan radiotherapie, meestal een combinatie van uitwendige radiotherapie en 
vaginale brachytherapie, wat meer morbiditeit en impact op de kwaliteit van 
leven heeft dan vaginale brachytherapie alleen. Om de vraag te beantwoorden 
of een afwachtend beleid beter is dan vaginale brachytherapie na de operatie, 
wat betreft de uiteindelijke uitkomst, vermindering van overbehandeling, 
gezondheidsimpact en kosten, is de PORTEC-4 trial geïnitieerd. In PORTEC-4 
trial worden endometriumcarcinoom patiënten met hoog-intermediare 
risicofactoren gerandomiseerd (2:1) tussen vaginale brachytherapie of geen 
aanvullende behandeling na de operatie. Daarnaast worden de patiënten in 
de vaginale brachytherapie groep gerandomiseerd (1:1) tussen de standaard 
dosis van 21 Gy in 3 fracties van 7 Gy of een lager dosisniveau (3 fracties 
van 5 Gy), om de vraag te beantwoorden of een lagere dosis even effectief is 
vergeleken met de standaard dosis.
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Uitwendige radiotherapie is tegenwoordig alleen nog geïndiceerd voor 15% 
van de endometriumcarcinoom patiënten met hoog risico kenmerken. 
Lopende trials (PORTEC-3, GOG#249 en GOG#258) onderzoeken de rol van 
chemotherapie en de combinatie van chemotherapie met radiotherapie voor 
deze patiënten.
Een andere manier om over- en onderbehandeling van endometriumcarcinoom 
te verminderen is het integreren van nieuwe moleculaire prognostische 
factoren in het huidige systeem van risicoclassificatie, dat gebaseerd is op 
klinisch-pathologische factoren. De pilotstudie in 65 geselecteerde PORTEC-2 
patiënten liet zien dat P53 expressie en microsatelliet-instabiliteit de sterkste 
individuele genetische prognostische factoren waren. Echter, de combinatie 
van multipele geactiveerde signaaltransductieroutes was de sterkste 
onafhankelijke ongunstige prognostische factor met een lagere ziektevrije 
overleving. Deze bevindingen zullen in een grote groep patiënten gevalideerd 
moeten worden. Voor dit doel zijn studies gepland die gebruik zullen 
maken van het tumormateriaal van patiënten uit de PORTEC-1 en PORTEC-2 
trial. Daarnaast zal een toekomstige analyse van het tumormateriaal uit de 
PORTEC-3 trial inzicht geven in moleculaire veranderingen die het gedrag 
van hoog-risico endometriumcarcinoom bepalen, en factoren die de respons 
op chemotherapie kunnen voorspellen, zowel voor endometrioide als non-
endometrioide tumoren, en mogelijk ook leiden tot toepassing van nieuwe 
(doelgerichte) middelen. 
In de nabije toekomst zullen verbeteringen in de techniek van beeldgestuurde 
radiotherapie leiden tot een verdere afname van behandelingsgerelateerde 
morbiditeit. Hiernaast zal door het gebruik van moleculaire prognostische 
factoren het individuele risico op recidief beter ingeschat kunnen worden. 
Hierdoor kan de afweging voor behandeling met radiotherapie, rekening 
houdend met de individuele voorkeuren van de patiënt, beter worden 
gemaakt. Dit zal er toe leiden dat minder laag risico patiënten worden 
blootgesteld aan onnodige behandelingsgerelateerde morbiditeit, en dat de 
behandelingsuitkomsten bij hoog risico patiënten verder kunnen worden 
verbeterd.
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PORTEC-1:
Erasmus MC Rotterdam/Daniel den Hoed Cancer Center: C.L. Creutzberg, 
P.C.M. Koper, J.W.M. Mens; W.L.J. van Putten, statistician; R. Dercksen, 
datamanager; M. van Lent, gynaecologic oncologist; H. Beerman, pathologist
Catharina Hospital Eindhoven: M.L.M. Lybeert
Medisch Spectrum Twente Enschede: J.J. Jobsen, J.H. Meerwaldt
University Medical Center Utrecht: C.C. Wárlám–Rodenhuis
Dr. B. Verbeeten Institute Tilburg: K.A.J. De Winter
MAASTRO Clinic, Maastricht: L.C.H.W. Lutgens
University Hospital Groningen: A.C.M. van den Bergh, E. Pras
Radiotherapy Institute Arnhem: E.M. v.d. Steen–Banasik
Radiotherapy Institute Deventer: M.C. Stenfert Kroese
University Medical Center Radboud, Nijmegen: L.A.M. Pop
University Medical Center Amsterdam: L. Uitterhoeve
Leiden University Medical Center: A.A. Snijders–Keilholz, R.A. Nout
Netherlands Cancer Institute Amsterdam: B.N.F.M. van Bunningen
Westeinde Hospital The Hague: J.H. Biesta
Leyenburg Hospital The Hague: F.M. Gescher
Reinier de Graaf Hospital Delft: J. Pomp
VU Medical Center Amsterdam: O.W.M. Meijer
Radiotherapy Institute Vlissingen: J.H. Tabak
Radiotherapy Institute Leeuwarden: A. Slot
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PORTEC-2:
University Medical Center Utrecht: I.M. Jürgenliemk-Schulz
Medisch Spectrum Twente, Enschede: J.J. Jobsen
MAASTricht Radiation Oncology Clinic, Maastricht: L.C.H.W. Lutgens
Arnhem Radiotherapy Institute, Arnhem: E.M. v.d. Steen–Banasik
Erasmus MC Rotterdam/Daniel den Hoed Cancer Center, Rotterdam: J.W.M. 
Mens, A.C. Ansink. gynaecologic oncologist.
Leiden University Medical Center, Leiden: C.L. Creutzberg, R.A. Nout; 
V.T.H.B.M. Smit, T. Bosse, pathologists; H. Putter, statistician; Trialbureau IKNL 
–Leiden: Ch. te Marvelde; Ph. van den Tol, L. Ruiter, L. Rijke, K. Adema.
Radiotherapy Institute Friesland, Leeuwarden: A. Slot
Radiotherapy Institute Stedendriehoek en Omstreken, Deventer: M.C. 
Stenfert Kroese
Netherlands Cancer Institute, Amsterdam: B.N.F.M. van Bunningen, B. van 
Triest
Catharina Hospital, Eindhoven: M.L.M. Lybeert
University Medical Center Radboud, Nijmegen: J.W. Leer
Sophia Hospital, Zwolle: P.R. Timmer
VU Medical Center, Amsterdam: O.W.M. Meijer, B. van Triest
University Medical Center Groningen: B. Pras; H.W. Nijman, gynaecologic 
oncologist
Medical Centre Haaglanden, The Hague: R. Wiggenraad
Academic Medical Center, Amsterdam: L. Uitterhoeve
Haga Hospital, The Hague: P.C.M. Koper
R. de Graaf Hospital, Delft: J. Pomp
Zeeuwsch Radiotherapy Institute, Vlissingen: V.L.M. Coen
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Remi Nout werd op 14 januari 1975 geboren in Ilesha, Nigeria. In 1993 behaalde 
hij het VWO diploma op het Christelijk Streek Lyceum in Ede. In dat jaar startte 
hij met de studie geneeskunde aan de Universiteit Maastricht. Na het volgen van 
een wetenschapsstage bij de afdeling huisartsgeneeskunde van de University 
of British Columbia, Canada (begeleider Dr. S. Grzybowski) behaalde hij in 
1997 zijn doctoraal examen. Na een klinische stage van drie maanden in het 
Moi University Hospital in Eldoret, Kenya, behaalde hij in 2000 zijn artsexamen. 
Op zoek naar het juiste specialisme werkte hij achtereenvolgens als arts-
assistent op de afdelingen spoedeisende hulp en orthopedie in het Laurentius 
Ziekenhuis in Roermond, als arts-assistent psychiatrie bij de crisisdienst van 
Mentrum in Amsterdam en volgde hij gedeeltelijk de opleiding tot huisarts aan 
het Academisch Medisch Centrum te Amsterdam. 
In 2003 begon hij met de opleiding tot radiotherapeut-oncoloog in het Leids 
Universitair Medisch Centrum (opleider: prof. dr. E.M. Noordijk). Tijdens zijn 
opleiding startte hij in 2007 met het onderzoek naar de uitkomsten van de 
PORTEC-2 trial en kwaliteit van leven studies. Sinds het voltooien van zijn 
opleiding in 2008 is hij als radiotherapeut-oncoloog werkzaam in het Leids 
Universitair Medisch Centrum, met als aandachtsgebieden gynaecologische 
oncologie en bot- en wekedelentumoren. Deze klinische werkzaamheden 
combineert hij met het werk als onderzoeker, o.a. voor de PORTEC trials en in 
het EMBRACE netwerk.
Remi is getrouwd met Maartje Schaap en ze hebben twee dochters, Anouk en 
Yfke. 
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Dankwoord
Het doen van onderzoek is teamwork. Dit geldt in het bijzonder bij het 
uitvoeren van klinische trials die aan de basis liggen van de resultaten in dit 
proefschrift. Dat de PORTEC trials succesvol en toonaangevend zijn geweest 
in de indicatiestelling en de wijze waarop endometriumcarcinoom patiënten 
postoperatief bestraald worden is te danken aan de inzet van velen. 
Allereerst wil ik alle patiënten bedanken die de moed hebben gehad deel te 
nemen aan deze studies en die hiermee het lot hebben laten beslissen over de 
uiteindelijke behandeling; zonder uw deelname waren deze resultaten er nooit 
gekomen.
Voordat ik een aantal personen in het bijzonder bedank wil ik het Landelijk 
Platform voor Radiotherapie bij Gynaecologische Tumoren, een betrokken 
groep radiotherapeuten van waaruit de PORTEC studies ontstaan zijn, en 
alle betrokken radiotherapie afdelingen bedanken voor de trouwe inzet en 
ondersteuning bij al het werk wat nodig is om deze landelijke studies mogelijk 
te maken.
Veel dank ben ik verschuldigd aan mijn (co)promotoren. Prof. Creutzberg, 
beste Carien, met jouw centrale rol in alle PORTEC studies heb je mij op een 
inspirerende wijze meegevoerd langs alle facetten die klinisch onderzoek 
doen zo boeiend maken. Dankzij jouw vermogen om mij daarbij mijn eigen 
verantwoordelijkheid te laten nemen en mij daarin te steunen heb ik hier 
veel van geleerd. Prof. Marijnen, beste Corrie, jij was het die me enthousiast 
bijstond in mijn allereerste schreden die ik in de radiotherapie heb gezet en 
mijn eerste wetenschappelijke werk op de afdeling. Dankzij jouw steun heb 
ik de afgelopen jaren het onderzoek voor dit proefschrift kunnen combineren 
met het klinische werk op onze afdeling. Dr. Smit, beste Vincent, tijdens 
het revisie werk heb jij mij veel bijgebracht over de (on)zekerheden van de 
pathologie van het endometriumcarcinoom. Jouw enthousiaste betrokkenheid 
in onze gezamenlijke projecten is aanstekelijk, en ik kijk dan ook uit naar onze 
verdere samenwerking.
Prof. Thomas, dear Gillian, many thanks for your enthusiastic support of my 
work and for sharing your personal views on clinical and scientific issues 
during these years.
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Alle coauteurs wil ik graag bedanken, het schrijven van een artikel en analyseren 
van resultaten doe je niet alleen. Beste Ina, Jan, Ludy, Elzbieta, Jan-Willem, 
Annerie, Marika, Carla en Marnix: veel dank voor jullie hulp bij het oplossen van 
alle vragen en naspeuren van ontbrekende informatie, en jullie steun tijdens de 
presentaties in de afgelopen jaren. Beste Hein en Wim, dankzij jullie geduldige 
adviezen en kritische blik heb ik veel geleerd van de statistische analyse van 
klinische trials. Beste Lonneke, jij hebt me wegwijs gemaakt in de wereld van 
het kwaliteit van leven onderzoek, veel dank voor het laagdrempelige contact 
en je enthousiaste steun. Beste Tjalling, met veel plezier heb ik de afgelopen 
periode met je samengewerkt, zonder jouw inzet was ons onderzoek naar de 
rol van de moleculaire prognostische factoren niet van de grond gekomen: veel 
dank hiervoor en voor alle goede gesprekken over wijn en wetenschap.
Gegevens komen niet vanzelf in een bestand terecht: hiervoor wil ik alle 
betrokken datamanagers bedanken voor het zorgvuldig beheren van alle data; 
Renée, Chantal, Philine, Lydia, Linda en Karen, dank voor jullie grote inzet en 
goede samenwerking. De afdeling Pathologie van het LUMC wil ik bedanken 
voor de ondersteuning bij al het revisie werk, de dozen blokjes en coupes die 
voorbij zijn gekomen, maar ook bij de uitvoering van de moleculaire analyses.
Grote dank gaat uit naar alle medewerkers van de afdeling Klinische Oncologie 
en de subafdeling Radiotherapie van het LUMC in het bijzonder, dankzij jullie 
inzet en collegialiteit heb ik met veel plezier de afgelopen jaren gewerkt. In 
het bijzonder wil ik mijn collega’s bedanken voor het begrip als ik ‘weer eens’ 
druk was met de wetenschap, en de dames van het brachyteam waarmee ik de 
afgelopen jaren veel directe patiëntenzorg heb geleverd: veel dank voor het 
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